Status: Approved ,Date: 18July 2016 1Janssen Research & Development*
Clinical Protocol
A Randomized, Double -blind, Multicenter, Active -controlled Study to Evaluate the 
Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in 
Elderly Subjects with Treat ment -resistant Depression
Trial of R apid-a cting Intra nasal E sketamine for Treatment -resistant Major Depressive Disorder 
(TRANSFORM -3)
Protocol ESKETINTRD3005; Phase 3
AMENDMENT 3
JNJ-54135419 (esketamine)
*Janssen Research & Development is a gl obal organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Product s, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen, Janssen Sciences Ireland UC; or Janssen 
Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these 
various legal entities; the sponsor is identi fied on the Contact Information page that accompanies the 
protocol .
This compound is being investigated in Phase 3 clinical studie s.
This study  will be conducted under US Food & Drug Administration IND regulations (21 CFR 
Part 312).
EudraCT NUMBER: 201 4-004588 -19
Status: Approved
Date: 18July 2016
Prepared by: Janssen Research & Development, LLC
EDMS n umber and version : EDMS -ERI-93094734 , 4.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, andapplicable 
regulatory requirements .
Confidentiality Statem ent
The information in this document contains trade secrets and commercial information that are privileged or 
confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any 
event, persons to whom the information is disclosed must be informed that the information is privileged or 
confidential and may not be further disclosed by them. These restrictions on disclosure will apply equally to all 
future information supplied to you that is indicated as privileged or confidential.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 2TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF A TTACHMENTS ............................................................................................................................ 4
LIST OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 5
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................. 32
TIME AND EVENTS SCHE DULE (Screening/Prospective Observational Phase and Double -
blind Induction Phase) .............................................................................................................................. 44
TIME AND EVENTS SCHE DULE (Follow -up Phase) .............................................................................. 49
ABBREVIA TIONS ...................................................................................................................................... 51
1. INTRODUCTION ................................................................................................................................ 53
1.1. Background .................................................................................................................................... 54
1.1.1. Summary  of Nonclinical F indings ............................................................................................... 54
1.1.2. Clinical Studies ........................................................................................................................... 57
1.1.2.1. Pharmacokinetics and Product Metabolism ............................................................................ 57
1.1.2.2. Pharmacodynamics and Efficacy ............................................................................................ 59
1.1.2.3. Safety and Tolerability ............................................................................................................. 61
1.1.3. Marketing Experience ................................................................................................................. 66
1.2. Active Comparators in Double -blind Induction Phase ................................................................... 66
1.2.1. Selective Serotonin Reuptake Inhibitors ..................................................................................... 67
1.2.1.1. Escitalopram ............................................................................................................................ 67
1.2.1.2. Sertraline ................................................................................................................................ .67
1.2.2. Serotonin and Norepinephrine Reuptake Inhibitors ................................................................... 68
1.2.2.1. Duloxetine ................................................................................................................................ 68
1.2.2.2. Venlafaxine Extended -release ................................................................................................ .69
1.3. Overall Rationale for the Study ...................................................................................................... 70
2. OBJECTIVES A ND HYPOT HESIS ................................................................................................... 70
2.1. Objectives ...................................................................................................................................... 70
2.2. Hypothesis ..................................................................................................................................... 71
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .71
3.1. Overview of Study Design .............................................................................................................. 71
3.2. Study Design Rationale .................................................................................................................. 74
3.2.1. Study Population ......................................................................................................................... 74
3.2.2. Study Phases .............................................................................................................................. 75
3.2.3. Blinding and Randomization ....................................................................................................... 77
3.2.4. Treatment Groups and Dose Selection ...................................................................................... 77
3.2.5. Efficacy  Measures ...................................................................................................................... 79
3.2.6. Safety Evaluations ...................................................................................................................... 79
3.2.7. Other Assessments .................................................................................................................... 81
3.2.8. Pharmacokinetic Assessments ................................................................................................... 81
3.2.9. Biomarker, Pharmacogenomic (DNA), and Expression (RNA) Evaluations .............................. 81
4. STUDY POPUL ATION...................................................................................................................... 82
4.1. Inclusion Criteria ............................................................................................................................ 82
4.2. Exclusion Criteria ........................................................................................................................... 84
4.3. Prohibitions and Restrictions ......................................................................................................... 90
5. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 91
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 36. DOSA GE A ND A DMINISTR ATION.................................................................................................. 92
6.1. Screening/Prospective Observational Phase ................................................................................ 92
6.2. Double -Blind Induction Phase ........................................................................................................ 93
6.2.1. Guidance for Blood Pressure Monitoring on Intranasal Treatment Session Day s..................... 95
6.3. Follow -up Phase ............................................................................................................................ 96
7. TREA TMENT COMPLIA NCE ............................................................................................................ 96
8. PRESTUDY A ND CONCOMI TANT THERA PY................................................................................ 97
9. STUDY EVA LUATIONS .................................................................................................................... 98
9.1. Study Procedures ........................................................................................................................... 98
9.1.1. Overview ..................................................................................................................................... 98
9.1.2. Screening/Prospective Observational Phase ............................................................................. 99
9.1.3. Double -Blind Induction Phase .................................................................................................. 101
9.1.4. Follow -up Phase ....................................................................................................................... 102
9.2. Efficacy ......................................................................................................................................... 103
9.2.1. Evaluations ............................................................................................................................... 103
9.2.1.1. Primary Efficacy  Evaluation ................................................................................................... 103
9.2.1.2. Secondary Efficacy Evaluations (Clinician -completed) ......................................................... 103
9.2.1.2.1. CGI-S................................................................................................................................ .103
9.2.1.3. Other Secondary Efficacy  Evaluations (Patient- reported Outcomes) ................................... 104
9.2.1.3.1. EQ-5D-5L........................................................................................................................... 104
9.2.2. Endpoints .................................................................................................................................. 104
9.2.2.1. Primary Endpoint ................................................................................................................... 104
9.2.2.2. Secondary Endpoints ............................................................................................................ 104
9.3. Pharmacokinetics ......................................................................................................................... 104
9.3.1. Evaluations ............................................................................................................................... 105
9.3.2. Analytical Procedures ............................................................................................................... 105
9.3.3. Pharmacokinetic Parameters ................................................................................................... 105
9.4. Pharmacokinetic/Pharmacodynamic Evaluations ........................................................................ 105
9.5. Biom arker, Pharmacogenomic (DNA), and Expression (RNA) Evaluations ................................ 105
9.6. Safety Evaluations ....................................................................................................................... 106
9.7. Other Evaluations ......................................................................................................................... 114
9.8. Sample Collection and Handling .................................................................................................. 115
10. SUBJECT COMPL ETION/WITHDRA WAL..................................................................................... 116
10.1. Completion ................................................................................................................................... 116
10.2. Withdrawal From the Study .......................................................................................................... 116
10.3. Withdrawal From the Use of Samples in Future Research .......................................................... 117
11. STATISTICA L METHODS ............................................................................................................... 117
11.1. Subject Information ...................................................................................................................... 117
11.2. Sample Size Determination ......................................................................................................... 118
11.3. Interim Analysis for Sample Size Re -estimation or Stopping f or Futility ...................................... 118
11.4. Efficacy  Analyses ......................................................................................................................... 119
11.5. Pharmacokinetic Analy ses........................................................................................................... 119
11.6. Pharmacokinetic/Pharmacodynamic Analyses ............................................................................ 120
11.7. Biom arker and Pharmacogenomic Analyses ............................................................................... 120
11.8. Safety Analyses ........................................................................................................................... 120
11.9. Independent Data Monitoring Committee .................................................................................... 122
12. ADVERSE EVENT REPORT ING.................................................................................................... 122
12.1. Definitions .................................................................................................................................... 123
12.1.1. Adverse Event Definitions and Classifications ......................................................................... 123
12.1.2. Attribution Definitions ................................................................................................................ 124
12.1.3. Severity Criteria ........................................................................................................................ 124
12.2. Special Reporting Situations ........................................................................................................ 125
12.3. Procedures ................................................................................................................................... 125
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 412.3.1. All Adverse Events .................................................................................................................... 125
12.3.2. Serious Adverse Events ........................................................................................................... 126
12.3.3. Pregnancy ................................................................................................................................ .127
12.4. Contacting Sponsor Regarding Safety ......................................................................................... 127
13. PRODUCT QUA LITY COMP LAINT HA NDLING ............................................................................ 127
13.1. Procedures ................................................................................................................................... 128
13.2. Contacting Sponsor Regarding Product Quality .......................................................................... 128
14. STUDY DRUG INFORM ATION....................................................................................................... 128
14.1. Physical Description of Study Drug(s) ......................................................................................... 128
14.2. Packaging .................................................................................................................................... 129
14.3. Labeling ........................................................................................................................................ 130
14.4. Preparation, Handling, and Storage ............................................................................................. 130
14.5. Drug Accountability ...................................................................................................................... 130
15. STUDY -SPECIFIC M ATERIA LS..................................................................................................... 131
16. ETHICA L ASPECTS ....................................................................................................................... 131
16.1. Study-specific Design Considerations ......................................................................................... 131
16.2. Regulatory Ethics Compliance ..................................................................................................... 134
16.2.1. Investigator Responsibilities ..................................................................................................... 134
16.2.2. Independent Ethics Committee or Institutional Review Board (IEC/IRB) ................................ .134
16.2.3. Informed Consent ..................................................................................................................... 135
16.2.4. Privacy of Personal Data .......................................................................................................... 136
16.2.5. Long- Term Retention of Samples for Additional Future Research .......................................... 137
16.2.6. Countr y Selection ..................................................................................................................... 137
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 137
17.1. Proto col Amendments .................................................................................................................. 137
17.2. Regulatory Documentation .......................................................................................................... 138
17.2.1. Regulatory Approval/Notification .............................................................................................. 138
17.2.2. Required Prestudy Documentation ........................................................................................... 138
17.3. Subject Identification, Enrollment, and Screening Logs .............................................................. 139
17.4. Source Documentation ................................................................................................................. 139
17.5. Case Report Form Completion .................................................................................................... 140
17.6. Data Quality Assura nce/Quality Control ...................................................................................... 140
17.7. Record Retention ......................................................................................................................... 141
17.8. Monitoring .................................................................................................................................... 141
17.9. Study Com pletion/Termination ..................................................................................................... 142
17.9.1. Study Com pletion ..................................................................................................................... 142
17.9.2. Study Termination ..................................................................................................................... 142
17.10. On-site Audits ............................................................................................................................... 142
17.11. Use of Information and Publication .............................................................................................. 143
REFERENCES .......................................................................................................................................... 145
INVESTIGA TOR A GREEMENT ............................................................................................................... 157
LIST OF ATTACHMENTS
Attachment 1: Prohibited Concomitant Medications with Intranasal Study Medication 
(Esketamine or Placebo) .......................................................................................... 150
Attachment 2: New York Heart Association Classification of Cardiac Disease ............................... 153
Attachment 3: Oral Antidepressant Titration Schedule for Double -Blind Induction Phase .............. 154
Attachment 4: Anticipated Events .................................................................................................... 155
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 5LIST OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Adverse Reactions Listed as Very Common, Common, or Frequent Occurrences in 
the Product Information of Anesthetic Ketamine and Esketami ne........................................... 62
Table 2: Mean Supine Blood Pressure and Heart Rate -Cohort 1 (ESKETINTRD1012) ...................... 63
Table 3: Intranasal Treatment Sessions Administration During the Double -blind Induction 
Phase ........................................................................................................................................ 93
Table 4 Dose Titration of Intranasal Esketamine* ................................................................................. 94
Table 5: Volume of Blood to Be Collected From Each Subject .............................................................. 99
FIGURES
Figure 1: Study Design for ESKETI NTRD3005 ....................................................................................... 74
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 6PROTOCOL A MENDMENTS
Protocol Version Issue Date
Original Protocol 10 March 2015
Amendment 1 08 June 2015
Amendment 2 10January 201 6
Amendment 3 18July 2016
Amendments below are listed beginning with th e most recent amendment.
Amendment 3 (18July 2016) 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and th e Council of the European Union.
The overall rea son for the amendment: The overall reason for the amendment is to improve recruitment while 
maintaining the integrity of the study. Changes are made that relate to the elderly population specifically (which 
differ in some aspects from younger patients) not included in the original protocol.
Applicable Section(s) Description of Change(s)
Rationale: Montgomery -Asberg Depression Rating Scale (MADRS )scores in the elderly, per multiple expert 
opinions are lower than in younger patients . This difference is attributed to the tendency of the elderly to minimize 
symptoms. Therefore, alower MADRS total cut-off score of 24will be used for the elderly  to align with a MADRS 
total score of 28 used in younger subjects .
Synopsis Overview of Study 
Design ;
Synopsis Stu dy Population;
3.1. Overview  of Study Design;
3.2.1. Study Population;
4.1. Inclusion Criteri on;
6.1. Screening/Prospective
Observational Phase;
9.1.2. Screening/Prospective
Observational PhaseMADRS total score changed from ≥28 to ≥2 4, wherever the origin al value 
of 28 occurs .
Rationale: The Inventory of Depressive Symptom atology -Clinician rated, 30-item scale (IDS-C30)scores in the 
elderly, as per multiple expert opinions, are lower than in younger subjects , because of the tendency to minimize 
symptoms (as with the MADRS scores). The refore, a low er IDS -C30 cut-off score of 31 for the elderly will be m ore 
align edwith the MADRS total score of ≥24that w ill be used in the elderly.
Synopsis Study Population;
3.2.1. Study Population;
4.1. Inclusion Criteri on;
9.1.2. Screening/Prospective
Observational PhaseIDS-C30 score changed from ≥34 to ≥31, w herever the original value of 34 
occurs.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 7Applicable Section(s) Description of Change(s)
Rational e:Criteria for the minimum number of oral antidepressant treatments in the current episode of depression 
with non-response at the start of the Screening/Prospective Observational Phase, has been revised from ≥2 to ≥1. 
The elderly are more likely to have longer episodes of depression, and to have been on more oral antidepressants
during the episode , than younger subjects. Therefore, the criteria for the maximum number of oral antidepressant 
treatments in the current episode of depression with non-response at the start of the Screening/Prospective 
Observational Phase, has been revised from  ≤5 to ≤8. This change is supported by discussions with multiple experts 
in geriatric psychiatry. 
Synopsis Study Population;
3.2.1. Study Population;
4.1. Inclusion Criteri on;
9.1.2. Screening/Pros pective
Observational PhaseChange in the number of oral a ntidepressants allowed during the current 
episode from ≥2 to ≤5 to ≥1to ≤8. 
Rationale: Patients with Parkinson’s disease were previously excluded as some have cognitive impairment. 
How ever, many patients with Parkinson’s disease who suffer from depressi on do not have cognitive impairment, 
and the exclusion criteria has therefore ,been revised to allow these patients to be included in the study .
Synopsis Study Population;
4.2. Exclusion Criteri aExclusion Criterion no. 12 has been modified:
The text prev iously stated that subjects with Parkinson’s will be excluded.
The text has been revised (new text in bold) : ‘Subjects with Parkinson’s 
disease with clinical evidence of cognitive impairment will be excluded’.
Rationale: Medical stabilization, allow ed during the Screening /Prospective Observation period, may take longer in 
the elderly where changes are slow er. 
Synopsis Overview of Study 
Design ;
Time & Events Table footnote (a);
3.1. Overview  of Study Design ;
3.2.2.Study Phases ;
9.1.2 Screening/Prospe ctive 
Observational PhaseThe text has been revised to indicate that the3 week period during the 
screening /prospective observational phase may be used foroptim ization of 
medical management if needed to facilitate subject participation: 
If clinically indicated, a subject’s current antidepressant treatm ent(s) may be 
tapered and discontinued over an additional, optional period of up to 
3weeks, per the local prescribing information or per clinical judgment.
The follow ing text has been added: “This 3-week period m ayalso be used to 
optimize medical management if needed to facilitate subject participation 
(eg, treatment of blood pressure or diabetes, wean from other medications, 
etc,). In such cases , if there is no planned taper, the oral regimen should be
continued in the interim and then discontinued by Day 1 of the double -blind 
induction phase. ”
Rationale: Testing is significantly slow er in the elderly population and subjects frequently complain of fatigue. 
Cognition testing, in particular, takes longer in the elderly than in the younger subject population . It is considered 
thata baseline may still be established, if values for cognition testing are obtained just prior to the initial d ate for the 
Double -Blind Induction P hase (Visit 2.1 ), rather than on the actual date itself .  
Time & Events Schedule ,
Screening/Prospective Observational 
PhaseChanges to the text added to allow  for some of the assessments (eg, 
cognition) to take place either during the last visit in the 
Screening/Prospective Observation al Phase (Visit 1.3) or prior to the initial 
visit f or the Double- Bind P hase (Visit 2.1). 
Legend s) Addition of a footnote (s) by cognition testing to indicate that these tests can 
precede Visit 2.1.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 8Applicable Section(s) Description of Change(s)
Rationale: Follow ing discussions with a leading exper t within the disease area, a decision has made to remove the 
Smell Threshold test, as this is operationally burdensome to perform and not required for the elderly population. 
Synopsis Safety Evaluation s;
Synopsis Statistical Methods ;
Time & Events Sched ule;
3.2.6. Safety Evaluation s;
9.6. Safety Evaluations ;
11.8. Safety AnalysesRemoval of Smell Threshold test throughout the study
Rationale: To decrease the pat ient burden, the UPSIT w ill be assessed prior to and post treatment , only.
Time & Events Schedule The UPSIT w ill be assessed on Visit 1.2. of the 
Screening/Prospective/Observational Phase (prior to treatment), and on 
either Visit 2.9 at the end of the Double- Blind Treatment Phase or at the 
Early Withdrawal ( EW)visit
Change :
The UPSIT w ill not be assessed on V isit 2.5. Double -Blind Induction Phase.
Rationale: Follow ing discussions with a leading expert within the disease area, it was decided that 3 booklets 
instead of the orig inal 4booklets were sufficient to generate UPSIT data for the elderl y population, while removal of 
one of the booklets will reduce the operational burden for the elderly subjects . 
9.6. Safety Evaluations The description of the UPSIT test has been changed to consist of 3 booklets 
instead of the original 4 booklets .
Rationale: Follow ing discussions with a leading expert within the disease area, it was decided that data from the 
UPSIT w as only required from 25% of subjects in the study, and that this would be sufficient to assess any potential 
change in smellin this popul ation . This was based on the expectation that at least 50% of elderly subjects will have 
some diminution of smell (not actual anosmia). Therefore, even if half of the subjects have anosmia (fewer 
expected) at least 25% of the subjects w ill be able to be ev aluated.
4.2. Exclusion Criteria Exclusion criterion no. 7 has been deleted.
An UPSIT score is not exclusionary 
Rationale: Analysis of data from elderly subjects in the Phase 3 clinical trial ESKETIN3004, and the Phase 1 
clinical trials ESKETINTRD1003 a nd ESKETINTRD1012, did not show  an effect of esketamine on the PR interval, 
as assessed by electrocardiography.  
4.2. Exclusion Criteria Exclusion criterion no.13.2has been modified:
The following text indicated has been deleted: ‘Evidence of 2ndand 3rd
degree AV block, or1stdegree AV block with PR interval ˃200 m sec(if the 
initial PR interval is <240 msec, may repeat the ECG once and use average 
of both readings), complete left bundle branch block (LBBB) or complete 
right bundle branch block (RBBB). 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 9Applicable Section(s) Description of Change(s)
Rationale: The Patient Health Questionaire -9 item ( PHQ -9)and the Sheehan Disability Scale (SDS), w ill not be 
used to evaluate efficacy. This w ill reduce patient burden, without having a marked impact on the data generated 
from this study. 
Synopsis Efficacy 
Evaluations /Endpoints ;
Synopsis Statistical Met hods;
Time & Events Schedule;
3.2.5. Efficacy Measures;
9.2.1. Evaluations;
9.2.1.2. Key Secondary Efficacy 
Evaluations (Patient -Reported)
9.2.2.2. Secondary Endpoints;
11.4. Efficacy Analys es;Reference to the Patient Health Questionaire- 9 item (PHQ -9) scale and the 
Sheehan Disability Scale (SDS) w as rem oved throughout. 
Rationale: To im prove recruitment, the antidepressant treatment requirements at study entry  (ie, tim e of signing the 
ICF) in inclusion criterion no. 3 were changed. In addition, the defin ition of nonresponse at the end of the 
screening/prospective observational phase was revised.
4.1. Inclusion Criteria Inclusion criteria no.3 has been revised as follows (bold text added , 
strikethrough text deleted ):
At the start of the screening/prosp ective/observational phase, subject must 
have had nonresponse ( ≤25% im provement) to ≥1but ≤8(if current episode 
is ˃2 years, upper limit applicable to only the last 2 years) oral 
antidepressant treatments in the current episode of depression, assessed 
using the MGH -ATRQ and confirmed by documented records (eg, 
medical/pharmacy/prescription records ora letter from a treating physician, 
etc). In addition , subject is taking a different oral antidepressant treatment 
(on the MGH -ATRQ) for at least the previou s 2 weeks at or above the 
minim umtherapeutic dose.
-For specific tricyclic antidepressants which are ongoing and being 
taken at a dose below  the MGH -ATRQ minimum therapeutic dose, 
a blood level that is within the therapeutic (antidepressant) range, is 
acceptable to establish the adequacy of the antidepressant 
treatment.
-Subjects must beadherent to the continued oral antidepressant 
treatment medication(s) through the screening/prospective 
observational phase, as documented on the PAQ. Missing ≥4 days 
of antidepressant medication in the prior 2week period will be 
considered as inadequate adherence.
-Subjects who are nonresponders to their current oral antidepressant 
medication(s) from the screening/prospective observational phase 
(as assessed by independent, remote raters) may be eligible for 
randomization if all other entry  criteria are met. Non-response at 
the end of the screening/pr ospective observational phase isdefined 
as ≤25% improvement in the MADRS total score from  Week1 to 
Week 4and a MADRS total score of ≥24 on Week 2 and 
Week 4.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 10Applicable Section(s) Description of Change(s)
Synopsis Overview of Study 
Design;
Synopsis Study Population;
Synopsis Dosage and 
Administration;
3.1. Overview  of Study Desig n;
3.2.1. Study Population;
6.1. Screening/Prospective 
Observational Phase;
9.1.2. Screening/Prospective 
Observational Phase ;
Attachment 1
Synopsis Overview of Study 
Design;
Synopsis Study Population;
3.1. Overview  of Study Design ;
3.2.1. Study Popula tion;
6.1. Screening/Prospective 
Observational Phase;
9.1.2. Screening/Prospective 
Observational Phase
16.1. Study -specific Design 
ConsiderationsText regarding antidepressant treatment during the screening/prospective 
observational phase was revised as f ollows (bold text added):
At the start of the screening/prospective observational phase, the subject 
must have had documented nonresponse to at least one antidepressant 
treatm ent (based on MGH-ATRQ criteria) in the current episode of 
depression, and the subject is taking a different oral antidepressant 
treatment (on the MGH -ATRQ) for at least the previous 2 weeks at or 
above the minimum therapeutic dose. This antidepressant treatm ent, as well 
as any other ongoing medications being taken for depression at screening 
(including adjunctive/augmentation therapies) will continue from the start of 
Week 1 through the end of Week 4 of the screening/prospective 
observational phase. Dose adjustment is permitted per clinical judgm ent, 
but the oral antidepressant treatm ent is to remain at or above the 
minimum therapeutic dose (per the MGH-ATRQ) through the end of 
Week 4.
Text regarding nonresponse to oral antidepressant at end of the 
screening/prospect ive observational phase (strikethrough deleted text) :
Non-response at the end of the screening/prospective observational phase is 
defined as ≤25% improvement in the MADRS total score from Week 1 to 
Week 4 for 2 consecutive visits and a MADRS total score of ≥24for 2 
consecutive visits on Week 2 and Week 4. 
Text regardi ng subject eligibility was revised as follows (bo ld text added):
For eligibility, subjects must have had nonresponse to at least one prior 
antidepressant treatm ent and be currently taking an antidepressant 
treatment at the start of the screening/prospecti ve observat ional phase 
that will be continued as prospective treatment in the screening/prospective 
observa tional phase. Only subjects with nonresponse to their current 
antidepressant treatment after 4 weeks of prospectively observed treatment 
(for a total duration of antidepressant treatment of at least 6weeks bythe 
end of the screening/prospective observational phase) will be eligible to 
proceed to the double -blind induction phase, when all subjects will receive a 
new oral antidepressant in addition to intranasal esketamine or placebo.
Rationale: The list of key secondary objectives hasbeen revised to exclude several analy ses in order to reduce 
patient burden .
Synopsis Objectives and 
Hypothesis;
2.1. Objectives and HypothesisThe following text have been deleted as indicated and the parameters listed 
below  will not be assessed:
Key Secondary  Objectives:
The key secondary objectives are to assess the effect of intranasal 
esketamine plus a newly initiated oral antidepressant compared with a newly
initiated oral antidepressant (active comparator) plus intranasal placebo in 
the following parameters in elderly subjects with TRD.
Functioning and associated disability
Depressive symptoms (subject -reported)
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 11Applicable Section(s) Description of Change(s)
Rationale: Inclusion criterion no. 9 w as revised to specify the same requirements for contraception for female 
partners of male subjects as specified for female subjects.
4.1. Inclusion Criteria The text of inclusion criterion no. 9 was revised as follows (bold text 
added):
During the study (ie, from Day 1 of the double -blind induction phase, prior 
to randomization) and for a minimum of 1 spermatogenesis cycle (defined as 
approximately 90 days) after receiving the last dose of intranasal study 
medication, a man who is sexually active with a wom an of childbearing 
potential
-must be practicing a highly effective method of contraception 
with his fem ale partner from those listed above (see examples of 
highly effective methods of contraception provided for female 
subjects). 
-must use a condom if his partn er is pregnant .
-must agree not to donate sperm.
The follow ing text has been deleted: ‘Alternatively female partners of 
childbearing potential may be practicing a highly effective method of birth 
control: eg, established use of oral, injected, or implanted horm onal methods 
of contraception; placement of an intrauterine device (IUD) or intrauterine 
system (IUS); or male partner sterilization.’
Rationale: The level of education is known to have an impact on the results of the MMSE, w ith those subjects 
withou t a high school educ ation having lower results. The exclusion criterion has been modified to allow  for this.
Synopsis Study Population;
4.2. Exclusion Criteria ;
9.7. Other EvaluationsExclusion criterion no. 11 has been modified as follows (bold text adde d):
Subject has a Mini Mental State Examination (MMSE) <25 or <22 for 
those subjects with less than an equivalent of a high school education.
Rationale: Exclusion criterion no. 16 w as revised to allow  prescription use of psychostimulants with dosing 
restrictions on intranasal treatment session days to allow  subjects to safely use at other permitted times during study 
participation.
4.2. Exclusion Criteria Text in exclusion criterion no. 16 w as  revised as follows (bold text added):
Subject has positive test result(s) for drugs of abuse (including barbiturates, 
methadone, opiates, cocaine, phencyclidine, and 
amphetamine/methamphetamine) at the start of the screening/prospective 
observational phase or Day 1 of the double -blind induction phase prior to 
randomization.
-Subjects who have a positive test result at screening due to 
prescribed psychostimulants (eg, amphetam ine, 
methylphenidate, etc.) taken for an indication other than MDD ,
are perm itted to continue to take this medication during the 
study in accor dance with Attachm ent 1.
-Otherwise, subjects who have a positive test result at screening 
due to prescribed/over -the-counter opiates ,or barbiturates may be 
permitted to continue in the screening/prospective observational 
phase if the medication is discont inued at least 1 week or 5 half-
lives, whichever is longer, before Day 1 of the double -blind 
induction phase (prior to randomization) in accordance with 
Attachment 1 restrictions. The result of the Day 1  ( prior to 
randomization) test for drugs of abuse must be negative for the 
subject to be randomized.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 12Applicable Section(s) Description of Change(s)
Rationale: Clarifications made regarding the usage of antidepressant treatments for indications other than 
depression during the screening/prospective observational phase, and the use of corticosteroids, psy chostimulants, 
and ADHD medications.
8. Prestudy and Concomitant 
Therapy
Attachment 1The follow ing text was added:
Any medication that is listed on the MGH -ATRQ and is being taken at the 
start of the screening/prospective observational phase for an indication other 
than depression (eg, insomnia) should be continued during the 
screening/prospective observational phase but must be discontinued before 
the start of the double -blind induction phase.
Prohibited Concomitant Medications with Intranasal Stu dy Medication
Changes to the text:
Antidepressants: “Even if used forother indications other than MDD (eg, 
trazodone or low dose tricyclic antidepressants forsleep ), the use of any 
medication listed on the ATRQ is not permi tted during the treatment pha se.”
Corticosteroids: changed from “oral” to “systemic”; episodic use perm itted 
(previously prohibited); the following text added: “intermittent IM/IV 
corticosteroids are permitted (chronic use prohibited) ”. 
Pseudoephedrine : clarified that itis an “orally”administered agent (not 
intranasal).
Psychostimulants: continuous use perm itted (previously prohibited); text 
added “prescribed psychostimulants taken for indications other than MDD 
can be continued but must not be taken within 12 hours prior to the 
intranasal treatment session or for 2 hours after the intranasal treatment 
session ”. 
ADHD medications: continuous use perm itted (previously prohibited); text 
added “Can be continued but must not be taken within 12 hours prior to the 
intranasal treatment session or for 2 hours after the intranasal treatment 
session ).
The follow ing text in the preceeding paragraph on prohibited concomitant 
medications has been revised (text added in bold; strikethrough text 
deleted ):
Except where specifically noted, the p rohibited medications listed in the 
following table are prohibited from 1 week (or 5 half -lives, whichever is 
longer) prior to the first dose of intranasal study medication until after the 
last dose of intranasal study medication. Note: If a medication is part of the 
antidepressant treatment regimen being taken at the time of signing the ICF 
(ie, start of screening/prospective observational phase), dose adjustment is 
permitted per clinical judgment, but the oral antidepressant treatm ent 
is to rem ain at or a bove the minimum therapeutic dose (per the MGH -
ATRQ) through the end of Week 4. .it must be continued unchanged until 
the end of week 4 of the screening/prospective observational phase. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 13Applicable Section(s) Description of Change(s)
Rationale: In the previous Amendment, inclusion of subjects who have thyroid-stimulating hormone (TSH) outside 
the normal ranges was permitted, how ever,the text indicating that a subject must have a normal TSH at screening 
was not removed. This has been corrected in the current Amendment.
4.1 Inclusion Criteria Inclusion criterion no. 7 revised as follows (bold text added) :
Delete following text: subject “must have thyroid stimulating horm one 
(TSH) within norm al range in the screening/prospective observational 
phase” and “if the free thyroxine (fT4) is norm al, the subject can be 
enrolled”.
-Subjects with a pre-existing history of thyroid disease/disorder who 
are treated with thyroid hormones must be on a stable dosage for 3 
months prior to the start of the screening/prospective observational 
phase.
-For any subject (regar dless of thyroid history), if the thyroid -
stimulating hormone (TSH )value is out of range, a free thy roxine 
(fT4) will be conducted. If the fT4 value is abnormal and 
considered to be clinically significant (after discussion with the 
medical monitor) , the s ubject is not eligible. 
Rationale: Provide clarification in the footnotes on antidepressant treatment in the screening/prospective 
observational phase, and guidance on repetition of the MADRS assessment.
Time and Events Schedule;
Screening/Prospective O bservational 
Phase ; Double -blind Induction 
Phase ;
Footnote a)
Double -blind Induction Phase ;
Footnote c)
Screening/prospective Observational 
Phase ;
Double -blind Induction Phase ;
Footnote q )Footnote a) revised as follows (bold text added): 
This 3 week period may also be used to optim ize medical m anagement if 
needed to facilitate subject participation. Subjects who do not require a 
taper and are thus eligible to immediately proceed to the double -blind 
induction phase canhave Visit 1.3 and Visit 2.1 occur on the same day or 
within 1 week of each other . (If not occurring on the same day, the 
antidepressant treatment regim en should be continued after Visit 1.3 
and then discontinued prior to Visit 2.1 ).
Delete “only” from footnote c) that refers to MADRS Visit 2.1 Efficacy 
Assessment.
Footnote q) revised as follows (bold text added , strike through deleted text ): 
The MADRS should be administered no more than 2 days prior to the 
subject’s targeted (not actual) scheduled clinic visit date (except Visit 2.9, 
which is within 1 day prior) . If performed on the day of the scheduled 
clinic visit for an intranasal treatment session, the MADRS must be 
performed prior to the intranasal treatment session.
Rationale: Revise the visit window  for Day 28 (Visit 2.9) of the Double -blind Induction Phase to allow more 
flexibility for conducting the visit.  
Time and Events Schedule, 
Double -blind Induction PhaseFor Visit 2. 9(Day 28) during the Double -blind Induction Phase, the visit 
window  has been revised to ±1 day (rat her than -1 day). 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 14Applicable Section(s) Description of Change(s)
Rationale: Addition of footnote to Time & Even ts Schedule stating that information on adverse events and 
concomitant therapies will be requested by site staff during the Follow -up Phase by remote assess ment.
Time and Events Schedule, F ollow -
up PhaseThe follow ing statement was added as a footnote (e) to the remote 
assessment (Visit 3.1) of the follow -up phase:
For the Remote Assessment (RA) V isit3.1, site staff will contact the subject 
by telephone to obtain information regarding adve rse events and 
concomitant therapies
Rationale: Removal of requirement to report arterial oxygen saturation <93% and any treatment -emergent change 
in the nasal examination as adverse events because adverse event reporting in these instances should be at t he 
discretion of the PI.
9.6. Safety Evaluations Text revised as follows (bold text added):
The follow ing statement was deleted from reporting arterial oxygen 
saturation :
Any arterial oxygen saturation <93% “and lasting for more than 
2minutes“…”will be reported as an adverse event”
Text now  states: “Any arterial oxygen saturation <93% should be confirmed 
by an additional measurement on another part of the body”.
The follow ing statement was deleted from the description of nasal 
examinations: 
“Any treatm ent-emergent change or w orsening from the baseline 
examination will be recorded as an adverse event ”.
Rationale: Removal of LSD and MDMA from urine drug screen results that will lead to discontinuation as LSD is 
not measured in the current urine drug scre en and prescribed psychostimulants are now  permitted.
4.3. Prohibitions and Restrictions Lysergic acid diethylamide (LSD) and MDMA were deleted from the list of 
drugs that will lead to discontinuation if detected in the urine drug screen 
during the study.
Rationale: Clarification of procedure to follow  if subjects wish to withdraw from the study.
10.2 Withdraw al from the Study Withdraw al of Consent : the follow ing text has been revised  (bold text 
added): 
Subjects who wish to withdraw from the study should be asked if they are 
agreeable tocontinue to an early withdrawal visit (if withdrawing from  
the double- blind induction phase) and the follow up phase, or to be 
contacted to collect follow -up information.
Rationale: Added definition of treatment -resistant depression (TRD) to the synopsis.
Synopsis Study Population Definition of TRD from Section 3.2.1 also added to the synopsis under 
Study Population.
‘Treatment -resistant depression (TRD) is defined as a lack of clinically 
meaningful improvement after treatment with at least 2 different 
antidepressant agents prescribed in adequate dosages for adequate duration.’
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 15Applicable Section(s) Description of Change(s)
Rationale: Clarification of adverse event reporting procedures in the instance of pregnancy. In addition, 
clarification that all SAEs must be reported using the SAE form.
12.3.1. All Adverse Events Text revised as follows (bold text added):
-The text stipulating 30 days for reporting serious adverse events has 
been deleted.
All adverse events and special reporting situations, whether serious or non -
serious, will be reported from the time a signed and dated ICF is obtained 
until completion of the subject's last study -related procedure (which may 
include contact for follow -up of safety), with the exception of pregnancy 
which will be reported up to6 weeks after the last dose of study 
medication (fem ales) or 90 days after the last dose of study medication 
(partners of male participants) . Serious adverse events, including those 
spontaneously reported to the investigator, to within 30 days after the last 
dose of study drug must be reported using the Serious Adverse Event Form . 
The sponsor will evaluate any safety information that is spontaneously 
reported by an investigator beyond the time frame specified in the protocol.
Rationale: Minor changes were made throughout the protocol for compliance with updated protocol template text 
and to correct errors.
9.3. Pharmacokinetics To correct an error, the text was revised to change “serum” to “plasma”:
Plasm acollected for PK may additionally be used to eva luate safety or 
efficacy aspects that address concerns arising during or after the study 
period.
17.5 Case Report Form Completion Delete text stating “All data relating to the study must be recorded in CRF.”
References Removed edition number and date f rom reference 42 .
Removed original reference number 49and86from the list and updated the 
reference list . 
Investigator Agreement Page Removed the “LAST PAGE” designation.
Amendment INT -2(10January 2016 )
This amendment is considered to be substantia l based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.  
The overall reason for the amendment: The overall reason for the amendment is to update and/or clarify protocol 
content based on ongoing feedback received during study initiation activities.
Applicable Section(s) Description of Change(s)
Rationale: Indicate that a subject will be excluded if the subject’s depressive symptoms have previously 
demonstrated nonrespon se to esketamine or ketamine in the current major depressive episode.
Synopsis, Study 
Population; 
4.2.Exclusion CriteriaExclusion criterion no.1 has been revised to state that potential subjects will be excluded 
if the subject’s depressive symptoms have previously demonstrated nonresponse to 
“esketamine or ketamine in the current major depressive episode, per clinical judgment”. 
The follow ing criterion for exclusion has been deleted: “Any subjects who have 
previously received esketamine or ketamine for depression.”
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 16Applicable Section(s) Description of Change(s)
Rationale: Clarify that “at least 7 treatments with unilateral ECT” (electroconvulsive therapy) encompasses bilateral 
as well as unilateral ECT treatments.
Synopsis, Study 
Population; 
4.2.Exclusion CriteriaExclusion criterion no.1 now  states “unilateral/bilateral” rather than only “unilateral.”
Rationale: Indicate that subjects who received vagal nerve stimulation in the current depressive episode are 
excluded.
Synopsis, Study 
Population; 
4.2.Exclusion Criteria Exclusion criterion no. 2 was revised to now exclude a subject who has received vagal 
nerve stimulation (VNS) in the current depressive episode. It previously stated subjects 
with a vagal nerve implant were excluded.
Rationale: Clarification of the description of major depressive disorder (MDD) and obsessive compulsive disorder 
in the exclusion criteria.
Synopsis, Study 
Population; 
4.2.Exclusion CriteriaThe text of exclusion criterion no.3. w as modified: 
 “MDD with psychosis” was revised to “MDD with psychotic features” 
 Only S ubjects w ith “current” obsessive compulsive disorder w ill be excluded.
Rationale: Clarification of the conditions for exclusion of subjects w ith coronary artery disease.
4.2.Exclusion Criteria The text of exclusion criterion no.8. w as modified such that the following cardiovascular 
conditions will now be excluded:
 Coronary artery disease with myocardial infarction, unstable angina, or 
revascularization procedure (eg, coronary angioplasty or bypass graft surgery) 
within 12 months before the start of the screening/prospective observational phase. 
Subjects who have had a revascularization perform ed >12 months prior to 
screening and are clinically stable and symptom -free, per investigator’s clinical 
judgment, can be included.
Rationale: Clarification of the wording used for describing a subject’s antihypertensive medication.
4.2. Exclusion Criteria The text of exclusion criterion no. 9 w as revised to now  state “antihypertensive 
medication(s)” rather than “antihypertensive medication regimen.”
Rationale: Clarification of definition of clinically significant ECG abnormalities as defined by QT interval 
corrected according to Fridericia’s formula (QTcF).
4.2. Exclusion Criteria Exclusion criterion no.13 has been revised as follows. The first subbullet in exclu sion 
criterion no. 13 w as separated into tw o subbullets (bold text was added):
 During screening, a QT interval corrected according to Fridericia's formula 
(QTcF )(ms): ≥450 ms; if the QTcF is prolonged on the initial ECG, the 
average QTcF of three ECGs, recorded at least 4 minutes apart, must not be 
≥450 m s.
 On Day 1 (predose), a QT interval corrected according to Fridericia's formula 
(QTcF): ≥450 ms based on the site-evaluated ECG; if the QTcF is prolonged 
on the initial ECG, the average QTcF of three ECGs, recorded at least 4 
minutes apart, must not be ≥450 ms.
In the second subbullet, the bold text was added as shown below :
 Evidence of 2nd and 3rd degree AV block, or1st degree AV block with PR 
interval >200 ms (if the initial PR interval is <240 ms, may repeat the ECG 
once and use average of both readings), complete left bundle branch block 
(LBBB), or complete right bundle branch block (RBBB).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 17Applicable Section(s) Description of Change(s)
Rationale: The use of concomitant medications that prolong the QT interval/corrected QT (QTc) are no longer 
excluded as there is no known QTc increase signal known with esketamine and extensive ECG monitoring is in 
place and precautions in case of increase in QTc are added.
4.2. Exclusion Criteria Exclusion criterion no. 14 has been revised as follows: 
Subject has a history of additional risk factors for Torsades des Pointes (eg, heart failure, 
hypokalemia, family history of Long QT Syndrome) , or the use of concom itant 
medicat ions that prolong the QT/QTc interval .
Rationale: Indicate that the screening test for abnormal ALT and AST may be repeated once during screening if 
there is an explanation for a transient out of range value.
4.2. Exclusion Criteria Text w as added to exclusion criterion no. 15 to specify that a repeat of the screening test  
for abnormal ALT and AST is permitted once during the screening period, per 
investigator discretion, provided there is an explanation for a transient out of range 
value.
Rationale: Clarification that a positive test for cannabinoids on Day 1 is exclusionary, but not at screening.
4.2. Exclusion Criteria Text of exclusion criterion no. 16 w as revised to clarify that a positive test for 
cannabinoids at the start of the screening/prospective phase is not exclusionary; 
however, a positive test for cannabinoids on Day 1 (predose) of the double -blind -
treatment phase is exclusionary.
Rationale: The term “secondary diabetes” was removed from exclusion criterion no. 18 because the criterion st ates 
that any uncontrolled diabetes mellitus is exclusionary.
4.2. Exclusion Criteria The text of exclusion criterion no. 18 w as modified to delete the phrase “or secondary 
diabetes”.
Rationale: Provide clarification that the investigator’s clinical judg ment based on assessment will be used to 
determine eligibility of subjects who have any anatomical or medical condition that may impede delivery or 
absorption of intranasal study drug.
4.2. Exclusion Criteria The text of exclusion criterion no. 20 w as modified to indicate that the “investigator’s 
clinical judgment based on assessment” will be used to determine eligibility.
Redundant text (ie, examples of structural or functional abnormalities) has been deleted.
Rationale: Exclusion criterion no. 21 is no longer required as it is covered as part of exclusion criterion no. 20.
4.2. Exclusion Criteria The text of exclusion criterion no. 21 has been deleted.
Rationale: Clarify that a subject with obstructive sleep apnea can be included if the subject receive s effective 
treatment/therapy, which results in an apnea -hypopnea index of <30.
Synopsis, Study 
Population; 
4.2. Exclusion Criteria The text of exclusion criterion no. 25 has been modified as follows (bold text 
added):
“Subject has a score of 5 on the S TOP -Bang questionnaire, in which case 
obstructive sleep apnea must be ruled out (eg, apnea -hypopnea index [AHI] <30). A 
subject w ith obstructive sleep apnea can be included if he or she is using a positive 
airway pressure device or other treatment/therapy that is effectively treating (ie, 
AHI <30) his or her sleep apnea.”
 In the list of exclusion criteria in the synopsis (Study Population), the text “STOP -
Bang quest ionnaire score of ≥5” has been deleted as this is not necessarily an 
exclusion per exclusion criterion no. 25.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 18Applicable Section(s) Description of Change(s)
Rationale: Clarify that a subject is excluded if the subject has participated in 2 or more interventional studies (for a 
psychiatric condition) with different investigational drugs, or the subject is enrolled in an investigational study, 
which is interventional.
4.2. Exclusion Criteria The text of exclusion criterion no. 26 has been modified as follow s (bold text added):
“Subject has received an investigational drug (including investigational vaccines) or 
used an invasive investigational medical device within 60 days before the start of the 
screening/prospective observational phase, or has participated in 2 or more MDD or 
other psychiatric conditi on clinical interventional studies (with different 
investigational drugs including investigational vaccines or investigational m edical 
devices for each study) in the previous 1 year before the start of the 
screening/prospective observational phase, or is c urrently enrolled in an investigational 
interventional study.”
Rationale: Subjects w ith severe renal impairment (creatinine clearance <30 ml/min) are being excluded (exclusion 
criterion no. 31) as a safety precaution, since the effect of impaired renal cl earance on the pharmacokinetics of 
intranasal esketamine is not fully known and subjects may be more vulnerable to blood pressure increases.
4.2. Exclusion Criteria Exclusion criterion no. 31 for all subjects was added: “Severe renal impairment 
(creatinin e clearance <30 ml/min).”
Rationale: Clarification added to inclusion criterion regarding nonresponse to oral antidepressant treatments in 
current episode of depression. 
Synopsis, Overview of 
Study Design, Study 
Population, Dosage and 
Administration; 
3.1. Overview of Study 
Design; 3.2.1. Study 
Population;
4.1. Inclusion Criteria; 
6.1. 
Screening/Prospective 
Observational Phase; 
9.1.2. 
Screening/Prospective 
Observational PhaseThe text of inclusion criterion no. 3 w as modified to state that the subject mu st:
 Have had nonresponse (≤25% improvement) to ≥2 but ≤5 (if current episode is >2 
years, upper limit applicable to only the last 2 years) oral antidepressant treatments 
in current episode of depression.
 Have had nonresponse confirmed by d ocumented records (eg, 
medical/ph armacy/prescription records, a letter from treating physician, etc.).
 Be taking one of the oral antidepressant treatment(s) with nonresponse that is 
documented on the MGH -ATRQ (ie, oral antidepressant treatm ent must be taken 
for at least 6 weeks at the minimum therapeutic dose with a lack of clinically 
meaningful improvement) at the start of the screening/prospective observational 
phase.
The following text was added to specify the criteria for non-response at the end of the 
screening/observational phase: “Non-response at the end of the screening/prospective 
observational phase is defined as ≤25% improvement in the MADRS total score for 2 
consecutive visits and a MADRS total score of ≥28 for 2 consecutive visits.”
Other sections of the text were revised to co rrespond to the changes in the inclusion 
criterion. 
Rationale: Indicate that the severity of a subject’s depressive symptoms in the current major depressive episode 
must also be confirmed using a Site Independent Qualification Assessment.
Synopsis, Stud y 
Population; 3.2.1. Study 
Population;
4.1. Inclusion Criteria; 
9.1.2. 
Screening/Prospective 
Observational PhaseThe text of inclusion criterion no. 5 w as modified as follows (bold text added): “The 
subject’s current major depressive episode , depression sy mptom  severity (Week 1 
MADRS total score ≥28 required), and antidepressant treatment response in the 
current depressive episode, must be confirmed using the Site Independent Qualification 
Assessment.”
Other sections of the text were revised to correspond t o the changes in the inclusion 
criterion.
Text w as added in Section 3.2.1 (Study Population) indicate that the severity of a 
subject’s depressive symptoms must be confirmed using a Site Independent 
Qualification Assessment.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 19Applicable Section(s) Description of Change(s)
Rationale: Clarify text in incl usion criterion regarding additional lab test for assessing levels of free thyroxine.
4.1. Inclusion Criteria; 
9.1.1 Overview, Table 5; 
9.6 Safety EvaluationsText w as added to inclusion criterion no. 7 to clarify that for any subject (regardless of 
thyro id history), if the TSH value is out of range, a free thyroxine (fT4) w ill be 
conducted. If the fT4 is normal, the subject can be enrolled. If the fT4 value is out of 
range, the subject is not eligible.
The follow ing statements were deleted from inclusion criterion no. 7:
 For those without a pre-existing history of hypothyroidism, a norm al thyroid -
stimulating hormone [TSH] is required at screening.
 If the TSH is below the normal range, free thyroxine (fT4) levels will be measured 
and if fT4 is w ithin the no rmal range the subject can be enrolled.
Other sections of the text were revised to correspond to the changes in the inclusion 
criterion.
Row was added to Table 5 in Section 9.1.1 (Overview) to specify the volume of blood 
per sample used to assess levels offT4, and footnote ‘e’ was added to this table to 
specify that for any subject (regardless of thyroid history), if the TSH value is out of 
range, a free thyroxine will be conducted.
Rationale: The text in inclusion criterion no. 9 w as revised to clarify t he description of methods of birth control for 
a man who is sexually active with a woman of childbearing potential or a w oman who is pregnant.
4.1. Inclusion Criteria The text of inclusion criterion no. 9 w as modified as follows (bold text w as added):
A man who is sexually active with a woman of childbearing potential and has not had a 
vasectomy must agree to use a barrier method of birth control eg, either condom with 
spermicidal foam/gel/film/cream/suppository or partner w ith occlusive cap (diaphragm 
orcervical/vault caps) with spermicidal foam/gel/film/cream/suppository from Day 1 of 
the double -blind induction phase (prior to randomization) through 3 months after the last 
dose of intranasal study medication. During the study (ie, from  Day 1 of the doub le-
blind induction phase, prior to random ization) and for a minimum of 1 
spermatogenesis cycle (defined as approximately 90 days) after receiving the last 
dose of intranasal study m edication, in addition to the user independent highly 
effective m ethod of contraception, a m an 
 who is sexually active with a wom an of childbearing potential must agree to 
use a double -barrier method of contraception (eg, diaphragm  or cervical/vault 
caps plus condom with spermicidal foam /gel/film/cream/suppository)
 who is sexually active with a wom an who is pregnant must use a condom
 must agree not to donate sperm .
Alternatively female partners of childbearing potential may be practicing a highly 
effective method of birth control: eg, established use of oral, injected, or implan ted 
horm onal methods of contraception; placement of an intrauterine device (IUD) or 
intrauterine system (IUS); or male partner sterilization.
Note: If the female partner’s childbearing potential changes after start of the study, a
thefemale partner of a m ale study subject, must begin a highly effective method of birth 
control, as described above.
Rationale: Correct a statement referring to the US prescribing information for duloxetine.
1.2.2.1. Duloxetine The phrase “Although not in the US prescribing in formation” w as deleted from the 
statement regarding evaluation of an initial dose of 30 mg/day as the US prescribing 
information for duloxetine does indicate that for some patients, it may be desirable to 
start at 30 mg once daily for 1 week, to allow  patients to adjust to the medication before 
increasing to 60 mg once daily. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 20Applicable Section(s) Description of Change(s)
Rationale: Text added to provide the details of predose procedures to be follow ed in the event an intranasal 
treatment session is postponed/delayed (w ithin the visit window ) due to a predose vital sign assessment.
Time & Events 
Schedule; 9.6. Safety 
EvaluationsText w as added in the description of safety evaluations to indicate that if an intranasal 
treatment session is postponed/delayed (w ithin the visit window ) due to a predose vi tal 
sign assessment , all time points of the following assessments must be repeated on the 
actual intranasal treatment session day: vital signs, 12-lead ECG, C -SSRS, MOAA/S, 
pulse oximetry, BPRS+, and CADSS.
In the Time & Events Schedule (Screening/prospect ive Observational Phase and 
Double -blind Phase), the text of footnote ‘o’ was revised for consistency with the text 
added in the description of safety evaluations, and footnote ‘o’ w as deleted from the row  
for CGADR assessment.
Rationale: MADRS total scor e is to be recorded at Study Day 22 (Visit 2.7); how ever, in the Time & Events 
Schedule the MADRS assessment was mistakenly omitted at this timepoint.
Time & Events 
ScheduleThe Time & Events Schedule (Screening/prospective Observational Phase and Double -
blind Phase) w as revised to indicate that the MADRS total score is to be recorded at 
Study Day 22 (Visit 2.7).
Rationale: The row  in the Time and Events Schedule showing assessment window s for the MADRS was removed 
due to misunderstandings it was creating relative to the visit windows.
Time & Events 
ScheduleIn the Time & Events Schedule (Screening/prospective Observational Phase and 
Double -blind Phase), the row  for “Remote MADRS interview window” was deleted, and 
the following guidance regarding MADRS as sessment window s was added to footnote 
‘q’: “The MADRS should be administered no more than 2 days prior to the subject’s 
scheduled clinic visit. If performed on the day of the scheduled clinic visit for an 
intranasal treatment session, the MADRS must be pe rformed prior to the intranasal 
treatment session.”
Rationale: Text revised to clarify the arterial oxygen saturation level that requires further monitoring.
9.6. Safety Evaluations Text regarding pulse oximetry measurement was corrected to indicate that postdose 
oxygen saturation levels <93% (not ≤93%) require further monitoring.
Rationale: Clarification of intranasal esketamine dose adjustments which are permitted after Day 15 for 
consistency.
3.2.4 Treatment Groups 
and Dose SelectionThe text in the Intranasal Study Drug section has been revised to clarify that the 
intranasal esketamine dose may be decreased by 28 mg after Day 15, while increases in 
esketamine dose are not permitted after Day 15 (for consistency with Section 6.2, 
Table 4).
Rationale: Remove restriction regarding up -titration in dose during the double -blind induction phase for subjects 
who had a previous down -titration in dose due to elevated blood pressure.
Synopsis, Dosage and 
Administration; 6.2 
Double -blind Induction 
PhaseThe fol lowing sentence has been deleted from the text “No up -titration in dose is 
permitted during the double -blind induction phase if there was a prior down titration due 
to elevated blood pressure.”
Rationale: Clarification of the description for the Hopkins V erbal Learning Test -Revised (HVLT -R) recall test.
Time & Events 
Schedule; 9.6. Safety 
EvaluationsText regarding cognition testing has been revised to clarify the description of the HVLT -
R recall text and to add text indicating that subjects will complete a practice session for 
the computerized cognitive battery, but not the HVLT -R, during the 
screening/prospective observational phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 21Applicable Section(s) Description of Change(s)
Rationale: Indicate that biomarkers will be assessed at the protein and RNA level and provide the rationale for 
recommend ation of subject adherence to a low  fat diet on the day of sample collection.
Synopsis, Biomarker, 
Pharm acogenomic 
(DNA), and Expression 
(RNA) Evaluations; 
3.2.9. Biomarker, 
Pharm acogenomic 
(DNA), and Expression 
(RNA) EvaluationsText w as added to specify that biomarkers will be assessed at both the protein and RNA 
level.
In addition, the following sentence was added: “On the day of biomarker sample 
collection, it is preferred that subjects adhere to low  fat diet (as an alternative to fasting) 
to reduce th e level of postprandial lipemia in blood samples because moderately or 
grossly lipemic specimens may interfere with assay results.”
Rationale: Blood volume table updated to include changes in blood volumes for biomarker (protein/DNA) 
assessment.
9.1.1. O verview, Table 5 Table 5 w as revised as follows:
 Volume of blood sample for Biomarker: protein was changed from 13 mL to 10 mL.
 Volume of blood sample for Biomarker: DNA was changed from 8.5 mL to 6 mL 
 Total Volume of Blood to be collected per subject waschanged from 125.5 mL to 
112.0 mL.
 Deleted footnote ‘d’ Blood volume listed under protein biomarkers represents the 
combined volume of several different collection tubes. 
 In Double -blind Induction Phase section of the table, merged the two rows for 
‘Biom arker: protein visits’ to a single row. Description now states: “Biomarker: 
protein (at Visits 2.1, 2.3, and 2.8). The volume of sample collected at each visit is 
10 mL, and the number of samples per subject w as revised to 3.
Rationale: Clarification of guidance on blood pressure monitoring on intranasal treatment session days, including 
clarification that discontinuation is mandatory for subjects who meet blood pressure criteria on intranasal treatment 
session days for discontinuation from further dosing .
6.2.1. Guidance on 
Blood Pressure 
Monitoring on Intranasal 
Treatment Session DaysIn the heading for the section, the term “Dosing Days” has been replaced w ith 
“Intranasal Treatment Session Days”.
The follow ing revisions were made to clarify guidance on blood pressure monitoring on 
intranasal treatment session days (bold text was added):
“Given the potential for treatment emergent transient elevation in systolic and diastolic 
blood pressure, the following guidance should be followed on intranasal dosing days:
If subsequent to fulfilling the inclusion and exclusion criteria on Day 1 (ie, 
applicable for all other intranasal treatm ent session days after Day 1), asubject ’s 
pre-dose SBP is >150 mmHg and/or DBP is >90mmHg, it is recommended that 
to repeat the blood pressure measurement is repeated after thesubject rests for 10 
minutes in sitting or recumbent position. If after rest and repeated measure ments,
thepre-dose SBP is >150 mmHg and/or theDBP is >90mmHg, then dosing 
should be postponed and the subject scheduled to return on the following day or 
within the given visit window . If the blood pressure elevation still persists on the next 
visit, the subject w ill be scheduled for a consultation by cardiologist , other specialist,
or a primary care physi cian,prior to further dosing.
If at any postdose time point on the dosing day the SBP is 180 mm Hg but <190 mm 
Hg and/or the DBP is 100 mm Hg but <110 mm Hg, further intranasal dosing 
should be interrupted and the subject should be referred to a cardi ologist , other 
specialist, consultation or primary care physician for a follow -up assessment.
 After the assessment by a cardiologist, other specialist, or prim ary care 
physician, if recommended by the referring doctor and provided considered 
appropriate according to the clinical judgment of the investigator for the 
subject is given approval to continue in the study, the subject may continue 
with intranasal dosing if the pre-dose blood pressure at the next scheduled 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 22Applicable Section(s) Description of Change(s)
visit is within the acceptable range (see bullet above).
If at any postdose time point on theadosing day the SBP is 190 mm Hg and/or the 
DBP is 110mm Hg, the subject should must discontinue from further dosing and be 
referred to a cardiologist , other specialist, or prim ary care physician for a follow -up 
assessment.
During the double -blind induction phase, at 1.5 hours postdose, if the SBP is 160 
mm Hg and/or the DBP 100 mm Hg, assessments should continue every 30 minutes 
until:
 the blood pressure is <160 mm Hg SBP and <100 mm Hg DBP ,or
 in the investigator’s clinical judgment, the subject is clinically stable and 
can be discharged from  the study site, or
 until the subject is referred for appropriate medical care if clinically indicated.
If the blood pressure rem ains ≥180 SBP and/or  ≥110 mmHg DBP 2 hours after 
dosing, the subject should be referred for immediate medical treatm ent.
Synopsis, Dosage and 
Administration; 6.2. 
Double -blind Induction 
PhaseFor consistency with exclusion criterion no. 9, the blood pressure requirements in the 
instru ctions for intranasal dosing were revised to state “Prior to intranasal dosing, 
subjects must not have a blood pressure >150 mm Hg systolic and/or >90 mm Hg 
diastolic” instead of “Prior to intranasal dosing, subjects must have a blood pressure 
≤150/90 mm Hg.”
Rationale: Alert site staff to ECG readings that w ould raise safety concerns and necessitate subject w ithdraw al and 
study discontinuation.
9.6. Safety Evaluations The follow ing text was added in the Single, 12 -lead ECG section:
The subject must be discontinued at any time point after baseline (Day 1, predose) if:
 QTcF change from baseline is ≥60 ms AND QTcF >480 ms, or
 QTcF >500 ms.
10.2. Withdraw al from 
the StudyThe follow ing bullet was added to the list of reasons for withdraw al from the study:
 At any time point after baseline (Day 1, predose), the subject has a:
 QTcF change from baseline ≥60 m s AND QTcF >480 ms, or
 QTcF >500 ms
Rationale: Provide further clarification reg arding how the current regimen should remain unchanged for the 
duration of the screening/prospective observational phase and provide the criterion for non -response at the end of 
the screening/prospective observational phase (ie, site investigators are no l onger blinded ).
Synopsis, Overview of 
Study Design, Study 
Population, Dosage and 
Administration; 
3.1. Overview  of Study 
Design; 3.2.1. Study 
Population; 6.1. 
Screening/Prospective 
Observational Phase; 
9.1.2. 
Screening/Prospective 
Observational PhaseText was revised to clarify that:
 At the start of the screening/prospective observational phase the subject’s 
antidepressant treatment, as well as any ongoing medications for depression 
(including adjunctive and augmentation therapies), will continue unchange d at the 
same dosage from the start of Week 1 through the end of Week 4 of the 
screening/prospective observational phase.
 During the screening/prospective observational phase, subjects taking 
benzodiazepines (at dosages equal to or less than the equivalent of 6 mg/day of 
lorazepam) and/or perm itted non-benzodiazepine sleep medications (eg, zolpidem, 
zaleplon) during the screening/prospective observational phase can continue these 
medications, but no dose increases beyond the equivalent of 6 mg/day of 
loraze pam or new benzodiazepine medications are permitted during the 
screening/prospective observational phase.
 Eligible subjects who do not require a tapered discontinuation of their 
antidepressant treatment(s) can proceed immediately into the double -blind 
induction phase.
 Non-response at the end of the screening/prospective observational phase is 
defined as ≤25% improvem ent in the MADRS total score for 2consecutive visits 
and a MADRS total score of ≥28 for 2 consecutive visits.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 23Applicable Section(s) Description of Change(s)
Rationale: Provide clarification that all medication(s) being used for depression must be discontinued after 
completion of the 4 -week prospective observational phase.
Synopsis, Overview of 
Study Design, Dosage 
and Administration; 
3.1. Overview  of Study 
Design; 3.2.2. Study 
Phases; 6.1.
Screening/Prospective 
Observational Phase; 
9.1.2. 
Screening/Prospective 
Observational PhaseText w as revised to clarify that eligible subjects who enter the double -blind phase will 
discontinue all of their current medication(s) being used for antidepressa nt treatment, 
including adjunctive/augmentation therapies.
Rationale: Indicate that during the double -blind induction phase dosing of the oral antidepressant is to follow the 
mandatory titration schedule and doses of oral antidepressant study medication are not to exceed the maximum dose 
defined in the titration schedule.
Synopsis, Dosage and 
Administration; 
3.2.4. Treatment Groups 
and Dose Selection; 
6.2 Double- blind 
Induction Phase; 
9.1.3. Double- blind 
Induction PhaseDeleted text stating that dosing of the oral antidepressant during the double -blind 
induction phase will follow the local prescribing information, with a forced titration 
to the maximum tolerated dose.
Added text stating that dosing of the oral antidepressant during the double -blind 
induction phase will follow a mandatory titration schedule (provided in Attachment 3).
Statement added to indicate that during the double -blind induction phase, doses of 
oral antidepressant study medication are not to exceed the maximum dose defined in 
the tit ration schedule.
Attachment 3 The follow ing statement was deleted from the first paragraph: “Adjustments to the 
titration schedule may be required in other countries in order to conform to local 
prescribing information.”
Rationale: Update and clarificati on to prohibited medications and substances and restrictions during the double -
blind induction phase.
Synopsis, Overview of 
Study Design; 3.1. 
Overvie w of Study 
Design; 4.3. 
Prohibitions and 
RestrictionsThe follow ing text was added to the list of Prohibi tions and Restrictions:
“Subjects taking benzodiazepines (at dosages equal to or less than the equivalent of 6 
mg/day of lorazepam) and/or permitted non -benzodiazepine sleep medications (eg, 
zolpidem, zaleplon) during the screening/prospective observationa l phase can continue 
these medications during the induction phase. No dose increases beyond the equivalent 
of 6 mg/day of lorazepam or new  benzodiazepine medications are permitted during the 
induction phase, with the exception of the use of permitted benzo diazepine rescue 
medication. Benzodiazepines and non -benzodiazepine sleeping medication (eg, 
zolpidem, zaleplon, eszopiclone, and ramelteon) are prohibited w ithin 12 hours prior to 
the start of each intranasal treatment session or cognition testing.”
4.3.Prohibitions and 
RestrictionsLysergic acid diethylamide (LSD) w as added to the list of drugs that will lead to 
discontinuation if detected in the urine drug screen from Day 1 of the induction phase 
through the final visit in the double -blind induction ph ase.
4.3. Prohibitions and 
RestrictionsRemoved restriction stating that subjects should not ingest grapefruit juice, Seville 
oranges, or quinine for 24 hours before intranasal dosing.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 24Applicable Section(s) Description of Change(s)
Rationale: Clarifications for the use of prestudy and concomitant the rapies.
4.3. Prohibitions and 
Restrictions; 8. Prestudy 
and Concomitant 
TherapyClarified that psychotherapy includes cognitive behavioral therapy (CBT); subjects 
receiving CBT must have had therapy ongoing for the last 3 months prior to the 
screening/pro spective observation phase; new CBT is prohibited, but new psychotherapy 
is allowed; and any change in existing therapy or new  therapy must be documented on 
the concomitant therapies form.
8. Prestudy and 
Concomitant TherapyAdded that antidepressant treatm ents which are not listed on the MGH -ATRQ but were 
used or are currently being used as antidepressant treatment in the current depressive 
episode must be recorded on the ‘Concomitant Therapy’ eCRF.
8. Prestudy and 
Concomitant TherapyClarified note rega rding the timing of oral antihypertensive medications relative to 
administration of intranasal study drug.
8. Prestudy and 
Concomitant TherapyClarified that unless clinically indicated, it is recommended that transient increases in 
blood pressure not be treated.
Rationale: Clarifications to Attachment 1 regarding prohibited concomitant medications.
Attachment 1 The follow ing changes were made in Attachment 1 describing prohibited concomitant 
medications with intranasal study medication (esketamine or pl acebo):
 Included the following statem ent proceeding the table listing prohibited 
medications: “Note:  If a medication is part of the antidepressant treatment regimen 
being taken at the time of signing the ICF (ie, start of screening/prospective 
observation al phase), it must be continued unchanged until the end of Week 4 of 
the screening/prospective observational phase. If the investigator determines it is 
clinically appropriate, the antidepressant medication may be tapered during the 
optional, up to 3 -week,taper period”.
 Deleted row  referring to CYP3A4 inhibitors as prohibited concomitant medication.
 Added a new row for prohibited non-stimulant ADHD medications (eg, 
atom oxetine, guanfacine).
 Added new text to comments on the use of antidepressants in this study, stating 
that “Even if used primarily  for sleep, trazodone or low dose tricyclic 
antidepressants are not permitted during the treatment phase”.
Attachment 1  Deleted text in comments on the use of non -benzodiazepine sleeping medication.
 Added phrase“( at dosages less than or equal to the equivalent of 6 mg/day of 
lorazepam)” to describe benzodiazepines in the “Drug Class” column for 
consistency with the text in other sections.
 Provided additional examples of anorexiants (phendimetrazine) that are prohib ited 
as concomitant medication for reasons of safety, anticonvulsants (pregabalin) that 
are permitted when used for indications other that seizures, and psychostimulants 
(methylphenidate, modafinil, armodafinil) that are prohibited due to cardiovascular 
safety.
 Added row for non-vitamin K antagonist oral anticoagulant agents (eg, dabigatran, 
rivaroxaban, apixaban).
 Added statement indicating that pseudoephedrine- containing products should not 
be used w ithin 12 hours prior to an intranasal treatment session.
 Added “Safety and PD interaction” as reason for prohibitions listed for cough/cold 
preparations/nasal solutions containing vasoconstrictors, decongestants.
 The comment regarding thyroid horm one supplements was deleted as it was not 
consistent with the text in inclusion criterion no. 7. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 25Applicable Section(s) Description of Change(s)
Rationale: Clarification of criteria for subject w ithdrawal.
10.2 Withdraw al from 
the StudyText pertaining to subject w ithdraw al from the study was clarified as follows:
 Added the following text to the “Withdraw al of Consent” bullet: “(Note: See 
“Withdraw  of Consent” section below ; this should only be selected as a reason for 
withdrawal if the subject does not agree to any further study assessments or 
procedures. If the subject is agreeable to participating in the Early W ithdraw al visit 
and the follow -up phase, another reason for withdraw al should be selected.)”
 Added text to specify that if the subject w ithdraws from the study before the end of 
the double -blind induction phase, an Early Withdraw al visit is to be performed .
 Added text to detail efforts study personnel must make to contact subjects to 
determine the reason for discontinuation/withdrawal: “This should include at least 3 
telephone calls, certified letters, email requests, etc. To ensure access to follow -up 
subjects, the study sites should attempt to obtain both primary and secondary 
telephone contact numbers (eg, home, work, and mobile phone numbers including 
phone numbers of relatives), as well as other contact information (eg, e-mail 
addresses) from subjects before randomization. In addition, the study site should 
emphasize the importance of follow -up information to the subject before 
randomization.”
 Added text to indicate that subjects w ho withdraw will not be replaced.
 The following text was deleted: “Study drug assigned to the withdrawn subject 
may not be assigned to another subject. If a subject withdraws from the study 
before the end of the double -blind induction phase for reasons other than 
withdrawal of consent, an early  withdrawal visit should be conduct ed within 1 
week of the date of discontinuation, followed by the follow -up phase.”
10.2 Withdraw al from 
the Study Added the following text under a separate heading (“Withdraw al of Consent”) to 
specify the conditions and procedures for withdrawal due to “withdrawal of 
consent”: 
“Every effort will be made in the study to ensure withdraw al of consent is not 
selected as a reason for discontinuation when in fact the subject withdrew  for an 
identifiable reason (eg, due to an adverse event or lack of efficacy).
Subjects who wish to withdraw  from the study should be asked if they are 
agreeable to be contacted to collect follow -up information. Subjects who are not 
agreeable to follow -up contact will be withdrawn from the study as “withdraw al of 
consent.” Subjects who no longer wish to take study drug but agree to provide 
follow -up inform ation will be withdrawn from the double -blind induction phase 
with the reason noted as “Other” and w ill specify the reason why. 
For a subject who withdraws consent, it is recommended that the subject withdraw 
consent in writing; if the subject refuses or is physically unavailable, the study site 
should document and sign the reason for the subject’s failure to withdraw consent 
in writing and maintain it with the subject’s source records.
The investigator will be responsible for making all required notifications to the 
Institutional Review Board (IRB) or Independent Ethics Committee (IEC).”
10. Subject 
Com pletion/Withdrawal; 
16.2.5. Long -Term  
Retention of Samples 
for Additional Future 
ResearchAdded a separate heading (10.3 Withdraw al From  the Use of Samples in Future 
Research) for description of withdrawal from the use of research samples. The text in 
this section has not been changed.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 26Applicable Section(s) Description of Change(s)
Rationale: A diary has been added to record oral antidepressant use, and information regarding oral antidepressant 
use and accountability has been clarified.
Synopsis, Dosage and 
Administration;
Time & Events 
Schedule;
6.2. Double -Blind 
Induction Phase;
7. Treatment 
Com pliance;
15. Study -Specific 
Materi alsThe follow ing changes were made:
 Text added to indicate that a diary will be provided for subjects to keep a record of  
oral antidepressant study medication use, to be review ed and updated (if 
applicable), and returned at the end of the double- blind induction phase, in the 
event of an early withdraw al, or at the end of the follow -up phase.
 Text regarding the timing of oral antidepressant medication administration has 
been revised to now state: “On intranasal dosing days, it is recommended the oral 
antide pressant medication not be taken until at least 3 hours after the intranasal 
treatment session.”
 Row in the Time & Events Schedule (Screening/prospective Observational Phase 
and Double -blind Phase) for “Additional supply of oral antidepressant” has been 
deleted and the inform ation has been added to the row “Dispensing of new oral 
antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine XR)”.
 Text revised to indicate that antidepressant treatment adherence will be assessed b y 
performing pill coun ts (ie, compliance check) and drug accountability during the 
follow -up phase as well as the double -blind induction phase.
Rationale: Provide further clarification regarding site staff training requirements for intranasal treatment sessions.
Synopsis, Dos age and 
Administration;
6.2. Double -blind 
Induction PhaseText revised to state that a site staff member with training in cardiopulmonary 
resuscitation (eg, Basic Life Support course or equivalent courses) that is up to date per 
local regulations must be p resent with the subject during the intranasal treatment 
sessions and the postdose observation period.
Rationale: Update list of study -specific materials
15. Study -Specific 
MaterialsGuidance document for the use of the MGH -ATRQ has been added.
Rationale: Clarification of study site personnel availability for on -site monitoring visits.
17.8. Monitoring Text revised to now  state: “It is expected that study -site personnel will be available to 
provide an update on the progress of the study at the study site .”
Minor revisions were also made to clarify the description of source documents and the 
comparison of recorded data with source data.
Rationale: Clarification of the content of data in the electronic case report form (eCRF)
17.11. Use of 
Information and
PublicationText revised to now  stipulate that the Clinical Study Report generated by the sponsor 
will contain eCRF data from all study sites that participated in the study and will 
represent uploaded data transferred from external service providers into the sponsor’s 
database.
Rationale: Include published data relating to adverse events associated w ith use of esketamine.
1.1.2.3. Safety and 
TolerabilityAdditional text added to include published data relating to adverse events associated 
with short -term use of esketamine.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 27Applicable Section(s) Description of Change(s)
Rationale: Clarification of text regarding oral antidepressant medication use in the follow -up phase
Synopsis, Overview of 
Study Design; Dosage 
and Administration; 
Time & Events 
Schedule; 3.1. Overview 
of Study Design; 6.3. 
Follow -up Phase; 9.1.3. 
Double -blind Induction 
Phase; 9.1.4. Follow -up 
PhaseText revised to now  state that following the 4 -week double blind treatment phase, the 
oral antidepressant medication should be continued for the 2 weeks of the follow -up 
phase unless determ ined as not clinically appropriate.
Rationale: Clarification of the language regarding subjects who develop treatment emergent ulcerative cystitis to 
indicate the discontinuation of such subjects is mandatory.
3.2.6 Safety 
Evaluations; 9.6. Safety 
Evalua tionsUpdated/ added text in these sections describing the BPIC -SS and instructions for 
discontinuing due to ulcerative cystitis, to read as follows,: “If a subject is determined to 
have a diagnosis of ulcerative cystitis the subject must be discontinued f rom the study 
and followed up with appropriate medical care.”
Rationale: Minor clarifications to the text were made.
Synopsis, Overview of 
Study DesignFor consistency with the information in Section 9.1.2 (Screening/Prospective 
Observation Phase), text in the synopsis regarding the study criteria for nonresponse has 
been revised to now state “The site investigators will be blinded to the study criteria for 
nonresponse; therefore, this information is maintained in a separate document.”
Time & Events 
Sche duleAdded footnote “r” to Visit 2.1 C -SSRS (Since Last Visit) assessment to indicate this is 
only performed for subjects who do not have Visit 1.3 and 2.1 occur on the same day.
1. Introduction The abbreviation TRD is now defined as “treatment -resistant depression”.
Text updated to indicate that the description of the mechanism of action of ketamine 
applies to esketamine as well.
1.1.2.2. 
Pharm cody namics and 
EfficacyThe follow ing text was added: “In Study ESKETINTRD2003, Panel A was conducted in 
the Uni ted States and Belgium and Panel B in Japan.”
4. Study Population Text revised to now  state: “If there is a question about the inclusion or exclusion criteria 
below , the investigator must consult with the appropriate sponsor representative and 
resolve any issues before enrolling a subject in the study. Waivers are not allowed.”
6.1. 
Screening/Prospective 
Observational PhaseFor consistency with other sections, a sentence was added to state that the sponsor w ill 
not supply antidepressant medication(s) duri ng the screening/prospective observational 
phase.
9.2.1.1. Primary 
Efficacy EvaluationThe MADRS item previously described as “interest level” was changed to “inability to 
feel (interest level)”.
9.3. Pharmacokinetics The follow ing text was added: “Whole blood samples will be used to evaluate the PK of 
esketamine. Serum collected for PK may additionally be used to evaluate safety or 
efficacy aspects that address concerns arising during or after the study period. Genetic 
analyses will not be performed on t hese serum samples. Subject confidentiality will be 
maintained”.
9.6. Safety Evaluations The statement in the section regarding vital signs now reads: “B lood pressure and 
pulse/heart rate measurements w ill be assessed in a supine position with a completel y 
automated device or using manual techniques”.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 28Applicable Section(s) Description of Change(s)
12.3.2. Serious Adverse 
EventsWith regard reporting serious adverse events, the following exception to reporting 
hospitalization of a subject has been modified to start: “For convenience the investigator 
may choose to hospitalize the subject during a treatment period”.
16.2.2. Independent 
Ethics Committee or 
Institutional Review 
Board (IEC/IRB)The phrase “where required” has been added to the following statement: “At least once a 
year, the IEC/IRB will be asked to review  and reapprove this study”.
17.4. Source 
DocumentationText has been revised to reflect current requirements for source documents.
17.5. Case Report Form 
Com pletionText has been revised to reflect current requirements for completion of CR Fs.
Throughout the protocol Minor corrections have been made to the abbreviations and definitions of abbreviations. 
Minor edits have been made that do not change the meaning of the text.
Rationale: Minor errors w ere noted.
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
Amendment INT -1(08 June 2015)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.  
The overall reason for the amendment: The overall reason for the amendment is to allow for a 28 mg dose 
throughout the study, based on pharmacokinetic data from study ESKETINTRD1012 in elderly subjects.
Applicable Section(s) Descri ption of Change(s)
Rationale: Based on pharmacokinetic data from study ESKETINTRD1012 a change was made to allow  a 28 m g 
dose of esketamine throughout the study which could potentially improve safety and tolerability
1.1.2.1. 
Pharm acokinetics and 
Product Metabolism; 
1.1.2.3. Safety and 
TolerabilityDescription of preliminary pharmacokinetic results for study ESKETINTRD1012 w as 
added in addition to a safety overview from the study.
1.1.2.2. 
Pharm acody namics 
and EfficacyJustification statement for includi ng the 28 mg dose beyond Day 1 w as added.
Synopsis Dosing and 
Administration;
3.1. Overview  of 
Study Design;
3.2.4. Treatment 
Groups and Dose 
SelectionChange made to allow  28 mg dose of esketamine throughout the study, not just on Day 1. 
New  table added to describe dose titration guidance.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 29Applicable Section(s) Descri ption of Change(s)
Synopsis;
1.2. Active 
Com parators in 
Double -blind 
Induction Phase; 
1.3. Overall Rationale 
for the Study;
2.1. Objectives;
3.1. Overview  of 
Study Design;
3.2.4. Treatment 
Groups and Dose 
Selection;
6.2. Double -Blind 
Induction Phase;
9.1.3. Double- Blind 
Induction PhaseAdded 28 mg to the list of intranasal doses of esketamine used in this study. Removed 
references of 28 mg only being allowed on Day 1.
Rationale: More conservative blood pressure parameters related to pat ient dosing were incorporated to improve 
subject safety
Synopsis Dosing and 
Administration; 
6.2. Double -blind 
Induction Phase; 
6.2.1. Guidance for 
Blood Pressure 
Monitoring on Dosing 
DaysAdded that prior to intranasal dosing, subjects must have a pre -dose blood pressure ≤ 
150/90 mm Hg and prior to dose escalation, subjects must have had  a post -dose blood 
pressure, on the prior intranasal dosing day, of  < 180 mm Hg for systolic and  <100 mm 
Hg for diastolic blood pressure.
Rationale: Correction to Day 28 study window
Time & Events 
ScheduleThe study window  for Day 28 of the induction phase was incorrectly listed as ±2 days. 
This w indow  has been corrected to be - 1 day.
Rationale: Collection of blood sample for Biom arker, Pharmacogenomic (DNA), and Express ion (RNA) 
Evaluations was moved to Study Day 28 so that it corresponds w ith the hematology sample collection
Time & Events 
ScheduleCollection of blood sample for Biomarker, Pharmacogenomic (DNA), and Expression 
(RNA) Evaluations was moved to Study Day 28 from the original Study Day 25.
Rationale: The frequency of assessments of the Sheehan Disability Scale was increased follow ing feedback from 
the FDA
Time & Events 
ScheduleAn additional assessment for the SDS was added on Day 15 of the Induction Phase.
Rationale: Footnote for predose procedures to be follow ed in case dosing is delayed (w ithin visit windows).
Time & Events 
ScheduleA footnote ‘o’ was added to Study Drug -Intranasal esketamine or placebo.
Rationale: Footnote for rescheduling smell tes t assessments in case the subject has significant nasal congestion
Time & Events 
Schedule;
9.6 UPSIT and Smell 
Threshold TestA footnote ‘p’ was added to UPSIT and Smell Threshold Test.
A note for rescheduling UPSIT and Smell Threshold Test in case of na sal congestion was 
added.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 30Applicable Section(s) Descri ption of Change(s)
Rationale: Study drug accountability was added at tw o weeks after the last intranasal dose
Time & Events 
ScheduleAn assessment for study drug accountability was added at Visit 3.2 of the follow -up phase.
Rationale: Inclusion c riteria modified to enroll subjects w ith a normal thyroid -stimulating hormone function or free 
thyroxine levels in case of subjects with no pre -existing history of hypothyroidism to ensure that the subject is 
medically stable
4.1. Inclusion Criteria 
Direct- entry Subjects; Inclusion criterion for direct -entry subjects was modified to ensure a norm al 
thyroid -stimulating horm one [TSH] function in case of subjects without a 
pre-existing history of hypothyroidism. If the TSH is below  the norm al 
range, free thyroxine (fT4) levels will be measured and if fT4 is within the 
norm al range the subject can be enrolled.
Rationale: Inclusion criterion was expanded to include subjects using specific tricyclic antidepressants at a dose 
below  the MGH -ATRQ minimum therapeuti c dose.
4.1. Inclusion Criteria 
Direct -entry SubjectsInclusion criteria for direct -entry subjects w as modified for accepting specific tricyclic 
antidepressants which are being taken at a dose below  the MGH -ATRQ minimum 
therapeutic dose but achieve a bloo d level that is within the therapeutic range.
Rationale: Exclusion criteria expanded to include additional DSM -5 diagnostic codes for intellectual disability and 
autism spectrum disorder
Synopsis Study 
Population;
4.2. Exclusion 
Criteria Direct -entry 
SubjectsExclusion criterion for direct -entry subjects was expanded to include additional DSM -5 
diagnostic codes for intellectual disability as well as autism spectrum disorder.
Rationale: Exclusion criteria modified to exclude all subjects who have previous ly received esketamine or ketamine 
regardless of the type of response based on PMDA feedback
Synopsis Study 
Population;
4.2. Exclusion 
Criteria Direct -entry 
SubjectsExclusion criterion was modified to exclude subjects who have previously received 
esketam ine or ketamine.
Rationale: Clarification of dosing for subjects using an intranasal decongestant
6.2 Double- blind 
Induction PhaseText describing the guidance for use of an intranasal decongestant to reduce congestion 
before administering esketamine.
Rationale: Accounting for blood volume to match inclusion criteria
9.1.1 Overview Six mL blood accounting for determining tricyclic antidepressant blood levels of specific 
tricyclic antidepressants which are being taken at a dose below  the MGH -ATRQ minimum
therapeutic dose.
Rationale: Correction to match T&E Schedule
9.1.1 Overview Volume of blood to be collected from each user was modified to include 2.5 mL for 
biomarker RNA in the screening/prospective observational phase thereby increasing total 
volume collected to 125.5 mL.
Rationale: Correction to description of MMSE
9.7. Other Evaluations The description of the MMSE was incorrect. The statement “attention (total score, 5), 
calculation (total score, 5)” was changed to “attention and calculation (tot al score, 5)”.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 31Applicable Section(s) Descri ption of Change(s)
Rationale: Clarification of  scoring of the PAQ assessments
9.7. Other Evaluations Text describing scoring of the PAQ was revised to indicate it is based on Question 1 (not 
1c through 1f). 
Rationale: Clarification that SIGMA is the struc tured interview guide of the MADRS
9.2.1.1 Primary 
Efficacy EvaluationThe follow ing sentence was added to describe the MADRS “The structured interview 
guide for the MADRS (SIGMA) will be used for each administration”.
Rationale: List of clinical laboratory tests revised to align with other protocols in the program
9.6. Safety 
EvaluationsTotal bilirubin was added to the serum chemistry panel.
Rationale: Correction to Site Independent Qualification Assessment
9.7. Other Evaluations Reference to telepho ne contact w as rem oved from the description of the Site Independent 
Qualification Assessment.
Rationale: Update to include new template text for reporting abnormal pregnancy outcomes
12.3.3. Pregnancy Instructions for the reporting of abnormal pregnancy outcomes ( eg, spontaneous abortion, 
fetal death, stillbirth, congenital anomalies, ectopic pregnancy) w ere added.
Rationale: Clarification of the supply of oral antidepressant that will be provided to subjects entering the follow -up 
phase
Time & Events 
ScheduleFootnote “n” was added to the Induction Phase T&E stating that subjects entering the 
follow -up phase will be provided with a 2 week supply of oral antidepressant.
Synopsis Overview of 
Study Design and 
Dosage and 
Administration; 
16.1. Study -specif ic 
Design 
Considerations; 
6.2 Double- blind 
Induction Phase;
9.1.4 Follow -up PhaseChange the supply of oral antidepressant given during the follow -up phase from 4 w eeks to 
2 weeks.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 32SYNOPSIS
A Randomized, Double -blind, Multicenter, Active -controlled Stu dy to Evaluate the Efficacy, Safety, 
and Tolerability of Intranasal Esketamine Plus an Oral Anti depressant in Elderly Subjects with 
Treatment -resistant Depression
Study Acronym: TRANSFORM -3
Major depressive disorder (MDD) ,a serious, recurrent, and disabl ing psychiatric illness ,is the second 
leading cause of years lost to disability worldwide .MDD is associated with excess mortality and with 
years of potential life lost .About 30% of patients fail to achieve remission despite treatment with multiple 
antidepressant medications, and are considered to have treatment -resistant depression (TRD). There is a 
significant need to develop novel treatments based upon relevant pathophysiologic pathways underlying 
MDD for the rapid relief of symptoms of depression, esp ecially in patients with TRD.
Depression in later life, traditionally defined as age older than 65years , is associated with disability, 
increased mortality, and poorer outcomes from physical illness . In addition, the condition is often under -
recognized and under -treated. In the PRISM -E study, a large study of older patients with MDD , 71% of 
the patients did not rem it even after 6 months of standard of care treatment in specialty or integrated care 
treatment centers . Factors associated with non-remission included severity of depression at baseline, a 
family history of depression, comorbid anxiety, and general medical comorbidity. According to the World 
Health Organization (WHO )data, proportionately more people aged over 65 years commit suicide than 
any other age group, and most have major depression. Older people who attempt suicide ,are more likely 
to die than younger people, while in those who survive, their prognosis is worse.
Ketamine and esketamine (S-ketamine, the Senantiomer of ketamine) are approved and widely used for 
the induction and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) administration. 
The desired analgesic -anesthetic effects of ketamine and esketamine are attributed to the blockade of 
ionotropic N-methyl -D-aspartat e (NMDA) glutamate receptors. The mechanism of action of ketamine and 
esketamine is distinct from conventional monoaminergic antidepressant treatments .Ketamine and 
esketamine profoundly affect fast excitatory glutamate transmission, increase brain -derived neurotrophic 
factor (BDNF) release, and stimulate synaptogenesis .
Janssen Research & Development (JRD) is developing intranasal esketamine as an antidepressant 
therapy . A higher NMDA receptor affinity of esketamine , as compared with ketamine, allows a lower 
volume of medication to be administered via the non-invasive and rapidly -absorbed intranasal route.
The current study is being conducted to evaluate the efficacy, safet y, and tolerability of flexibly -dosed 
intranasal esketamine ,plus a newly initiated oral antidepressant ,in elderly subjects with TRD. The study 
will serve as a pivotal Phase 3 short -term efficacy and safety study in support of regulatory agency 
requirements for registration of intranasal esketamine for the treatment of TRD.
OBJECTIVES AN D HYPOTHESIS
Primary Objective
The primary objective of this study is to evaluate the efficacy of switching elderly subjects with TRD 
from a prior antidepressant treatment (to which they have not responded) to flexibly dosed intranasal 
esketamine (28 mg, 56 mg or 84 mg) plus a newly initiated oral antidepressant ,compared with switching 
to a newly initiated oral antidepressant (active comparator) plus intranasal placebo, in improving 
depressive sympt oms, as assessed by the change from baseline in the Montgo mery -Asberg Depression 
Rating Scale (MADRS) total score from Day 1 (pre-randomization )to the end of the 4-week double -blind 
induction phase . 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 33Secondary Objectives
To assess the effect of intranasal esketamine plus a newly initiated oral antidepressant com pared with
a newly initiated oral antidepressant (active comparator) plus intranasal placebo onthe following
parameters in elderly subjects with TRD :
o Depression response rates
o Depression remission rates
o Overall severity of depressive illness
o Health- related quality of life and health status
To investigate the safety and tolerability of intranasal esketamine plus a newly initiated oral 
antidepressant compared with a newly initiated oral antidepressant (active comparator) plus intranasal 
placebo in elderly subjects with TRD, including the following :
o Treatment -emergent adverse events (TEAEs), including AEs of special interest
o Local nasal tolerability
o Effects on heart rate, blood pressure, respiratory rate, and blood oxygen saturation
o Effects on alertness and s edation
o Potential psychosis -like effects
o Dissociative symptoms 
o Potential e ffects on cognitive function 
o Potential effects on suicidal ideation/behavior 
o Potential treatment -emergent symptoms of cystitis and/or lower urinary tract symptoms 
o Potential withd rawal and/or rebound symptoms following cessation of intranasal 
esketamine treatment
o Potential effects on sense of smell 
To assess the pharmacokinetic s(PK) of intranasal esketamine in elderly subjects with TRD receiving  
intranasal esketamine plus a newly -initiated oral antidepressant
Exploratory Objectives
 To assess the PK/pharmacodynamic (PK/PD) relationship of intranasal esketamine and MADRS 
total score in elderly subjects with TRD.
 To assess the potential relationship of biomarkers with response/nonre sponse to intranasal 
esketamine or oral antidepressants inelderly subjects with TRD.
Hypothesis
The hypothesis for this study is that ,in elderly subjects with TRD, switching from a failed antidepressant 
treatment to intranasal esketamine plus a newly initiated oral antidepressant is superior to switching to a 
newly initiated oral antidepressant treatment (active comparator) plus intranasal placebo in improving 
depressive symptoms.
OVERVIEW OF STUDY DESIGN
This is a randomized, double -blind, active -control led, multicenter study in male and female elderly 
subjects with TRD to assess the efficacy, safety, and tolerability of flexibly dosed intranasal esketamine 
(28 mg, 56 mg or 84 mg) plus a newly initiated oral antidepressant, compared with a newly initiated oral 
antidepressant (active comparator) plus intranasal placebo.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 34The study has 3 phases which are briefly described below.
Screening/prospective observational phase (4 -week duration + optional 3 -week taper period )
This phase will prospectively assess treatment response to the subject’s current oral antidepressant
treatment regimen. 
At the start of the screening/prospective observ ational phase, the subject must have had documen ted 
nonresponse to at least one antidepressant treatment (based on MGH -ATRQ criteria) in the current 
episode of depression, andthe subject is taking a different oral antidepressant treatment(s) (on the MGH -
ATRQ) for at least the previous 2weeks at or above the minimum therapeutic dose. This antidepressant 
treatment, as well as any other ongoing medications being taken for depression at screening (including 
adjunctive and augmentation therapies), will continue from the start of Week 1 through the end of Week 4 
of the screening/prospective observational phase .Dose adjustment is permit ted per clinical judgment, but 
the oral antidepressant treatment is to remain at or above the minimum therapeutic dose (per the MGH -
ATRQ) through the end of Week 4.
After 4 weeks, subjects who are nonresponders to their current oral antidepressant treatment may be 
eligible to proceed to the double -blind induction phase. Non-response at the end of the 
screening/prospective observational phase is defined as ≤25% improvement in the MADRS total score 
from Week 1 to Week 4 and a MADRS total score of ≥24on Week 2 and Week 4. 
Eligible subjects who are entering the double -blind induction phase will discontinue all of their current 
medication(s) being used for antidepressant treatment , including adjunctive/augmentation therapies. Of 
note, subjects taking benzodiazepines (at dosages equal to or less than the equivalent of 6 mg/day of 
lorazepam) and/or permitted non-benzodiazepine sleep medications (eg, zolpi dem, zaleplon) during the 
screening/prospective observational phase can continue these medications, but no dose increases beyond 
the equivalent of 6 mg/day of lorazepam or new benzodiazepine medications are permitted during the 
screening/prospective observ ational phase . If clinically indicated, a subject’s current antidepressant 
treatment (s) may be tapered and discontinued over an additional, optional period ofup to 3week sper the 
local prescribing informa tion or per clinical judgment. This 3week period may also be used to optimize 
medical management if needed to facilitate subject participation (eg, treatment of blood pressure or 
diabetes, wean from other medications, etc,). In such cases, if there is no planned taper, the oral regimen 
should be continue d in the interim and then discontinued by Day 1 of the double -blind induction phase.
As a new oral antidepressant will be initiated on Day 1 of the double -blind induction phase, eligible 
subjects who do not require a tapered discontinuation of their antidepressant treatment (s) can proceed 
immediately into the double -blind induction phase.
Double -blind induction phase (4 -week duration)
Approximately 148 eligible subjects will be randomly assigned at a 1:1 ratio (n=74per treatment arm) to 
receive double -blind intranasal treatment with either esketamine [28 mg, 56 mg or 84mg], or placebo , 
starting with an initial dose of 28 mg on Day 1 . The intranasal treatment sessions (esketamine or placebo) 
will occur twice weekly. In addition, all subjects will initiate a new, open- label oral antidepressant on Day 
1 that will be taken daily forthe duration of thisphase. The assigned oral antidepressant will be 1 of 4 
oral antidepressant medications (duloxetine, escitalopr am, sertraline, or venlafaxine extended release 
[XR] ) that the subject has not previously had a nonresponse to in the current depressive episode, has not 
been previously intolerant to (lifetime), and is availabl e in the participating country .
Subjects taking benzodiazepines (at dosages equal to or less than the equivalent of 6 mg/day of 
lorazepam) and/or permitted non-benzodiazepine sleep medications (eg, zolpidem, zaleplon) during the 
screening/prospective observational phase can continue these medications during the induction phase. No 
dose increases beyond the equivalent of 6 mg/day of lorazepam or new benzodiaz epine medications are 
permitted during the induction phase, with the exception of the use of permitted benzodiazepine rescue 
medication.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 35After completing the double -blind induction phase, subjec ts may be eligible to participate in the 
subsequent Study ESKETINTRD3004 if they meet all other study entry criteria. Subjects who do not 
complete the double -blind induction phase of this study will not be eligible to participate in the 
ESKETINTRD3004 study. ESKETINTRD3004 is a long -term open -label safety study involving repeated 
open -label treatment sessions of intranasal esketamine.
If a subject withdraws from the study before the end of the double -blind induction phase for reasons other 
than withdrawal of consent, an Early Withdrawal visit should be conducted within 1 week of the date of 
discontinuation, followed by the follow -up phase.
Follow -up phase (2 -week duration)
This phase will include all subjects who withdraw early before the end of the double -blind induction 
phase , or choose not to participate ,in the subsequent ESKETINTRD3004 safety study, and have received 
at least 1 dose of intranasal study medication in the double -blind induction phase. There will be no 
intranasal treatment sessions administ ered during this phase.
At the start of the follow -up phase, further clinical/standard of care for the treatment of depression will be 
arranged by the study investigator and/or the subject’s treating physician. All subjects will be provided 
with an additio nal 2-week supply of the oral antidepressant medication to ensure that there is no 
interruption of oral antidepressant therapy during the transition to further clinical/standard of care. The 
decision to continue the oral antidepressant in this phase will be at the discretion of the investigator .
However , in order to better assess potential withdrawal symptoms from intranasal study medication and 
facilitate maintenance of clinical benefit following cessation of intranasal dosing , the oral antidepressant 
medi cation should be continued for the 2 weeks of the follow -up phase unless determined as not clinically 
appropriate.
Taking into consideration the up to 3-week optional taper period, the maximum duration of an individual 
subject’s study participation will be up to 13 weeks (for subjects completing the follow -up phase).
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study.
STUDY POPULATION
The study population will include elderly men and women, 65 years (inclusive) and older, who meet the 
Diagnostic and Statistical Manual of Mental Disorders (5th Edition; DSM -5) diagnostic criteria for 
single -episode MDD ( if a single episode MDD , the duration of the episode must be 2years) or recurrent 
MDD, without psychotic features, based upon clinical assessment, and confirmed by the 
Mini -International Neuropsychiatric Interview (MINI) .In addition, the subject must have an Inventory of 
Depressive Symptomatology- Clinician rated, 30-item (IDS -C30) total score of 31, which corresponds to 
moder ate to severe depression.
At the start of the screening/p rospective observational phase, subjects must have had a nonresponse (ie, 
lack of clinically meaningful improvement , defined as ≤25% improvement )to 1but 8(if current
episode is >2 years, upper limit isonly applicable to the last 2 years) oral antidepressant treatment staken 
at an adequate dosage and for an adequate duration, as assessed using the Massachusetts General 
Hospital –Antidepressant Treatment Response Questionnaire (MGH -ATRQ) and docume nted by records 
(eg, medica l/pharmacy /prescription records, a letter from the treating physician , etc.) for the current 
episode of depression. 
In addition, the subject must currently be taking a different oral antidepressant treatment (on the MGH -
ATRQ) for at least the previous 2 weeks at or above the minimum therapeutic dose. This antidepressant 
treatment, as well as any other medications being used for depression treatment (including 
adjunctive/augmentation therapies), will continue from the start of Week 1 through the end of Week 4 of 
the screening/prospective observational phase . Dose adjustments are permitt ed per clinical judgment, but 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 36the oral antidepressant treatment is to remain at or above the minimum therapeutic dose (per the MGH -
ATRQ) through to the end of Week 4.
Non-response at the end of the screening/prospective observational phase is defined as ≤25% 
improvement in the MADRS total score and a MADRS total score of ≥24on Week 2 and Week 4.
Treatment -resistant depression (TRD )is defined as a lack of clinically meaningful improvement after 
treatment with at least 2 different antidepressant agents prescribed in adequate dosages for adequate 
duration.
The subject’s current major depressive episode , depression symptom severity (Week 1 MADRS total 
score ≥24 required), and antidepressant treatment response in the current depressive episode
(retrospectively assessed) must be deemed valid for participation in the clinical study based on a Site
Independent Qualification Assessment. The Site Independent Qualification Assessment is a tool to 
facilitate subject selection for MDD clinical studies, with a goal to ensure enrollment of subjects who 
have symptoms that reflect the current state of illness and that these symptoms can be reliably measured 
with appropr iate measurement tools.
Potential subjects will be excluded from participating in the study if they have previously demonstrated 
nonresponse of depressive symptoms to esketamine or ketamine in the current major depressive episode, 
to all 4 of the oral antidepressant treatment options available for the double -blind induction phase (ie, 
duloxetine, escitalopram, sertraline, and venlafaxine XR) in the current major depressive episode (based 
on MGH -ATRQ), or to an adequate course of treatment with electroconvul sive therapy (ECT) in the 
current major depressive episode, defined as at least 7 treatments with unilateral /bilateral ECT. Subjects 
who received vagal nerve stimulation (VNS) or who received deep brain stimulation (DBS) in the current 
major depressive episode will be excluded. Subjects will also be excluded if they have a current or prior 
DSM -5 diagnosis of a psychotic disorder or MDD with psychotic features , bipolar or related disorders 
(confirmed by the MINI), obsessive compulsive disorder (current only) , neurodegenerative disorder (eg, 
Alzheimer’s Disease, Vascular dementia, Parkinson’s disease with clinical evidence of cognitive 
impairment ) or evidence of mild cognitive impairment (MCI), a Mini Mental State Examination (MMSE) 
score <25 or <22 for those subjects with less than an equivalent of high school education, intellectual
disability (only DSM -5 diagnostic code s317, 318.0, 318.1, 318.2, 315.8, and 319), autism spectrum 
disorder, borderline personality disorder, antisocial personality disorder, hist rionic personality disorder, or 
narcissistic personality disorder; if they have homicidal ideation/intent or suicidal ideation with some 
intent to act within 6 months prior to the start of the screening/prospective observational phase per the 
investigator’ s clinical judgment and/or based on the Columbia Suicide Severity Rating Scale (C-SSRS); 
or if they have a history of moderate or severe substance or alcohol use disorder according to DSM -5 
criteria .
DOSAGE AND ADMINISTRATION
Screening/ prospective observat ional phase
At the start of the screening/prospective observational phase, the subjects must have had documented 
nonresponse to at least one antidepressant treatment (based on MGH -ATRQ criteria) in the current 
episode of depression, and the subject is taking a different oral antidepressant treatment (on the MGH -
ATRQ ) for at least the previous 2 weeks at or above the minimum therapeutic dose. This antidepressant 
treatment, as well as any other medications being taken for depression at screening (including 
adjunctive/augmentation therapies), will continue from the start of Week 1 through the end of Week 4 of 
the screening/prospective observational phase for the prospective observation of a response or a 
nonresponse . Dose adjustment is permitted per clinical judgment, but the oral antidepressant treatment is 
to remain at or above the minimum therapeutic dose (per the MGH- ATRQ) through the end of Week 4.
The sponsor will not supply these antidepressant medications . Antidepressant treatment adherence during 
this phase will be assessed using the Patient Adherence Questionnaire (PAQ).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 37Subjects who are eligible to enter the double -blind induction phase : After the completion of 4 weeks of 
prospective antidepressant treatment and assessment of the antidepressant treatme nt response, all 
antidepressant treatment (s) will be discontinued, including adjunctive/augmentation therapies. If 
clinically indicated (eg, antidepressant treatments with short half-lives, such as paroxetine and
venlafaxine XR, or tolerability concerns ), the antidepressant treatment (s)may be tapered off and stopped 
over a period of up to 3 weeks per the local prescribing information or clinical judgment .
As a new oral antidepressant will be initiated on Day 1 of the double -blind induction phase, eligible 
subjects who do not require a tapered discontinuation of their antidepressant treatment (s) can proceed 
immediately into the double -blind induction phase .
Double -blind induction phase
During this phase, subjects will receive double -blind intranasal treatmen t with esketamine or placebo. In 
addition, subjects will simultaneously initiate a new, open -label oral antidepressant on Day 1 that will be 
continued for the duration of this phase.
Intranasal Study Medication
All subjects will self-administer the intrana sal study drug (esketamine or placebo) at treatment sessions 
twice a week for 4 weeks at the study site. The first treatment session will be on Day 1. Intranasal 
treatment sessions should not take place on consecutive days .
 Prior to the first intranasal dose on Day 1, subjects will practice spraying (into the air, not 
intranasally) a demonstration intranasal device that is filled with placebo solution.
 Instructions for intranasal dosing:
 After Day 1 (dose 28 mg), a ll dosing decisions are to be determined by the investigator based on 
efficacy and tolerability.
 Prior to intranasal dosing, subjects must not have a blood pressure >150 mm Hg systolic and/or 
>90 mm Hg diastolic.
 Prior to any dose escalation, subjects must have had a post-dose blood pressure, on the prior 
intranasal dosing day, of <180 mm Hg for systolic and <100 mm Hg for diastolic blood 
pressure.
 Dose t itration of intranasal esketamine will be performed as outlined in the table below:
Dose Titration of Intranasal Esketamine*
Day Dose Dose Titra tion Guidance
Day 1 28 mg
Day 4 28 or 56 mg The dose may remain at 28mg or be increased to 56mg, as 
determined by the investigator based on efficacy and tolerability
Days 8, 11, 15 28, 56 or 84 mg The dose may be maintained, increased or reduced by 28m g from 
the previous dosing session, as determined by the investigator 
based on efficacy and tolerability. No dose increase is permitted 
beyond Day 15.
Days 18, 22 and 25 28, 56 or 84 mg No dose increase is permitted beyond Day 15. If needed for 
tolerabil ity, dose reduction by 28mg from the previous dose is 
permitted on Days 18, 22 and 25.
* Dose changes are determined by the investigator based on efficacy and tolerability and in accordance w ith blood 
pressure guidelines.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 38From Day 8 to Day 15, inclusive, for those who have had a prior down titration from a higher dose, a 
dose increase by 28 mg is allowed based on clinical judgment . 
On all intranasal treatment session days, a site staff member with training incardiopulmonary 
resuscitation (eg, Basic Life Support course or equivalent courses) that is up to date per local regulations 
must be present with the subject during the intranasal treatment session sand the postdose observation 
period. In addition, equipment for supportive ventilation and resuscitat ion needs to be present. Subjects 
must remain at the site until study procedures have been completed and the subject is ready for discharge .
Atthe time of discharge, subjects should be accompanied by a responsible adult when released from the 
clinical site. Subjects must not drive a car or work with machines for 24hours after receiving intranasal 
study drug. 
Oral Antidepressant Study Medication
Starting on Day 1, a new, open -label oral antidepressant treatment will be initiated in all subjects. The 
oral antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or 
venlafaxine XR). The antidepressant medication will be assigned by the investig ator based on review of 
MGH -ATRQ and relevant prior antidepressant medica tion information, and will be one that the subject 
has not previously had a nonresponse to in the current depressive episode, has not been previously 
intolerant to (lifetime), and is available in the participating country. 
Dosing of the oral antidepressan t will begin on Day 1. A mandatory titration schedule is provided in the 
protocol. D oses are not to exceed the maximum dose defined in the titration schedule . If higher doses are 
not tolerated, a down- titration is permitted based on clinical judgment.
All subjects will be provided with an additional 2-week supply of the oral antidepressant medication, to 
ensure that there is no interruption of oral antidepressant therapy during the transition to further 
clinical/standard of care in the follow -up phase.
Study-site personnel will instruct subjects on how to store and take the oral antidepressant treatment
supplied during this study for at -home use. A subject diary will be provided to capture oral antidepressant 
study medication use.
On intranasal dosing days, it is recommended that the oral antidepressant medication not be taken until at 
least 3 hours after the intranasal treatment session.
Follow -upphase
At the start of the follow -up phase, further clinical/standard of care for the treatment of depression wi ll be 
arranged by the study investigator and/or the subject’s treating physician.
No intranasal study medication will be administered during this phase.
The decision to continue the oral antidepressant medication in this phase will be at the discretion ofthe 
investigator, however, in order to better assess potential withdrawal symptoms from intranasal study  
medication, the oral antidepressant medication should be continued for the follow -up phase unless 
determined as not clinically appropriate.
Subjects entering thefollow -up phase will have 2 follow -up visits conducted at 1 and 2 weeks after the 
last dose of study medication. The follow -up visitsat 1 and 2 weeks after the last dose of study  
medication will be a telephone contact and a clinical visit, res pectively .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 39EFFICACY EVALUATIONS/ENDPOINTS
Primary Efficacy Evaluation and Endpoint
The primary efficacy/ evaluation will be the MADRS total score . The MADRS will be performed by 
independent remote raters during the study. The MADRS is a clinician- rated scale designed to measure 
depression severity and detects changes d ue to antidepressant treatment.
The primary efficacy endpoint will be the change from baseline in MADRS total score from Day 1 
pre-randomization, to the end of the 4 -week double -blind induction phase .
Secondary Efficacy Evaluations and Endpoints
Secondary efficacy evaluation endpoints include the change from baseline (Day 1 prior to randomization) 
to the end of the 4- week double -blind induction phase in:
Proportion of responders (50% reduction from baseline in MADRS total score) at the end of the 
4-week double -blind induction phase
Proportion of subjects in remission (MADRS 12) at the end of the 4-week double -blind induction 
phase
Change from baseline (Day 1 prior to randomization) to the end o f the 4 -week double -blind induction 
phase in:
oSeverity of depressive illness, using the Clinical Global Impression –Severity ( CGI-S)
oHealth- related quality of life and health status, as assessed by the EuroQol -5 dimension -5 
level (EQ -5D-5L).
PHARMACOKINET IC EVALUATIONS
Plasma samples will be analyzed to determine concentrations of esketamine (and noresketamine, if 
warranted) using a validated, specific, achiral, and sensitive liquid chromatography -tandem mass 
spectrometry (LC-MS/MS) method by or under the supervision of the sponsor. Plasma samples may be 
analyzed to document the presence of circulating metabolites using a qualified research method. In 
addition, plasma PK samples may be stored for future analysis of the metabolite profile .
BIOMARKER, PHARMAC OGENOMIC (DNA), AND EXPRESSION (RNA) EVA LUATIONS
Assessment of biomarkers (protein and RNA) and their potential relationship to intranasal esketamine 
plus a newly initiated oral antidepressant and to maintenance/stabilization of response, nonresponse, and 
relapse will be explored. Blood samples will be collected to measure genetic and epigenetic markers 
(including but not limited to BDNF allelic variants) and protein markers (including but not limited to 
growth factors, inflammation, endocrine, or metabolic markers). Samples of deoxyribonucleic acid 
(DNA) and biomarkers (protein and RNA) may be used to help address emerging issues and to enable the 
development of safer, more effective, and ultimately individualized therapies.
SAFETY EVALUATIONS
Safety evaluations will include:
Monitoring of TEAEs , including TEAEs of special interest, clinical laboratory tests (including 
hematology, serum chem istry, and urinalysis ), urine drug screen, 12- lead electrocardiogram, vital 
signs, pulse oximetry, physical examination , and body weight measurements
Nasal examinations and nasal symptom questionnaire
Columbia Suicide Severity Rating Scale (C -SSRS), to assess potential suicidal ideation and behavior
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 40Clinician Administered Dissociative States Scale (CADSS), to assess thetreatment -emergent 
dissociative symptoms
Four -item positive symptom subscale of the Brief Psychiatric Rating Scale (BPRS+), to assess 
potential treatment -emergent psychotic symptoms
Modified Observer’s Assessment of Alertness/Sedation (MOAA/S), to measur e treatment -emergent 
sedation
Clinical Global Assessment of Discharge Readiness (CGADR), to document the subject’s current 
clinical status and is the clinician’s assessment of the readiness to be discharged from the study site
Physician Withdrawal Checklis t (20 items; PWC- 20) to assess potential withdrawal symptoms 
following cessation of intranasal esketamine treatment
Bladder Pain/ Interstitial Cystitis Symptom Score (BPIC -SS), to monitor subjects for potential 
symptoms of cystitis, bladder pain, and inter stitial cystitis
Computerized cognitive battery and Hopkins Verbal Learning Test-Revised (HVLT -R), to assess the 
effect of intranasal esketamine on cognition
University of Pennsylvania Smell Identification Test (UPSIT ), to assess any potential treatment -
emergent effects on the sense of smell .
STATISTICAL METHODS
Subject Information
The primary efficacy and safety analysis sets are defined below.
 Full Analysis Set: All randomized subjects who receive at least 1 dose of intranasal study 
medication and 1 dose of oral antidepressant medication in the double- blind induction phase.
 Safety Analysis Set: All randomized subjects who receive at least 1 dose of intranasal study 
medication or 1 dose of oral antidepressant medication in the double -blind induction phase.
Sample Size Determination
The maximum sample size planned for this study was calculated assuming a treatment difference at the 
end of the double -blind induction phase of 6.5 points in MADRS total score between esketamine and the 
active comparator, a standa rd deviation of 12, a 1 -sided significance level of 0.025, and a drop -out rate of 
25%. A maximum of about 74 subjects will need to be randomized to each treatment group to achieve 
80% power using a fixed design with no interim analysis. The treatment diffe rence and standard deviation 
used in this calculation were based on results of Panel A from the ESKETINTRD2003 study and on 
clinical judgment.
Interim Analysis for Sample Size Re -Estimation or Stopping for Futility
One unblinded interim analysis will be performed 4 weeks after randomizing 50 subjects in the study 
(approximately 25 per treatment group). It is projected that at that time approximately 36 subjects in the 
full analysis set would have completed the double -blind induction phase of the study (appr oximately 
18subjects per treatment group). The dropout rate will be monitored to ensure a sufficient number of 
subjects areincluded in the interim analysis. As the assumptions of the expected treatment difference and 
variability may or may not be upheld, the purpose of the interim analysis is to either re-estimate sample 
size or to stop the study due to futility. The sample size may be adjusted to achieve the desired power 
while maintaining control of the overall Type I error. The maximum sample si ze planned for this study is 
74per treatment group .The study team will be blinded to the results of the interim analysis and any 
adjustments that will be made to the sample size. However, the clinical supplies group will be informed 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 41of the decision made at theinterim analysis so that only the required amount of study medication will be 
packaged.
Primary and Secondary Efficacy Analyses
With the exception of theEuropean Union (EU) dossier, the primary efficacy  variable, change from 
baseline in MADRS total score at Week 4 in the double -blind induction phase, will be analyzed using a 
mixed -effects model for repeated measures (MMRM). The model will include baseline MADRS total 
score as a covariate, and treatment, country, class of antidepressant (Serotonin and Nore pinephrine 
Reuptake Inhibitors [SNRI] or Selective Serotonin Reuptake Inhibitors [SSRI]), day, and 
day-by-treatment interaction as fixed effects, and a random subject effect. Comparison of the intranasal 
esketamine plus oral antidepressant arm versus oral antidepressant plus intranasal placebo will be 
performed using the appropriate contrast.
For the EUdossier, the primary efficacy analysis will be based on an analysis of covariance (ANCOVA) 
model using last observation carried forward (LOCF) data. The model will include factors for treatment, 
country, and class oforal antidepressant (SNRI or SSRI) and baseline MADRS total score as a covariate. 
Comparison of the intranasal esketamine plus oral antidepressant arm versus intranasal placebo plus oral 
antidepr essant will be performed using the appropriate contrast.
Response and remission rates will be summarized at each visit
The ranks of change from baseline in CGI -S scores at the end of the double -blind induction phase will be 
analyzed based on LOCF data usi ng an ANCOVA model, with country and class of antidepressant (SNRI 
or SSRI) as factors, a nd the baseline score (unranked ) as the covariate . 
Dimension scores of the EQ-5D-5L,descriptive system, thehealth status index, and the EQ visual analog 
scale (EQ-VAS) score swill be summarized over time.
Additionally, scores of all efficacy endpoints will be summarized for all visits in the double -blind 
induction phase. Summaries will be provided to show consistency of effect among relevant subgroups 
(eg, antidepres sant class SNRI and SSRI ).
PK Analyses
Plasma esketamine (and noresketamine , if warranted) concentrations will be listed for all subjects. The 
plasma concentration- time data of esketamine (and noresketamine, if warranted) will be analyzed using  
population PK m odeling. Data may be combined with those of other selected studies to support a relevant 
structural model. Typical population values of basic PK parameters will be estimated together with the 
inter-individual variability. Effects of subject demographic s, laboratory parameter values, and other 
covariates on the PKof esketamine will be explored. The results of the population PK analyses may be 
reported separately.
PK/PD Analyses
The relationship between the MADRS total score (and possibly selected advers e events as additional PD
parameters) ,and PKmetrics of esketamine ,may be evaluated. If there is any visual trend in graphical 
analysis, suitable models will be applied to describe the exposure -effect relationships. The results of the 
PK/PD analyses may be reported separately.
Biomarker, Pharmacogenomic (DNA), and Expression (RNA) Analyses
Baseline biomarker values and changes from baseline biomarker values to the time points specified in the 
Time and Events Schedule will be summarized . Exploratory biomar ker analyses may include 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 42comparison sof biomarker measures between the treatment groups, correlation with efficacy and other 
measures, and relationships with clinical response, relapse, and nonresponse.
The analysis plan and summarized results from both biomarker and pharmacogenomics analyses will be 
reported separately.
Safety Analyses
All safety data will be analyzed separately for the double -blind induction phase and the follow -up phase.
The verbatim terms used in the electronic case report form (eCRF ) by investigators to identify adverse 
events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). All reported 
adverse events with onset during the double -blind induction phase (ie, TEAEs , and adverse events that 
have worsened since baseline) will be included in the analysis. For each adverse event, the percentage of 
subjects who experience at least 1 occurrence of the given event will be summarized by treatment group.
Adverse events occurring during the follow -up phase will be summa rized separately .
TEAEs of special interest will be examined separately grouped in the following categories: Drug abuse, 
dependence and withdrawal (standardized MedDRA  queries [SMQ]), increased blood pressure, increased 
heart rate, transient dizziness/ver tigo, impaired cognition, anxiety ,and cystitis. Adverse events of special 
interest will be further listed in the SAP.
Subjects who die, who discontinue treatment due to an adverse event, or who experience a severe or a 
serious adverse event will be summar ized separately .
Laboratory data will be summarized by type of laboratory test. Reference ranges and markedly abnormal 
results (specified in the SAP) will be used in the summary of laboratory data. Descriptive statistics will be 
calculated for each laborat ory analyte at baseline and at each scheduled time point in each phase of the 
study. Changes from baseline results will be presented. Frequency tabulations of the abnormalities will be 
provided. Listings of subjects with laboratory results outside the reference ranges and m arkedly abnormal 
results will also be provided.
Electrocardiogram (ECG) data will be summarized by ECG parameter . Descriptive statistics will be 
calculated at baseline and for observed values and changes from baseline at each scheduled time point. 
Frequency tabulations of the abnormalities will be made. The ECG variables that will be analyzed are 
heart rate, PR interval, QRS interval, QT interval, and corrected QT (QTc) interval using the following 
correction methods: QT corrected according to Fridericia’ s formula (QTcF), which will be the primary 
correction factor ,and QT corrected accor ding to Bazett's formula (QT cB).
Descriptive statistics of QTc intervals and changes from double -blind baseline will be summarized at each 
scheduled time point. The percentage of subjects with QTc interval >450 msec, >480 msec, or >500 msec 
will be summarized, as will the percentage of subjects with QTc interval increases from baseline 
<30msec, 30 -60 msec, or >60 msec.
Descriptive statistics of temperature, pulse/heart rate, respiratory rate, pulse oximetry, and blood pressure 
(systolic and diastolic) (supine) values and changes from baseline will be summarized at each scheduled 
time point. The percentage of subjects with values beyond clinically important l imits will be summarized.
Changes in findings from the baseline nasal examination (including the upper respiratory tract/throat) will 
be listed by treatment group. Examinations will provide ratings (absent , mild, moderate, or severe) that 
are based on a visual inspection of the nostrils, nasal mucosa, and throat for nasal erythema, rhinorrhea, 
rhinitis, capillary/blood vessel disruption and epistaxis. A shift table for changes from double -blind 
baseline in ratings for each examination will be presented by t reatment group.
Scoring from the nasal symptom questionnaire will be summarized descriptively for each scheduled time 
point by treatment group.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 43Suicide -related thoughts and behaviors based on the C-SSRS will be summarized by treatment group in 
incidence and shift tables. Separate endpoints for suicidal ideation and suicidal behavior will be defined 
and summarized descriptively by treatment group.
Descriptive statistics of the CADSS, BPRS+ , and MOAA/S scores and changes from predose will be 
summarized at each scheduled time point.
Descriptive statistics of the CGADR, PWC-20, BPIC -SS, UPSIT scores and changes and/or percent 
changes from baseline will be summarized at each scheduled time point.
Descriptive statistics of each cognitive domain score and changes from baseline will be summarized at 
each scheduled time point.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18 July 2016 44TIME A ND EVENTS SCHE DULE (Screening/Prospective Observational Phase and Double- blind Induction Phase )
PhaseScreening /
Prospective Observational Phase Double -blind Induction Phase
Visit numbe r 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 EWb
Week Week 1End of 
Week 2End of
Week 4 1 2 3 4
Study day - - -1
(baseline) 4 8 11 15 18 22 25 28 EW
Clinic alvisit window (in days) - ±2 ±2 - ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 -
Clinical visit (C) C C C C C C C C C C C C C
Screening/Administrative
Informed consent (ICF) X
Medical history, psychiatric history, 
demographics , and employment statusX
MINI X
MMSE X
MGH- ATRQ X
Site Independent Qualification 
AssessmentX
Height X
Inclusion/exclusion criteria X X
Prestudy therapy X
Preplanned surgery/procedures X
STOP Bang questionnaire 
(including assessment of BMI and 
neck circumf erence)X
IDS-C30 X
Study Drug
Randomization X
Dispensing of new oral antidepressant 
(duloxetine, escitalopram, sertraline, 
or venlafaxine XR)X XnX
Practice session for use of intranasal 
deviced X
Intranasal esketamine or placebooX X X X X X X X
Drug accountability (intranasal study 
medication)X X X X X X X X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18 July 2016 45PhaseScreening /
Prospective Observational Phase Double -blind Induction Phase
Visit numbe r 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 EWb
Week Week 1End of 
Week 2End of
Week 4 1 2 3 4
Study day - - -1
(baseline) 4 8 11 15 18 22 25 28 EW
Clinic alvisit window (in days) - ±2 ±2 - ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 -
Clinical visit (C) C C C C C C C C C C C C C
Drug accountability (oral 
antidepressant study medication)X X X
Dispense subject diary for oral 
antidepressa ntX
Revie w subject diary and update (if 
applicable)X X X X X X X X X
Oral antidepressant compliance check X X X X X
Return of subject diary if not entering 
follow  up phaseX
Safety Assessments (Clinician)
Physical examination X X X X
Nasal examinationdX X X X
Vital signs: blood pressure, pulse, 
respiratory rate, temperatured,o X X X X X X X X X X
Vital signs (postdose): blood pressure, 
pulse, respiratory ratee,o X X X X X X X X
Weight X X X X
12-lead ECGf,oX X X X X X X X X X
C-SSRS: Baseline/Screening version X
C-SSRS: Since last visit versiond,oX X XrX X X X X X X X X
MOAA/Sg,oX X X X X X X X
Pulse oximetryg,oX X X X X X X X X
BPRS+h,oX X X X X X X X
CADSSh,oX X X X X X X X
CGADRiX X X X X X X X
PWC -20 XjX
Safety Assessments (Subject -completed)
Nasal symptom questionnairekX X X X X
BPIC -SSdX X X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18 July 2016 46PhaseScreening /
Prospective Observational Phase Double -blind Induction Phase
Visit numbe r 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 EWb
Week Week 1End of 
Week 2End of
Week 4 1 2 3 4
Study day - - -1
(baseline) 4 8 11 15 18 22 25 28 EW
Clinic alvisit window (in days) - ±2 ±2 - ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 -
Clinical visit (C) C C C C C C C C C C C C C
Assessment of Sense of Sm ell
UPSITd,pX X X
Efficacy Assessments (Clinician)
MADRS (performed by independent, 
remote raters )X XqXqXc,qXd,qXd,qXd,qXqX
CGI-SdX X X X X X X X X X X
Efficacy Assessments (Subject -completed)
PAQ X X X
EQ-5D-5LdX X X X X
Cognition Testings
Practice sessions for computerized 
test batteryX
Com puterized test battery and HVLT -
RXdX X
Clinical Laboratory Assessments
TSH, HbA1 c X
Lipid panel (fasting) X
Hem atology, chemistrydX X X X
Urine drug screendX X X X
Alcohol breath test X X
UrinalysisdX X X X X
Pharm acokinetics
Blood collectionlX
Biom arker, Pharmacogenomic ( DNA), and Expression (RNA) Evaluations
Blood sample collection (protein)m,dX X X X X
Blood sample collection (DNA)m,dX X X
Blood sample collection (RNA)m,dX X X X X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18 July 2016 47PhaseScreening /
Prospective Observational Phase Double -blind Induction Phase
Visit numbe r 1.1 1.2 1.3a2.1a2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 EWb
Week Week 1End of 
Week 2End of
Week 4 1 2 3 4
Study day - - -1
(baseline) 4 8 11 15 18 22 25 28 EW
Clinic alvisit window (in days) - ±2 ±2 - ±1 ±1 ±1 ±1 ±1 ±1 ±1 ±1 -
Clinical visit (C) C C C C C C C C C C C C C
Ongoing Subject Review
Concomitant Therapy Ongoing
Adverse Events Ongoing
Footnotes:
Abbreviations: BMI=body mass index; BPIC -SS=Bladder Pain/Interstitial Cystitis Symptom Score; BPRS +=Four -item positive symptom subscale of the 
Brief Psychiatric Rating Scale ;CADSS =Clinician Administered Dissociative States Scale ;CGADR=Clinical Global Assessment of Discharge 
Readiness ;CGI-S=Clinical Global Impression –Severity ; C-SSRS =Columbia Suicide Severity Rating Scale ;DNA=deoxyribonucleic acid; 
ECG=electrocardiogram ;EQ-5D-5L= EuroQol -5dimension , 5-level ;EW=early withdrawal ;HbA1C= glycosylated hemoglobin ;HVLT -R=Hopkins 
Verbal Learning Test -Revised; IDS-C30=Inventory of Depressive Symptomatology Clinician -rated 30-item scale ;MADRS =Montgomery -Asberg 
Depression Rating Scale ;MGH -ATRQ= Massachusetts General Hospital Antidepressant Treatment History Questionnaire ;MINI =Mini International 
Neuropsychiatric Interview ;MMSE= Mini Mental State Examination; MOAAS =Modified Observer's Assessment of Alertness/Sedation ;PAQ =Patient 
Adherence Questionnaire ; PWC-20=20- item Physician W ithdrawal Checklist ;RNA=ribonucleic acid; STOP -Bang=Snoring, Tired, Observed Apnea, 
High Blood Pressure, Body mass index, Age, Neck Size, Gender (a q uestionnaire );TSH =thyroid- stimulating hormone ;UPSIT= University of 
Pennsylvania Smell Identification Test
Note: On intranasal dosing days, time 0 is defined as the time of the fir st intranasal spray. Therefore postdose time points are referenced from this.
a)An additional, optional period of up to 3 weeks is permitted to taper and discontinue current antidepre ssant treatment (s) after completion of the 
Week 4 (Visit 1.3) assessments, per the local prescribing information or clinical judgment. This 3 week period may also be usedto optimize 
medical manag ement if needed to facilitate subject participation. Subject s who do not require a taper and are thus eligible to immediately 
proceed to the double -blind induction phase canhave Visits 1.3 and 2.1 occur on the same day or within 1week of each other (if not occurring 
on the same day, the antidepressant treatment r egimen should be continued after visit 1.3. and then discontinued prior to Visit 2.1).
b)If a subject withdraws before the end of the double -blind induction phase (ie, before completing Visit 2.9/Day 28) for reasons other than withdrawal 
of consent, and an e arly withdrawal visit should be conducted within 1 week of the date of discontinuation, followed by the follow -up phase. If the 
early withdrawal visit is conducted on the s ame day as a scheduled visit, duplicate assessments are not required.
c)Performed for subjects requiring a taper period during the screening/prospective observational phase; the result will be the subject’s base line MADRS 
for the double -blind induction phase. For all other subjects, the baseline MADRS for the double- blind induction phase wi ll be the MADRS performed 
at the end of Week 4 of the screening/prospective observational phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18 July 2016 48d)Predose (if/when performed on intranasal dosing days). Predose subject -reported outcome assessments should be administered before all other study -
related proce dures during a clinic visit.
e)Postdose vital signs will be measured at 40 minutes, 1 hour, and 1.5 hours postdose. Please refer to Section 6.2.1 for guidance on blood pressure 
monitoring on dosing days.
f)Twel ve-lead ECG will be performed predose and at t=1 hour postdose at Visit 2.1. Twelve -lead ECG will be p erformed at t=1 hour postdose (no 
predose) at Visits 2.2 through 2.8. A time window of ±15 minutes is permitted.
g)The MOAA/S will not be performed at Visit 1 (p ulse oximetry only). The MOAA/S will be performed every 15 minutes from predose to t=+1.5 hours 
postdose (please refer to Section 9.6for further guidance on MOAA/S assessments ). Pulse oximetry will be performed every 15 minutes from predose 
to t=1.5 hours postdose (please refer to Section 9.6for further guidance regarding on timing of pulse oximetry assessments ).
h)The BPRS+ and CADSS to be performed predose and at 40 minutes and 1.5 hours postdose. 
i)CGADR to be performed at 1 hour and 1.5 hours postdose; if the response is not “Yes” at 1.5 hours postdose, the assessment wi ll be repeated every 
15 minutes until a “Yes” response is achieved or until the subject is referre d for appropriate medical care if clinically indicated. A subject should not 
be discharged prior to the 1.5 hour time point.
j)PWC- 20 to be performed predose on all subjects .
k)Nasal symptom questionnaire will be performed predose and at 1 hour postdose.
l)PK bl ood collection will be performed at t=40 minutes and t=2 hours postdose (where time=0 is defined as the time of the first int ranasal spray).
m)Blood samples should be collected prior to dosing. It is preferred that subjects adhere to a low fat diet on the d ay of sample collection.
n)Only s ubjects entering the follow -up phase will be provided with a 2 -week supply of oral antidepressant .
o)If intranasal dosing is postponed (but occurs within visit window) due to vital sign results (eg, blood pressure elevation), a ll assessment time points 
(including predose ) must be performed on the actual intranasal dosing day.
p)If on the day of the scheduled smell test assessments the subject has significant nasal congestion, the site should consider postponing to the next 
schedule d visit.
q)The MADRS should be administered no more than 2 days prior to the subject’s targeted (not actual) clinic visit date (except V isit 2.9, which is within 
1 day prior) . If performed on the day of the scheduled clinic visit for an intranasal treatment session, the MADRS must be performed prior to the 
intranasal treatment session.
r)Performed only if Visit 1.3 and Visit 2.1 do not occur on the same day.
s)Testing can precede Visit 2.1. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18 July 2016 49TIME A ND EVENTS SCHE DULE (Follow -up Phase)
Visit NumberFollow -up Phase
3.1 3.2
Weeks after last intranasal dose 1 2
Visit window for clinic visit or rem ote assessments only (days) ±3 ±3
Clinic al visit (C) or remote assessments only (RA) RAeC
Oral antidepressant compliancea
Oral antidepressant compliance check X
Retu rn of subject diary X
Safety assessments (Clinician -completed )
Physical examination X
Nasal examination X
Vital signs: Blood pressure, pulse, respiratory rate, temperature X
12-lead ECG X
C-SSRS: Since last visit version X
PWC -20 XbX
Safet y assessments (Subject -completed)
BPIC -SS X
Efficacy assessments (Clinician -completed )
MADRS (performed by independent, remote raters )cX X
CGI-S X
Efficacy assessments (Subject -completed)
EQ-5D-5L X
Cognition testing
Com puterized test battery and HVLT -R X
Clinical laboratory assessments
Hem atology, chemistry X
Urinalysis X
Biom arker and Expression (RNA) evaluations
Blood sample collection (protein)dX
Blood sample collection (RNA)dX
Study Drug
Drug Accountability X
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18 July 2016 50Visit NumberFollow -up Phase
3.1 3.2
Weeks after last intranasal dose 1 2
Visit window for clinic visit or rem ote assessments only (days) ±3 ±3
Clinic al visit (C) or remote assessments only (RA) RAeC
Ongoing subject review
Concomitant therapy Ongoing
Adverse events Ongoing
Footnotes:
Abbreviations: BPIC -SS=Bladder Pain/Interstitial Cystitis Sym ptom  Score ;CGI-S=Clinical Global Impression – Severity ; C-SSRS =Columbi a Suicide 
Severity Rating Scale; ECG=el ectrocardiogram ;EQ-5D-5L= EuroQol -5D, 5 -level ;HVLT -R=Hopkins Verbal Learning Test -Revised; PWC-20=20- item 
Physician Withdrawal Checklist ;RNA=ribonucleic acid .
Note: No intranasal study medication will be administered dur ing this phase.
a)In order to better assess potential withdrawal symptoms from intranasal study medication, the oral antidepressant medication should be continued for 
the 2 weeks of the follow -up phase, unless determined to be not clinically appropriate .
b)Performed by telephone by qualified s ite staff.
c)MADRS will be performed by an independent remote rater. At Visit 3.1 (Week- 1 of follow -up) the subject will have the MADRS assessment with a 
remote rater visit, in addition to a follow -up call from the site.
d)It is preferred that subjects adhere to a low fat diet o n the day of sample collection.
e)For the Remote Assessment (RA) Visit 3.1, site staff will contact the subject by telephone to obtain information regarding adverse events and 
concomitant therapies.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 51ABBREVIA TIONS
AHI apnea -hypopnea index
ANCOVA analysis of covariance
ASA American Society of Anesthesiologists
AUC area under the plasma concentration -time curve
BDNF brain -derived neurotrophic factor
BMI body mass index
BPIC -SS Bladder Pain/ Interstitial Cystitis Symptom Score 
BPRS+ four-i tem positive symptom subscale of the Brief P sychiatric Rating Scale
CADSS Clinician Administered Dissociative States S cale
CGADR Clinical Global Assessment of Discharge Readiness
CGI-S Clinical Global I mpression – Severity
C clinic visit
Cmax maximum plasma concentration
C-SSRS Columbia Suicide Severity Rating S cale
CYP cytochrome P450 , with appended letters (eg, 2B6, 3A4) indicating subtype
DBP diastolic blood pressure
DBS deep brain stimulation
DNA deoxyribonucleic acid
DSM -5 Diagnostic an d Statistical Manual of Mental Disorders (5th Edition)
ECG electrocardiogram
eCRF electronic case report form
ECT electroconvulsive therapy
eDC Electronic Data Capture
EQ-5D-5L EuroQol; 5 dimension; 5 level
EQ-VAS EuroQol group : Visual Analogue Scale
EU European Union
EW Early Withdrawal
FAS fullanalysis set
FDA Food and Drug Administration
fT4 free thyroxine
GCP Good Clinical Practice
HbA1c glycated hemoglobin 
HDRS Ham ilton Depression Rating Scale
HIV human immunodeficiency virus
HPA hypo thalam icpituitary adrenal
HVLT -R Hopkins Verbal Learning Test -Revised
ICF informed consent form
ICH International Conference on Harmonisation
IDMC Independent Data Monitoring Committee
IDS-C30 Inventory of Depressive Symptomatology -Clinician rated, 3 0-item scale
IEC Independent Ethics Committee
IM intramuscular
IRB Institutional Review Board
IV intravenous
IWRS interactive web response system
LC-MS/MS liquid chromatography -tandem mass spectrometry
LOCF last observation carried forward
MADRS Montgomery Asberg Depression Rating Scale
MAO I monoamine oxidase inhibitor
MDD major depressive disorder
MedDRA Medical Dictionary for Regulatory Activities
MGH- ATRQ Massachusetts General Hospital –Antidepressant Treatment Response Questionnaire
MINI Mini International Neuropsychiatric Interview (mental status questionnaire)
MOAA/S Modified Observer’s Assessment of Alertness/Sedation
MMRM mixed -effects model for repeated measures
NMDA N-Methyl -D-Aspartate
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 52PAQ Patient Adherence Questionnaire
PCP phencyclidine
PD pharmacodynamics
PK pharmacokinetic s
PQC product quality complaint
PRISM -E Primary Care Research in Substance Abuse and Mental Health for the Elderly
PWC -20 Physician Withdraw al Checklist ; 20-item
QIDS -SR16 Quick Inventory of Depress ive Symptomatology – Self Report 
QTc QT interval corrected
QTcB QT interval corrected according to Bazett's formula
QTcF QT interval corrected according to Fridericia's formula
RA remote assessments only
RNA ribonucleic acid
SAP statistical analysis plan
SBP systolic blood pressure
SmPC Summary of Product Characteristics
SMQ standard Medical Dictionary for Regulatory Activities query
SNRI Serotonin and Norepinephrine Reuptake Inhibitors
SSRI Selective Serotonin Reuptake Inhibitors
STOP -Bang snoring, tired, o bserved apnea, high blood pressure, body mass index, age, neck size, gender 
(questionnaire)
SUSAR suspected unexpected serious adverse reaction
Tmax time to reach the maximum plasma concentration
TEAE treatment -emergent adverse event
TRD treatment -resistant depression
TSH thyroid -stimulating hormone
UPSIT University of Pennsylvania Smell Identification Test
US United States
US FDA United States Food and Drug Administration
VNS vagal nerve stimulation
XR extended release
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 531. INTRODUC TION
Major depressive disorder (MDD) is a serious, recurrent, and disabling psychiatric illness.90It is 
the second leading cause of years lost to disability  worldwide and is associated with excess 
mortality ,and the estimated median years of potential life lost is 10 years.91,95About 30% of 
patients fail to achieve remission despite treatment with multiple antidepressant m edications, and 
are considered to have treatment -resistant depression (TRD).32,77In patients who respond to 
antidepressant treatments, the time to onset of effect is typically  4 to 7 weeks , during which time 
patients continue to suffer from their s ymptoms and continue to be at risk of self -harm, as well as 
being impacted by the associated harm to their personal and professional lives.77,80Therefore, 
there is a significant need to develop novel treatments based upon relevant pathoph ysiologic 
pathway s underly ing MDD for the rapid relief of depressive symptoms, especiall y in patients 
with TRD.19,25
Depression in later life, traditionally  defined as age older than 65years, is associated with 
disability , increased mortality , and poorer outcomes from physical illness and in addition, the 
condition is often under -recognized and under -treated.73In the Primary  Care Research in 
Substance Abuse and Mental Health for the Elderly  (PRISM-E)study , a large study of older 
patients with major depressive disorder, 71% of the patients did not remit even after 6 months of 
standard of care treatment in specialty  or integrated care treatment centers.2Factors associated 
with non-remission included severity  of depression at baseline, a family  history  of depression, 
comorbid anxiety , and general medical comorbidity . According to the World Health 
Organization (WHO) data, proportionately  more people aged over 65yearscommit suici de than 
any other age group ; most have major depression. Older people who attempt suicide ,are more 
likely  to die than younger people, while in those who survive, prognosis is worse for older 
adults.49
Ketamine and esketamine (S-ketamine, the Senantiomer of ketamine) are approved and widel y 
used for the induction and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) 
administration.45The desired analgesic -anesthetic effects of ketamine and esketamine are 
attributed to the blockade of ionotropic N-methy l-D-aspartate (NMDA) glutamate 
receptors.52,66,98
Monoamines (serotonin, norepinephrine, and/or dopamine) are only modulatory  transmitters; 
therefore, conventional monoaminergic antidepressant treatments would not be expected to 
robustly  affect synaptic transmission, activity-dependent release of brain -derived neurotrophic 
factor (BDNF), or synaptogenesis.25In contrast, the mechanism of action of ketamine and 
esketamine is distinct from conventional antidepressant treatments because both ketamine and 
esketamine profoundl y affect fast excitatory  glutamate transmission, increase BDNF release, and 
stimulate sy naptogenesis.25
Most literature reports of the antidepressant effects of ketam ine describe studies using IV 
administration of the racemate.16,60Janssen Research & Development (JRD) is developing 
intranasal esketamine as an antidepressant thera pybecause it has higher NMDA receptor affinity 
which allows a lower volume of medication to be administered via the intranasal route.51,62,67
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 54For the most comprehensive nonclinical and clinical information regarding esketamine 
(JNJ-54135419), please refer to the latest edition of the Investigator’ s Brochure .42
The term “sponsor ”used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
1.1. Background
1.1.1. Summary  of Nonclinical Findings
Safety Pharmacology
The following text is quoted from the US prescribing information for anesthetic Ketalar®
(ketamine hydrochloride [HCl] injection) .45Intravenous Ketalar produces a fall in arterial blood 
pressure in the Rhesus monkey  and a rise in arterial blood pressure in th e dog. In this respect the 
dog mimics the cardiovascular effect observed in man. The pressor response to Ketalar injected 
into intact, unanesthetized dogs is accompanied by  a tachy cardia, rise in cardiac output and a fall 
in total peripheral resistance. The pressor response to Ketalar is reduced or blocked by 
chlorpromazine (central depressant and peripheral α-adrenergic blockade), by β-adrenergic 
blocka de, and b y ganglionic blockade.
Finding sfrom animal studies suggest that the increase in blood pressure produced by 
ketamine/esketamine is due to selective activation of central cardiac stimulating mechanisms 
leading to an increase in cardiac output.
In a 3-month repeat -dose toxicity  study with intranasall y administered esketamine in dogs, no 
relevant electrocardiogram (ECG )changes were noted up to the highest dose tested, ie, 
72mg/d ay.Heart rate was slightly  increased. The cardiovascular safet y of racemic ketamine and 
esketamine in humans and animals is summarized in the Investigator’s Brochure .42
Toxicology
Repeat -Dose Toxicity Studies
In repeat -dose toxicity  studies with intranasally  administered esketamine in rats up to 9 mg/day  
for 6 months, and dogs up to 72 mg/day for 3 months of duration , the clinical observations 
mainly  related to the central nervous sy stem (e g, changes in activity  and gait) . No adverse effects 
were noted up to the highest dose tested, ie, 9 mg/day  in rats and 72 mg/day  in dogs. These 
observations reflected the (exaggerated) pharmacology  of the test compound. Minor histologic 
findings were note d in the nasal cavity . These tissue changes were not considered adverse.
In 3-and 9 -month repeat -dose toxicity  studies with intranasall y administered esketamine in dogs, 
no relevant electrocardiogram (ECG) changes were noted up 72 mg/day. Heart rate was slightly 
increased. 
Further details can be found in the Investigator’s Brochure .42
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 55Genetic Toxicity
A series of in vitro and in vivo genotoxicity  studies wereconducted with ketamine and 
esketamine . The weight of evidence indicates that esketamine poses no genotoxic risk to 
humans.42
Neurotoxicity
Racemic ketamine has been reported to induce neurotoxicity  in animal fetuses, and in juvenile, 
adolescent, and adult animals, as evidenced by histopathologic brain lesions and functional 
sequelae. The precise thresholds for dose and duration of exposure causing neurotoxicity  in 
animals remain to be established. The relevance to humans of ketamine’s neurotoxic action in 
animals is unknown.
In studies exploring neurotoxic effects of ketamine on juvenile and prenatal monkey s, 
neuroapoptosis was observed to be more widespread in fetal brains than in neonatal brains, after 
administration of ketamine anesthesia IV for 5 hours . In fetal brains, the cerebellum, caudate 
nucleus, putamen, and nucleus accumbens were most severel y affected. In neonatal brains, the 
cerebellum was not affected; the strongest neuroapoptotic response was noted in the basal 
ganglia and several thalamic areas.
Injuvenile rodents, ketamine induced apoptotic neurodegeneration was observed, that was more 
widespread than in adult rodents, with the developing brain affected in several major regions. 
Neuronal cell death was induced in the dorsolateral thalamus atblood levels of ketamine of 
14µg/mL  (7 times the human anesthetic blood level of approximately  2 µg/mL ).
No significant neurotoxic effects occurred in juvenile Rhesus monkey s if the anesthesia was 
administered as IM induction followed by IV maintenance duratio n was 3 hours. Ketamine 
infusion for 9 or 24 hours increased neuronal cell death in the frontal cortex, but no significant 
changes were noted in the hippocampus, thalamus, striatum, or amygdala. Cognitive 
impairments were observed beginning around 10 month s of age, and persisted at 3.5 years of 
age.
The clinical studies will exclude neonates, infants, children, pregnant women, and breastfeeding 
women. Therefore, ketamine’s neurotoxicity  in juvenile animals does not represent a safet y risk 
to eligible elder ly subjects. Moreover, the large dosages and prolonged treatment durations 
associated with neurotoxicity  in juvenile animals do not suggest a concern.
Chronic treatment with ketamine at high dose levels affected the brain of adolescent monkey s, as 
evidence d by histopathologic lesions and functional impairment.
The neurotoxicity  of ketamine in adult animals is also associated with high dose levels, in 
contrast to the relatively  low dose levels of esketamine associated with antidepressant efficacy  in 
humans. In single -dose and 14-day repeated -neurotoxicity  studies with intranasall y administered 
esketamine in rats, no histopathologic brain lesions were noted even upon high exposures, as 
achieved at 54 mg/day  in the 14-day study. In the 6-month rat and 9-month dog repeat -dose 
toxicology  studies with intranasall y administered esketamine, where the animals were of 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 56adolescent age at initiation of treatment, and in the pre-and post-natal developmental toxicit y 
study  in rats, no evidence of neurotoxicity  was found. Consequentl y, the risk of neurotoxicity  
associated with intranasal administration of esketamine to adult and adolescent patients is 
considered low .42
Abuse Potential
Animal studies with ketamine suggest that it would have abuse potential in humans. These 
studies included self -administration and withdrawal experiments in several species.42
Reproductive Toxicity
In a rat fertility  and early embry onic developmental toxicit y study  with intranasall y administered 
esketamine, no adverse effects on fertility  or reproductive capacity  or performance were found.
Rat and rabbit embry o-fetal developmental toxicity  studies with intranasall y administered 
racemic ketamine did not reveal evidence of reproductive toxicity . However, when monkey 
fetuses were exposed in utero to high dose levels of racemic ketamine, neurotoxicity  was 
observed. 
Intranasall y administered esketamine did not affect pre-and postnatal development in rats. 
However , high dose levels of racemic ketamine induced neurotoxicity  in early postnatal rat 
pups.42
Considering the neurotoxic potential of ketamine and esketamine; and the fact that no threshold 
for these effects has been demonstrated, female subjects of childbearing potential should be 
adequatel y protected from becoming pregnant and pregnant women should not be enrolled .
Cardiovascular toxicity
In guinea pig tissues, ketamine -induced negative inotropic effects and shortening of action 
potential duration at the 0-mV level was observed, likely  as a result of the suppression of inward 
calcium current, whereas in rat left atria and ketamine -induced positive inotropic effects and 
prolongation of action potential duration at the 0-mV level was observed, likely  as a result of a 
decrease in calcium -insensitive transient outward current.27The inhibitory action on membrane 
currents may  partl y explain the species and tissue differences in inotropic responses to ketamine.
Blood pressure responses to ketamine also vary with the laboratory  species and with 
experimental conditions. Blood pressure is increased in normotensive and renal hy pertensive rats 
with and without adrenalectom y and unde r pentobarbital anesthesia. The US prescribing 
information for the anesthetic Ketalar (ketamine HCl for injection) provides the following 
guidance.45
Intravenous Ketalar produces a fall in arterial blood pressur e in the Rhesus monkey  and a rise in 
arterial blood pressure in the dog. In this respect the dog mimics the cardiovascular effect 
observed in man. The pressor response to Ketalar injected into intact, unanesthetized dogs is 
accompanied by a tachycardia, rise in cardiac output and a fall in total peripheral resistance. It 
causes a fall in perfusion pressure following a large dose.The tachycardia and increase in 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 57myocardial contractile force seen in intact animals does not appear in isolated hearts. These 
observations support the hypothesis that the hy pertension produced by  Ketalar is due to selective 
activation of central cardiac stimulating mechanisms leading to an increase in cardiac output. 
The dog would be considered the most predictive species in terms of ketamine’s cardiovascular 
effects in humans, but the antidepressant effects of ketamine were studied only in rodent models. 
The myocardial contractility  effects and blood pressure responses to ketamine vary between 
species.42Consequently , a margin of safety  could not be reliably  derived from the available 
animal data.
Overall Conclusion
The currentl y available nonclinical safety  studies support chronic intranasal administration of 
esketamine in human subjects up to a dosag e of 84 mg/day .
Further details can be found in the Investigator’s Brochure .42
1.1.2. Clinical Studies
1.1.2.1. Pharmacokinetics and Product Metabolism
Metabolism and Excretion
Ketamine and esketamine undergo extensive metabolism by hepatic cytochrome P450 (CYP). In 
humans, N-demeth ylation to norketamine is the major route of metabolism, which can undergo 
further metabolism to form hydroxynorketamine. Ketamine and norketamine are extensively 
hydroxylated to a serie s of 6 hydroxynorketamine metabolites and 2hydroxyketamine 
metabolites.94Like ketamine, norketamine is a noncompetitive antagonist at the NMDA 
receptor.26,39Norketamine has a half- life in plasma of approximately  5 hours.37The major human 
hepatic CYPs that catalyze ketamine N-demethy lation in vitro are CYP2B6 and CYP3A4.38,68,96
The CYP enzymes responsible for the formation of norketamine metabolites include CYP2A6 
and CYP2B6.68Published results of a clinical pharmacokinetic (PK) study  indicate that 
esketamine does not invert to the R-enantiomer.34Racemic ketamine and its metabolites have 
been previousl y shown to be predominantly  excreted in the urine. An average of 91% and 3% of 
a tritium -labeled dose (1mg/kg) administered to 6healthy  subjects was recovered in urine and 
feces, respectivel y.6Less than 3% of an administered dose was excreted in urine as parent drug.93
A summary  of the PK of esketamine administered by the IVand intranasal routes is provided 
below.
Intravenous Esketamine 
Subjects with TRD received 0.2 mg/kg or 0.4 mg/kg esketamine as a 40-minute IVinfusion 
during Study  ESKTIV TRD2001.12Maximum concentrations of esketamine were observed at the 
end of the infusion. Mean maximum plasma concentration (Cmax) and area under the plasma 
concentration -time curve (AUC) values increased with an increase in the esketamine dose 
administered (80.9 and 135 ng/mL , respectivel y, and 150 and 218 ng*h/mL , respectively , for 
0.2mg/kg and 0.4 mg/kg esketamine ). The mean plasma clearance of esketamine was high 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 58(109 L/h and 141 L/h for the 0.2 mg/kg and 0.4 mg/kg doses, respectivel y),as it was similar to or 
exceeded hepatic blood flow in humans .16The large volume of distribution suggest s that 
esketamine distributes widely  into tissues (236 L and 303 L, respectively ). The half-life of 
esketam ine in plasma was 2.14 and 2.65 hours, respectivel y, for the 2 doses .
Intranasal Esketamine
Plasma esketamine PK results from Studies ESKETINTRD1001, ESKTINTRD1002, 
ESKETINTRD1003, and the double -blind phase of Panel A of the ESKETIN TRD2003 that 
inform dose selection for the Phase 3 program are described below. The results demonstrate that 
plasma esketamine concentrations produced by effective IVregim ens(0.2 mg/kg and 0.4 mg/kg 
as 40 -minute infusions) may  be achieved by  the intranasal route. 
Study  ESKETINTRD1001 included 3 cohorts of subjects who were healthy  male and female 
subjects.6The intranasal esket amine treatments were self-administered under the direct 
supervision of the investigator or designee. Subjects in Cohorts 1 and 3 received esketamine 
doses that ranged from 28 to 112 mg. The regimens were self-administered in the upright 
position. No instructions were given with regard to sniffing after administration. The reported 
median time to reach C max(Tmax)of esketamine ranged from 0.37 to 0.83 hours from the time the 
first spray  was administered (ie , 0.33 to 0.5 hours after the last spray  was admini stered). The 
doses of 28 to 112mg produced mean Cmaxvalues ranging from 63.3 to 151 ng/mL, while mean 
AUC ∞values ranged from 164 to 565 ng*h/mL. Mean Cmaxand AUC values of esketamine 
increased in a less than dose-proportional manner across the dose regimens. Further more, there 
was substantial overlap in the range of individual Cmaxand AUC values among the 3 doses. The 
mean terminal half -life of eske tamine ranged from 5.86 to 9.83 hours across all treatments.
Subjects in Cohort 2 received 84 mg in a semi -reclined position and were instructed to sniff after 
each spray . Higher mean Cmaxand AUC ∞values were observed in this cohort (174 ng/mL and 
453ng*h/mL, respectively ) compared with the same esketamine dose self-administered by 
subjects in Cohort 1 (107 ng/mL and 400ng*h/mL , respectivel y). The semi -reclined position of 
the head and the instruction to subjec ts to sniff gently  following intranasal dosing are believed to 
be the cause for the increase in exposure observed in Cohort 2 compared with Cohort 1. As a 
result, the instructions for self-administration of intranasal esketamine were adapted to include 
thesemi -reclined position of the head and sniffing following dosing for all future studies.10
During the P hase 1 study ESKETINTRD1002 ,healthy  Japanese and Caucasian subjects received 
single intranasal doses of esketamine 28 mg, 56 mg, and 84 mg in a crossover manner.10On 
average, plasma esketamine C maxand AUC values were up to 48% higher in Japanese subjects as 
compared with Caucasian subjects.
Study  ESKETINTRD1003 compared the PK, safety , and tolerability  of intranasa lly administered 
esketamine in healthy  elderly  (65 years of age) and younger adult subjects (18 to 55 years of 
age, inclusive).11Subjects received a single intranasal treatment of esketamine 28 mg. Median 
time to reach the maximum plasma concentration (tmax) of esketamine was approximately 
30minutes for both age groups. The geometric means of the Cmaxand area under the plasma 
concentration -time curve from time 0 to infinite time, AUC ∞, for esketamine were 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 59approximately  21% and 17% higher, respectivel y, in the elderl y compared with younger adult 
subjects.11
Study  ESKETINTRD1012 evaluated the pharmacokinetics and safety of a single intranasal 
84-mg dose, which was self-administered by 8healthy  subjects who were ≥75 years of age and 
8healthy  younger adults (18 to 55 years of age).8Preliminary  data showed the median time to 
reach the maximum plasma concentration (tmax) of esketamine was 0.53 hours and 0.83 hours , in 
healthy  elderl y subjects ≥75 years of age and y ounger adults, respectivel y. The means of the C max
and area under the plasma concentration -time curve from time 0 to infinite time (AUC ∞), for 
esketamine were approximately  48% and 31% higher, respectively , in the elderly  compared with 
younger adult subjects. Differences were greater based on median Cmaxand AUC ∞values (97% 
and 63% higher in the elderly , respective ly).
Study  ESKETINTRD2003 is an ongoing 2-panel, doubly  randomized, double -blind, 
placebo- controlled, multicenter stud y.70Panel A was conducted in the United States and Belgium 
and Panel B in Japan. Panel A assessed the efficacy  and safety  of 3 dose strengths of intranasal 
esketamine (28, 56, and 84 mg) administered twice a week in subjects with TRD. Panel B 
(ongoing) is designed to assess the efficacy  and safet y of 14-mg and 56 -mg dose strengths. 
Results of a preliminary  analysis of data from the double -blind phase of Panel A indicate mean 
(standard deviation) esketamine concentra tions at 40 minutes postdose were 36.4 ng/mL  (16.4), 
58.1 ng/mL  (24.5), and 72.5 ng/mL  (34.2), respectively , for the 3 doses . The mean esketamine 
concentrations in plasma samples collected on Days 1 and 11 were similar ,suggesting that the 
PK results are consistent after repeated administration.
1.1.2.2. Pharmacody namics and Efficacy
The efficacy  of subanesthetic doses (0.5 mg/kg IV administered over 40 minutes) of IVketamine 
has been evaluated in approximately  192 subjects with MDD (cases and controls), and in 2 
studies in bipolar depressed subjects (meta -analyses).33This recently published meta -analysis of 
studies suggests that ketamine has a rapid onset (within 1 day) of antidepressant efficacy ,
including in those who have not benefitted from other antidepressant treatment s, used as 
monotherapy or in combina tion with oral antidepressant treatments .
Esketamine (0.2 and 0.4 mg/kg administered over 40 minutes) has similar, rapid, and robust 
antidepressant effect as that seen with IV ketamine. Adouble -blind, double -randomization, 
placebo- controlled study (ESKETIV TRD2001) enrolled 30 adult subjects with TRD : 10 in the 
IV placebo group, 9 in the IV esketamine 0.20-mg/kg group, and 11 in the IV esketamine 
0.40-mg/kg group (based on Day 1 randomization).12The full analysis set (FAS) of the primary  
efficacy  variab le(change in Montgomery -Asberg Depression Rating Scale [MADRS] total score 
from baseline Day 1 to Day 2)indicated that the improvement in both esketamine dose groups 
was statistically  significant (1-sided p-value=0.001 in both dose groups) compared with the 
placebo group. The mean (standard deviation) change from baseline Day 1 to Day 2 in MADRS 
total score was -4.9 (4.72) in the placebo group, -16.8 (10.12) in the esketamine 0.20-mg/kg 
group, and -17.8 (9.45) in the esketamine 0.40 -mg/kg group. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 60The studies listed above assessed the efficacy  of ketamine or esk etamine after a single dose as 
the primary  endpoint. The average duration of response to a single dose of ketamine (0.5 mg/kg) 
wasapproximately  5 days. Anopen -label study  demonstrated that the response to the first dose 
could be maintained by multiple infusions 3times a week over 2 weeks. The duration of 
response lasted for approximately  19 day s.1
The KETIVTRD2002 study  assessed whether multiple doses ofketamine given twice a week 
would also maintain the antidepressant response ;the data from this study  suggest thatketamine 
(0.50 mg/kg IV over 40 minutes) administered twice a week was sufficient for maintain ing the 
initial effect over a 4 -week treatment period.13
As noted above, Study  ESKETI NTRD2003 is a 2-panel, doubly  randomized, double -blind, 
placebo- controlled, multicenter stud y.70Panel A was conducted in the U nited States and Belgium 
and Panel B in Japan. Panel A assessed the efficacy  and safety  of 3 dose strengths of intranasal 
esketamine (28, 56,and 84 mg) administered twice a week in subjects with TRD. Panel B 
(ongoing) is designed to assess the efficacy  and safet y of 14-mg and 56- mg dose strengths. In 
Panel A, subjects in period 1 (1-week duration) were randoml y assigned in a 3:1:1:1 ratio to 
placebo (33 subjects), esketamine 28 mg (11subjects), esketamine 56 mg (11subjects) ,or 
esketamine 84 mg (12 subje cts). An initial analysis of the data from the double -blind phase of 
Panel A indicates that of the 67 subjects randomized in Period 1, 63 entered Period 2(1-week 
duration), in which 28 placebo subjects who were eligible for re-randomization at the end of 
Period 1, were randoml y assigned in a 1:1:1:1 ratio to placebo (N=6), esketamine 28 mg (N=8), 
esketamine 56 mg (N=9), or esketamine 84 mg (N=5). Subjects eligible for re -randomization had 
to have a Quick Inventory of Depressive Symptomatology –Self Report (QIDS-SR16) total score 
>11 at the end of Period 1. 
The improvement (with respect to change in MADRS total score from baseline Day 1 to Day 8) 
in all 3 esketamine dose groups reached statistical significance (p=0.021, p=0.001 ,and p<0.001 
for esketamine 28mg, 56 mg,and 84 mg, respectively ) compared with placebo. The results of 
the 2periods were consistent. The mean differences from placebo on Day 8(after 1 week of 
treatment), estimated using data from the combined periods ,were: 
Esketamine 28 mg: -4.2 (SE 2.09)
Esketamine 56 mg: -6.3 (SE 2.07)
Esketamine 84 mg: -9.0 (SE 2 .13)
The Cohen’s D effect sizes in P eriod 1 for esketamine compared with placebo were:
Esketamine 28 mg: low,0.43 (CI  -0.259 -1.118)
Esketamine 56 mg: high, 0.92 (CI 0.201- 1.621)
Eske tamine 84 mg: high,1.19 (CI 0.473 -1.883)
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 61The duration of effect with the 28-mg dose appears to be shorter ,with the MADRS total score 
higher on D ay 8 than on D ay 2. The duration of effect for the 56-and 84-mg doses appears to 
support twice -a-week dosing .
These data with intranasal esketamine support the hypotheses that intranasal esketamine is 
effective as a treatment fordepressive symptoms , that it has rapid onset of effect (typically
within 2 hours),and that multiple repeated sessions dose-dependentl yshow sustained response 
throughout the study  duration. A clear dose response was seen in the double -blind data in Panel 
A,and the point estimates and confidence interval ssuggest a high effect size (Cohen’s D) with 
the 56-mg and 84-mg dose group s, suppor ting further development. Based on PK data from 
ESKETINTRD1012 it is also possible that the 28-mg dose in the elderl y may overlap with the 
56mg dose in younger patients, so addition of the 28-mg dose in the elderly  may provide an 
efficacious dose while im proving safet y.
1.1.2.3. Safety  and Tolerability
Ketamine is a rapidl y acting general anesthetic that is approved and widel y used intravenousl y or 
intramuscularl y for the induction and maintenance of anesthesia in children and adults at a dose 
of 1 to 3 mg/kg given as a bolus. Ketamine is marketed as a racemic mixture and inEurope also 
as the S-enantiomer, esketamine. Ketamine was first introduced as an anesthetic in 1963 and is 
considered to have an excellent medical safety  profile (Ketalar®USPI  2012; Ketanest®S 
Summary  of Product Characteristics [SmPC] 2011 ).36,45,46,71,84
In the US prescribing information for ketamine HCl for injection and the SmPC for esketamine 
HCl for injection, the following adverse reactions were listed as very common, common, or 
frequent occurrences: Emergence or recovery  reactions, elevated blood pressure and pulse rate, 
stimulation of respiration, nausea, and vomiting. See Table 1 for details.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 62Table 1: Adverse Reactions Listed as Very Common, Common, or Frequent Occurre nces in the Product 
Inform ation of Anesthetic Ketam ine and Esketamine
System  Organ 
Class"Frequent" Adverse Reactions
Per Anesthetic Ketamine USPI45,a"Very Common" or "Common" Reactions
Per Anesthetic Esketam ine SmPC89,b
Psychiatric 
disordersFrequency: Emergence reactions occurred in 
approximately 12% of patients.
Characteristics: Severity varied from pleasant 
dreamlike states, vivid imagery, hallucinations, and 
emergence delirium. Some states were accompanied 
by confusion, excitement, and irrational behavior, 
which some patients recalled as an unpleasant 
experience.Frequency: Recovery reactions were common. When 
esketamine was the sole anesthetic, up to 30% of 
patients displayed dose -dependent recovery reactions.
Characteristics: Reactions included vivid dreams 
(including nightmares), nausea and vomiting, increased 
salivation, blurred vision, dizziness, and motor 
restlessnessc
Cardiac 
disordersBlood pressure and pulse rate were frequently 
elevated after administration. However, hypotension 
and bradycardia have been observed. Arrhythmia 
has also occurred.Common occurrences were temporary tachycardia and 
increase in blood pressure and heart rate 
(approximately 20% of the initial value was typical).
Respiratory, 
thoracic, and 
mediastinal 
disordersAlthough stimulation of respiration was a frequently 
observed effect, severe depression of respiration or 
apnea also could occur after rapid intravenous 
administration o f high doses.Common effects were increase in vascular resistance in 
pulmonary circulation and increase in mucus secretion. 
Increased oxygen consumption, laryngospasms, and 
temporary respiratory depression were common; the 
risk of respiratory depression wa s noted to depend on 
dose and injection speed.
Gastro -
intestinal 
disordersNo gastrointestinal effects were listed as frequent, 
but the USPI stated that anorexia, nausea, and 
vomiting have been observed.Common effects included nausea and vomiting.
Abbr eviations: SmPC, Summary of Product Characteristics; USPI, United States Prescribing Information
a."Frequent" was not defined numerically, except in the case of emergence reactions (12%). The terms "very common" and 
"common" did not appear in the adverse effects section of the USPI.
b."Very common" was defined in the SmPC as 1/10 and "common" was defined as 1/100 to <1/10.
c.The incidence of these events can be greatly reduced by the administration of a benzodiazepine.
Source: Investigator's Brochure f or esketamine (JNJ -54135419).42
Adverse Events Associated with Short -term Use of Intranasal Esketamine in Patients w ith 
MDD
Accordi ng to the SmPC for the esketamine solution for injection/infusion44,the following are 
reported as common adverse effects: transient tachy cardia, vivid dreams (including nightmares), 
nausea and vomiting, increased blood pressure, increased salivation, blurred vision, dizziness, 
motor unrest, increase in vascular resistance in pulmonary  circulation and increase in mucus 
secretion, increased oxygen consumption, laryngospasms, and temporary  respiratory  depression. 
It is reported that the risk of respiratory  depression ty picall y depends on the dosage and injection 
speed.44
Administration of esketamine is associated with a number of adverse events, which are transient 
in nature and typicall y resolve in 2 h ours or less from the start of drug administr ation. The phase 
1 study  ESKETINTRD1003 evaluated the pharmacokinetics and safet y of a single intranasal 
esketamine 28mg in 14 healthy  elderly subjects (65 years of age, with 3 subjects 75 years of 
age) and 20 health y younger adult subjects (18 to 55 years of age, inclusive). The incidences of 
the treatment emergent adverse events (TEAEs) were slightl y higher in young subjects (100% 
[20 subjects]) as compared with elderl y subjects (85.7% [12 subjects]). The most commonly 
reported TEAEs by preferred term (>20%) in elderl y subject s were dysgeusia and vertigo 
(9[64%], of 14 subjects each).11
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 63Additionally , another recently  completed Phase 1 study , ESKETINTRD1012, evaluated the 
pharmacokinetics and safety  of a single intranasal 84-mg dose,which was self-administered by 
8healthy  elderl y subjects who were ≥ 75 years of age (Cohort 1) and 8 healthy  younger adults 
(18 to 55 years of age–Cohort 2). An initial review noted TEAEs occurred in all subjects in 
both cohorts (100% [16 subjects – 8 in each cohort]) .The TEAE of illusions was reported in 
5younger subjects (62.5%) and in none of the elderly  subjects. In elderl y subjects, the incidence 
of TEAEs of vascular disorders (6subjects [75%] including hot flush [2 subjects , 25%] and 
hypertension [3subjects, 37.5% ])was higher than in younger adults (1subjec t, 12.5% -
hypertension). Vertigo and vertigo positional were more common in elderly  subjects (5subjects, 
62.8% and 1 subject , 12.5%, respectively ) than in y ounger adults (vertigo – 3 subjects , 37.5%).
In both cohorts, the maximal mean increase in systolic and diastolic blood pressure as well as 
heart rate was observed at 32 minutes post dose measurement time point. The mean increase in 
supine systolic blood pressure and pulse rate was slightly  greater in Cohort 1 (Table 2) than in 
Cohort 2, while the mean increase in the supine diastolic blood pressure was greater in Cohort 2. 
In both Cohort 1 and Cohort 2, the mean systolic and diastolic blood pressure returned to 
baseline within 4 hours post dose.
Table 2: Mean Supine Blood Pressure and Heart Rate -Cohort 1 (ESKETINTRD1012)
Supine SBP (mm Hg) Mean RangeMean Change 
from  Baseline Range
Day 1, predose 133.5 104; 164
Day 1, 32 min 165.3 141; 194 31.8 16; 44
Day 1, 50 min 154.1 127; 17 7 20.6 -5; 38
Day 1, 1.5 h 145.6 123; 177 12.1 -11; 32
Day 1, 4 h 130.4 130; 170 -3.1 -36; 31
Supine DBP (mm Hg)
Day 1, predose 68.0 54; 79
Day 1, 32 min 81.5 64; 93 13.5 3; 20
Day 1, 50 min 77.1 65; 87 9.1 -3; 17
Day 1, 1.5 h 76.5 63; 81 8.5 -6; 14
Day 1, 4 h 68.5 57; 81 0.6 -16; 17
Supine Heart Rate (beats/min)
Day 1, predose 60.0 48; 79
Day 1, 32 min 74.8 53; 102 14.8 3; 38
Day 1, 50 min 70.9 53; 96 10.9 1; 32
Day 1, 1.5 h 62.9 46; 81 2.9 -7; 17
Day 1, 4 h 78.0 55; 97 18.0 -6; 39
Abbreviations: SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure
In Panel A of the Phase 2 study  with intranasal esketamine (ESKETINTRD2003), the most 
common TEAEs (>10% of subjects in the pooled esketamine treatment groups) during the 
double -blind phase were : dizziness, headache, dissociation, dysgeusia (metallic taste), nausea, 
dissociative disorder, and oral hypoesthesia.78Dissociative symptoms were the most typical of 
these adver se events observed postdose and were characterized by feeling unreal or detached 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 64from reality  or by  perceptual changes. Transient perceptual changes (dissociation), dizziness, and 
nausea were t ypically seen immediately  after drug administration, resolving by2hours.
No deaths were reported in the double -blind or open -label phases ofthe ESKETINTRD2003 
study . One subject experienced an SAE of esophagitis in Panel A (double -blind phase, 
placebo/placebo treatment group ). A total of 3subjects withdrew during the double -blind phase 
because of adverse events. One subject in esketamine 28 mg group experienced a TEAE of 
syncope of severe intensity  on Day 2 of Period 1, 1 day after receiving the first dose of study 
medication. The subject discontinued from the study and received no further study  medication.  
The event resolved on the same day, and the investigator considered the event to be possibly 
related to the study  agent. Another subject in the placebo/esketamine 56 mg group experienced a 
TEAE of headache of moderate intensity  on Day 11 of Period 2. Study  medication was stopped 
following this event , which resolved on the same day. The investigator considered the event to 
be very likely related to the study  agent. A third subject in the esketamine group 
(84mg/es ketamine 84mg) experienced a TEAE of dissociative disorder (verbatim term: 
Dissociative syndrome) of moderate intensity  on Day 8 of Period 2 (day of the third esketamine 
84 mg dose in the study ). The subject discontinued from the study due to the event of
dissociative disorder, which resolved on the same day. The investigator considered the event to 
be very  likel y related to the study agent.78
In Panel A dissociative symptoms measured on the Clinician Administer ed Dissociative States 
Scale (CADSS) were dose-dependent and were observed to reduce significantly  with multiple 
doses over 2 weeks. No psychotic symptoms were seen. Transient increases in mean blood 
pressure (systolic and diastolic) were observed post dose following the intranasal esketamine 
administration.
The mean (standard deviation; SD) peak systolic blood pressure after the first administration in 
each dose group in Panel A was :
Placebo: 124.2 (11.51) mmH g; mean increase of 5.4 (7.84) mm Hg
Esketamine 28 mg: 131.8 (15.49) mmHg; mean increase of 10.4 (10.44) mm Hg
Esketamine 56 mg: 130.4 (18.64) mmHg; mean increase of 11.2 (15.01) mm Hg
Esketamine 84 mg: 146.1 (19.9) mmH g; mean increase of 17.1 (15.5) m Hg
Mean (standard deviation; SD) peak diastolic blood pressure after the first administration in each 
dose group was: 
Placebo: 81.2 (8.36) mmH g; mean increase of 3.8 (7.99) mmHg
Esketamine 28 mg: 85.7 (9.16) mmH g; mean increase of 6.5 (7.00) mmHg
Esketamine 56 mg: 86.5 (11.34) mmH g; mean increase of 7.2 (9.67) mm Hg
Esketamine 84 mg: 87.8 (10.62) mmHg; mean increase of 8.1 (9.12) mmHg
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 65The blood pressure increase ty picall y resolve dwithin 2 hours. Unlike dissociative symptoms , the 
blood pressure changes observed donot appear to attenuate over time with multiple doses . 
Transient increases in heart rate were also observed in parallel with blood pressure change . There 
was no clinicall y meaningful change in blood ox ygen level.
Adverse Events Associated with Chronic Use of Ketamine
There are no controlled studies of long-term use with esketamine/ketamine in patients with 
MDD. Much of the literature on chronic use of ketamine comes from data gathered from 
street /illegal use of the drug ,rather than sy stematically  conducted clinical studies. Data therefore 
should be interpreted with caution, as in many  cases, no baseline pre-drug data are available and 
drug exposure is poorly  documented. 
In a 1-year longitudinal study , 150 subjects were divided into 5 groups of 30subjects each. 
Frequent ketamine users (more than 4 times per week), infrequent ketamine users (at least once a 
month), abstinent users (abstinent for at least 1 month), polydrug controls, and non- users of illicit 
drugs.57Eight y percent of the participants were retested at the end of 1year. Cognitive deficits 
(including impairment in spatial working memory , pattern recognition memory  and category 
fluency ) were mainl y observed in frequent users and not with the infrequent users. Short -lasting ,
dose-dependent effec ts of psychosis were associated with ketamine users. There was no increase 
in symptoms over time,and symptoms were completely  reversible upon stopping use of 
ketamine. As noted, these data should be interpreted with caution, as baseline data predating 
drug use were not available. Furthermore, in their recent review, Morgan and Curran report that 
there is little evidence of any link between chronic, heav y use of ketamine and diagnosis of a 
psychotic disorder.56
The principal action of ketamine is at the NMDA receptor, and the consequences of ketamine use 
on cognition have been fairly widel y investigated. Several studies have examined cognitive 
function in infreque nt and frequent ketamine users.15,56,57,61Overall, infrequent or recreational 
ketamine use does not appear to be associated with long-term cognitive impairment .56The most 
robust findings are that frequent ketamine users (more than 5 times a week) exhibit impairments in 
both short -and long-term memory .54Although dosages have varied, dosages reported by ketamine 
users in this study  were much higher than the dosages of ketamine or equivalent doses of 
esketamine intended for use in treating TRD. Memory  impairments may be reversible when 
individuals stop using the drug, as they  were not found in a group of 30 ex -ketamine users who had 
been abstinent for at least a y ear.56,57
Ketamine -induced ulcerative cystitis is a recentl y identified complication.56The most common 
symptoms are frequency and urgency  of urination, dysuria, urge incontinence , and occasionall y 
painful hematuria (blood in urine). Computerized tomog raphy scans of these subjects revealed a 
marked thickening of the bladder wall, a small bladder capacit y,and perivesicular stranding 
consistent with severe inflammation. At cystoscopy ,all patients had severe ulcerative cystitis. 
Biopsies in 4of these cases found denuded urothelial mucosa with thin layers of reactive and 
regenerating epithelial cells,and ulcerations with vascular granulation tissue and scattered 
inflammatory  cells. Cessation of ketamine use provided some relief of symptoms. Most of the 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 66described cases are in near-daily users of ketamine for recreational purposes. The prevalence is 
difficult to determine ,as it is seen in recreational users who often do no t seek help.
The majority  of cases resolve after stopping ketamine use, one -third re maining static.
Abuse Liability, Dependence, and Withdrawal
There are a number of reports of ketamine dependence in the literature but no large -scale studies, 
and so the incidence of ketamine dependence is largel y unknown.41,43,55,56,65An interview study  
of 90 ketamine users found that57% of frequent users, 43% of infrequent users, and 60% of ex-
users expressed concerns about ketamine addiction.59The majority  of frequent users in that study  
reported using the drug without stopping until supplies ran out, so compulsive patterns of 
behavior are also a concern. Oral ketamine has also been evaluated as a positive control in 
human abuse potential studies, with dosages of 65 mg and 110 mg reported as appropriate for 
use as positive controls for future abuse potential studies of compounds with a similar 
mechanism of action or with possible perception- altering effects.79There is conflicting evidence 
of the existence of a "withdrawal syndrome" after cessat ion of ketamine use.56Cravings seem to 
be a key problem in frequent users: 28 of the 30 daily  users in 1 study  reported having tried to 
stop taking the drug but failed; all reported ketamine cravings as the reason for failure.56The 
same study  found that 12 of the 30 daily  users reported withdrawal symptoms characterized by 
anxiety , shaking, sweating, and palpitations when they stopped using. A few published case 
studies also show craving and somatic and psychological aspects of anxiety  as withdrawal 
symptoms.14However, a specific ketamine withdrawal s yndrome has not yet been described.56
Please refer to the Investigator’s Brochure for a summary  of the adverse events reported in 
ketamine and esketamine studies.42
1.1.3. Marketing Experience
No intranasal formulation of esketamine is currently  marketed.
1.2. Active Comparator sin Double -blind Induction Phase
This study  will evaluate a flexible dose regimen of intranasal esketamine (28 mg, 56 mgor
84mg) plus a newly  initiated oral antidepressant, compared with a newly  initiated oral 
antidepressant ( active comparator) plus intranasal placebo.
In the double -blind induction phase, subjects will be assigned to receive 1 of 4 commerciall y 
available oral antidepressant medications from 2 different classes of antidepressant medications, 
selective serotonin reuptake inhibitors (SSRI s: Escitalopram orsertraline ),or serotonin and 
norepinephrine reuptake inhibitors (SNRI s:Duloxetine or venlafaxine extended release [ XR]).
The indications and safety information provided below for each oral antidepressant are from the 
USPI .24,28,81,87For further information, please refer to the appropriate package insert applicable to 
the local country  in which the study  is being conducted.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 67In the US, all of the oral antidepressant options include a black box warning in the prescribing 
information regarding suicidality  and antidepressant drugs. The black box warning informs the 
prescriber that antidepressant treatment s increased the risk, as compared with placebo, of suicidal 
thinking and behavior (suicidality ) in children, adolescents, and young adults in short -term 
studies of MDD and other psychiatric disorders. It states that anyone considering using the 
antidepressant in this population must balance the risk with the clinical need. Refer to the US 
prescribing information for the entire content of the black box warning.24,28,81,87
1.2.1. Selective Serotonin Reuptake Inhibitors
1.2.1.1. Escitalopram
Escitalopram is indicated in adults for acute and maintenance treatment of MDD and acute 
treatment of generalized anxiety  disorder.28
The starting dosage for MDD in the USPI is 10 mg once dailywith a maximum of 20 mg once 
daily . If the dosage is increas ed to 20 mg, this should occur after a minimum of 1 week. No 
additional benefits have been seen at 20 mg/day  dose; 10 mg/day  is the recommended dose for 
most elderly  patients and this is the maximum dose that will be used in the current study .
In adult MDD subjects treated with escitalopram, the most commonly  observed adverse reactions 
with escitalopram (incidence of approximately  5% or greater and approximately  twice the 
incidence in placebo subjects) were insomnia, ejaculation disorder (primarily  ejaculat ory delay), 
nausea, sweating increased, fatigue, and somnolence.
Contraindications to the use of escitalopram include serotonin s yndrome and monoamine oxidase 
inhibitor (MAOI) use (concomitant use with MAOIs intended to treat psychiatric disorders, 
linezolid, or IV methy lene blue; use within 14 days of stopping treatment with an MAOI 
intended to treat psychiatric disorders [in addition, an MAOI should not be used within 14days 
of stopping escitalopram]); concomitant use with pimozide; and known hypersensit ivity to 
escitalopram or citalopram or any  of the inactive ingredients.
As with most SSRI s, a gradual reduction in the dosage rather than abrupt cessation of 
escitalopram treatment is recommended whenever possible.
1.2.1.2. Sertraline
Sertraline HCl is indicated inadults for the treatment of MDD, obsessions and compulsions in 
patients with obsessive compulsive disorder, panic disorder (with or without agoraphobia), 
post-traumatic stress disorder, premenstrual d ysphoric disorde r, and social anxiety  disorder.81
According to the US prescribing information , sertraline should be administered at a dose of 
50mg once daily for the treatment of MDD . While a relationship between dose and effect has 
not been established for MDD , obsessive compulsive disorder , panic disorder, post-traumatic 
stress disorder, or social anxiety  disorder, patients were dosed in a range of 50- 200 mg/day  in the 
clinical trials demonstrating the effectiveness of sertraline for the treatment of these indica tions. 
Consequently , a dose of 50 mg, administered once daily, is recommended as the initial 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 68therapeutic dose. Patients not responding to a 50 mg dose may benefit from dose increases up to 
a maximum of 200 mg/day . Dose adjustment is recommended in the elde rly.
In the current study , to improve tolerability , an initial starting dose of 25 mg is used based on 
experience in clinical practice with elderl y patients. Given the 24 hour elimination half-life of 
sertraline, dose changes should not occur at intervals of less than 1 week. In the current study , 
the highest dose is 150mg/day and patients not tolerating higher doses of sertraline may  have the 
dose reduced to a minimum of 50 mg/day .
Contraindications to the use of sertraline include serotonin syndrome and MAOI use 
(concomitant use with MAOIs intended to treat psychiatric disorders, linezolid, or IV methy lene 
blue; use within 14 days of stopping treatment with an MAOI intended to treat psychiatric 
disorders); concomitant use with pimozide; and known hy persen sitivity  to sertraline or any  of the 
inactive ingredients. 
In adult subjects, the most common TEAEs associated with the use of sertraline (incidence of at 
least 5% for sertraline or at least twice that for placebo within at least one of the indications) 
were ejaculation failure, dry mouth, increased sweating, somnolence, tremor, dizziness, fatigue, 
pain, malaise, abdominal pain, anorexia, constipation, diarrhea/loose stools, dyspepsia, nausea, 
agitation, insomnia, and decreased libido.
As with most SSRI s, a gradual reduction in the dosage rather than abrupt cessation treatment is 
recommended whenever possible.
1.2.2. Serotonin and Norepinephrine Reuptake Inhibitors
1.2.2.1. Duloxetine
Duloxetine is indicated in adults for MDD, generalized anxiety  disorder ,diabetic periphe ral 
neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.24
The starting dosage for MDD in the USPI is 40 to 60 mg/day . The dosage for acute treatment is 
40to 60mg/day , with maintenance treatment at 60 mg/day . A starting dose of 30 mg/day has 
also been evaluated.91In the current study , for improved tolerability in an elderly  patient 
population , the initial starting dose is 30 mg/day.
No dose adjustment is recommended for elderly  patients on the basis of age. As with any drug, 
caution should be exercised in treating the elderly . When individualizing the dosage in elderl y 
patients, extra care should be taken when increasing the dose. The maximum dosage is 
120mg/day , although there is no evidence that dosages greater than 60 mg/day  confer any 
additional benefits. The maximum dose to be used in this study  is 60 mg/day.
For pooled studies for all approved indications, the most commonly  observed adverse reacti ons 
in duloxetine -treated subjects (incidence of at least 5% and at least twice the incidence in 
placebo subjects) were nausea, dry  mouth, somnolence, fatigue, constipation, decreased appetite, 
and hyperhidrosis. As observed in diabetic peripheral neuropat hy studies, duloxetine treatment 
worsens gl ycemic control in some subjects with diabetes.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 69Contraindications to the use of duloxetine include use of an MAOI  concomitantly  or within 
2weeks of MAOI use; and use in patients with uncontrolled narrow -angle glau coma
A gradual reduction in the dosage rather than abrupt cessation is recommended whenever 
possible.
1.2.2.2. Venlafaxine Extended-r elease
Venlafaxine XR is indicated in adults for MDD and social anxiety  disorder.87
Thestarting dosage for MDD in the USPI  is 75 mg/day  (in some patients, 37.5 mg/day  for 4 to 
7days), with a dosage increase by 75 mg/day at intervals of 4 days or longer, and a maximum 
dosage of 225mg/day. No dose adjustment is recommended for the elderly  on the basis of age 
alone, although other clinical circumstances, some of which may  be more common in the elderl y, 
such as renal or hepatic impairment.
Dosage reductions are recommended for hepatic impairment (including mild) and renal 
impairment. In the current study , the starting dose of venlafaxine is 37.5 mg and the maximum 
dose attained is 150 mg based on the 4 week double -blind treatment duration. Patients not 
tolerating higher doses of venlafaxine XR may have the dose reduced to a minimum of 
75mg/day .
Contraindications to the use of venlafaxine XR include serotonin syndrome and MAOI use 
(concomitant use with MAOIs intended to treat psychiatric disorders, linezolid, or IV methy lene 
blue; use within 14 days of stopping treatment with an MAOI intended totreat psychiatric 
disorders ); concomitant use with pimozide; and known hy persensitivity  to venlafaxine XR or an y 
of the inactive ingredients.
In adult subjects with MDD, adverse events in short -term studies that occurred in at least 5% of 
the subjects receiving venlafaxine XRcapsules and at a rate at least twice that of the placebo 
group were abnormal ejaculation, gastrointestinal complaints (nausea, dry mouth, and anorexia), 
central nervous s ystemcomplaints (dizziness, somnolence, and abnormal dreams), and sweating.
Sustained hypertension is noted within the Warnings and Precautions section. Preexisting 
hypertension should be controlled before treatment with venlafaxine XR. It is recommended that 
patients receiving venlafaxine XRtablets have regular mon itoring of blood pressure. For patients 
who experience a sustained increase in blood pressure while receiving venlafaxine XR, either 
dosage reduction or discontinuation should be considered.
Across most indications, a dose-related increase in supine systolic and diastolic blood pressure 
was evident in venlafaxine XR-treated patients. Across all clinical studies , 1.4% of subjects in 
the venlafaxine XR-treated groups experienced a 15 mmHg increase in supine diastolic blood 
pressure ,with blood pressure 105 mmHg ,compared with 0.9% of subject s in the placebo 
groups. Similarly , 1% of subjects in the venlafaxine XR-treated groups experienced a 
20mmHg increase in supine systolic blood pressure ,with blood pressure 180 mmHg ,
compared with 0.3% of subjects in the placebo groups.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 70A gradual dosage reduction, individualized as necessary , is recommended to avoid 
discontinuation sy mptoms.
1.3. Overall Rationale for the Study
This study  is being conducted to evaluate the efficacy , safet y, and tolerability  of flexibly  dosed
intranasal esketamine (28 mg, 56 mg or 84mg) plus anewly  initiated oral antidepressant in 
elderl ysubjects with TRD . The study  will serve as a pivotal Phase 3 short- term efficacy  and 
safet y study  in support of regulatory  agency requirements for registra tion of intranasal 
esketamine for the treatment of TRD .
2. OBJECTIVE SAND HYPOTHESIS
2.1. Objectives
Primary Objective
The primary  objective of this study  is to evaluate the efficacy  of switching elderly  subjects with 
TRD from a prior antidepressant treatment (to which they have not responded) toflexibly -dosed 
intranasal esketamine (28 mg, 56 mg or 84 mg) plus a newly  initiated oral antidepressant 
compared with switching to a newly  initiated oral antidepressant (active comparator) plus 
intranasal placebo, in improving depressive symptoms, as assessed by the change from baseline 
in the MADRS total score from Day  1 (pre-randomization )to the end of the 4 -week double -blind 
induction phase. 
Secondary Objectives
To assess the effect of intranasal esketamine plus a newl y initiated oral antidepressant 
compared with a newl y initiated oral antidepressant (active comparator) plus intranasal 
placebo on the following parameter s in elderly subjects with TRD:
Depression response rates,
Depression remission rates,
Overall severit y of depressive illness,
Health-related qualit y of life and health status.
To investigate the safet y and tolerability  of intranasal esketamine plus a newly  initiated oral 
antidepressant compared with a newly  initiated oral antidepressant (active comparator ) plus 
intranasal placebo in elderly subjects with TRD, including the following parameters:
Treatment -emergent adverse events (TEAEs) , including TEAEs of special interest
Local nasal tolerability
Effects on heart rate, blood pressure, respiratory  rate, and blood oxy gen sat uration
Effects on alertness and sedation
Potential p sychosis -like effects
Dissociative sy mptoms 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 71Potential e ffects on cognitive function 
Potential e ffects on suicidal ideation/behavior 
Potential t reatment -emergent s ymptoms of cy stitis and/or lower urinary  tract symptoms 
Potential withdrawal and/or rebound symptoms following cessation of intranasal 
esketamine treatment
Potential e ffects on sense of smell 
To assess the PKof intranasal esketamine in elderl y subjects with TRD receiving 
intranasal esketamine plus a newl y-initiated oral antidepressant.
Exploratory Objectives
To assess the pharmacokinetic /pharmacody namic (PK/PD) relationship of intranasal 
esketamine and MADRS total score in elderl y subjects with TRD.
To assess the potential relationship of biomarkers with response/nonresponse to intranasal 
esketamine or oral antidepressants inelderl ysubjects with TRD.
2.2. Hypothesis
The hypothesis for this study  is that,in elderly subjects with TRD, switching from a failed 
antidepressant treatm ent to intranasal esketamine plus a newly  initiated oral antidepressant is 
superior to switching to a newly  initiated oral antidepressant treatment (active comparator) plus 
intranasal placebo in improving depressive s ymptoms .
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview of Study  Design
This is a randomized, double -blind, active -controlled, multicenter study in male and female 
elderl y subjects with TRD to assess the efficacy , safet y, and tolerability  of flexibly  dosed 
intranasal esketamine (28 mg, 56 mg or 84 mg) plus a newly  initiated oral antidepressant, 
compared with a new ly initiated oral antidepressant (active comparator) plus intranasal placebo. 
The study  has3phases which are briefl y described below.
Screening/prospective observational phase (4-week duration + optional 3-week taper 
period )
This phase will prospectively  assess treatment response to the subject’s current oral 
treatment regimen. At the start of the screening/prospective observational phase, the subject 
must have had documented nonresponse to atleast one antidepressant treatment (based on 
MGH -ATRQ criteria ) in the current episode of depression , and the subject is taking a 
different oral antidepressant treatment (on the MGH -ATRQ) for at least the previous 
2weeks at or above the minimum therapeu tic dose . This antidepressant treatment, as well as 
any other ongoing medications being taken for depression at screening (including 
adjunctive/augmentation therapies), will continue from the start of Week 1 through the end 
of Week 4 of the screening/prospective observational phase. Dose adjustment is permitted 
per clinical judgment, but the oral antidepressant treatment is to remain at or above the 
minimum therapeutic dose (per the MGH -ATRQ) through the end of Week 4. After 4 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 72weeks, subjects who are nonres ponders totheir current oral antidepressant treatment (as 
assessed by independent, remote raters) may be eligible to proceed to the double -blind 
induction phase. Non-response at the end of the screening/prospective observational phase is 
defined as ≤25% improvement in the MADRS total score from Week 1 to Week 4 and a 
MADRS total score of ≥24 on Week 2 and Week 4.
Eligible subjects who are entering the double -blind induction phase will discontinue all of
their current antidepressant treatment (s), including adjunctive/augmentation therapies. Of 
note, subjects taking benzodiazepines (at dosages equal to or less than the equivalent of 
6mg/day  of lorazepam) and/or permitted non-benzodiazepine sleep medications (eg, 
zolpidem, zaleplon) during the screening/prospective observational phase can continue these 
medications. No dose increases beyond the equivalent of 6 mg/day  of lorazepam or new 
benzodiazepine sare permitted during the screening/prospective observational phase . If 
clinically  indicated, a subject’s current antidepressant treatment (s) may be tapered and 
discontinued over an additional , optional period of up to 3week sper the local prescribing 
information or per clinical judgment. This 3 week period may also be used to optimize 
medical management if neede d to facilitate subject participation (eg, treatment of blood 
pressure or diabetes, wean from other medications, etc,). In such cases, if there is no planned 
taper, the oral regimen should be continued in the interim and then discontinued by  Day1 of 
the double -blind induction phase.
As a new oral antidepressant will be initiated on Day 1 of the double -blind induction phase, 
eligible subjects who do not require a tapered discontinuation of their antidepressant 
treatment (s) can proceed immediately  into the double -blind induction phase.
Double -blind induction phase (4-week duration)
Approximately  148eligible subjects will be randomly  assigned at a 1:1 (n=74 subjects per 
treatment arm) to receive double -blind intranasal treatment with either esketamine (28 mg,
56 mg or 84mg) or placebo. Starting with a dose of 28 mg on Day 1, the intranasal 
treatment sessions (esketamine or placebo ) will occur twice weekly  for 4weeks . In addition, 
all subjects will initiate a new, open -label oral antidepressant on Day 1 that will be taken 
daily  for theduration of the induction phase. The assigned oral antidepressant will be 1 of 4 
oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR) 
that the subject has not previously  had a nonresponse to in the current depressive episode, 
has not been previously  intolerant to (lifetime), and is available in the participating country .
Subjects taking benzodiazepines (at dosages equal to or less than the equivalent of 6 mg/day 
of lorazepam) and/or permitted non-benzodiazepine sleep medications (eg, zolpidem, 
zaleplon) during the screening/prospective observational phase can continue these 
medications during the induction phase. No dose increases beyond the equivalent of 
6mg/day  of lorazepam or new benzodiaze pine medications are permitted during the 
induction phase, with the exception of the use of permitted benzodiazepine rescue 
medication.
At the end of the double -blind induction phase, regardless of response status, subjects may 
be eligible to participate in the subsequent study  ESKETINTRD3004 if they meet all other 
study  entry criteria. ESKETINTRD3004 is along-term open -label safety  study involving 
repeated treatment sessions of intranasal esketamine .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 73If a subject withdraws from the study  before the end ofthe double -blind induction phase for 
reasons other than withdrawal of consent, an Early  Withdrawal visit should be conducted 
within 1 week of his/her discontinuing from the study , followed by the follow -up phase .
Follow -up phase (2- week duration)
This phase will include all subjects who withdraw early before the end of the double -blind 
induction phase , or choose not to participate in the subsequent ESKETINTRD3004 safet y 
study , and have received at least 1 dose of intranasal study  medication in the double -blind 
induction phase. There will be no intranasal treatment sessions administered during this 
phase.
At the start of the follow -up phase, further clinical/standard of care for the treatment of 
depression will be arranged by the study  investigator and/or the subject’s treating physician. 
All subjects will be provided with an additional 2-week suppl y of the oral antidepressant 
medication to ensure thatthere is no interruption of oral antidepressant therap y during the 
transition to further clinical/standard o f care. The decision to continue the oral 
antidepressant in this phase will be at thediscretion of the investigator, however, in order to 
better assess potential withdrawal symptoms from intranasal study  medication the oral 
antidepressant medication shoul d be continued for the2 weeks of the follow -up phase unless 
determined as not clinically  appropriate.
Taking into consideration the up to 3-week optional taper period, the duration of a subject’s 
study  participation will be 8 to 11weeks (for subjects continuing into ESKETINTRD3004) or 
13weeks (for subjects completing the follow -up phase).
A diagram of the stud y design is provided in Figure 1.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 74Figure 1: Study Design for ESKETINTRD3005
*followed by optional, up to 3 week Taper  if clinically indicated.
AD=antidepressant. DB=double- blind. D/C=discontinued. Esk=Esketamine. MDD= major depressive disorder . 
OL=open -label. PBO=placebo.
Note: Subjects who withdraw  early from the double -blind induction phase and receive at least 1 dose of intranasal 
study medication in the double- blind induction phase willhave an Early Withdrawal visit performed and then
proceed into the follow -up phase.
A planned interim anal ysis is de scribed in Section 11.3.
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study . 
Please r efer to Section 11.9, Independent Data Monitoring Committee, for details.
3.2. Study Design Rationale
3.2.1. Study Population
The study  population will include elderly men and women ,therefore the lower age limit of 
65years (inclusive) , is appropriate. 
Subject swill meet Diagnostic and Statistical Manual of Menta l Disorders (5th Edition; DSM -5)
diagnostic criteria for single -episode MDD (if a single episode, duration of episode must be 
2years) or recurrent MDD , without psychotic features, based upon clinical assessment, and 
confirmed by the Mini -International Neuropsy chiatric Interview (MINI). At the start of the 
screening/prospective observational phase, the subject must have an Inventory  of Depressive 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 75Symptomatology -Clinician rated, 30-item (IDS-C30) total score of 31, which corresponds to
moderate to severe d epression. 
Treatment -resistant depression is defined as a lack of clinicall y meaningful improvement after 
treatment with at least 2 different antidepressant agents prescribed in adequate dosages for 
adequate duration. At the start of this study , subjects must have had nonresponse (defined as 
≤25% improvement) to 1but 8(if current episode is >2 years, upper limit applicable to only
the last 2 years) oral antidepressant treatment staken at adequate dosage and for an adequate 
duration, as assessed on the Massachusett s General Hospital –Antidepressant Treatment 
Response Questionnaire ( MGH -ATRQ) and documented by records (eg, medical 
/pharmacy /prescription records, a letter from the treating physician , etc.) for the current episode 
of depression. Subjects who have had some initial response, but then lose the respons e (eg, 
tolerance effects/brad yphylaxis etc.), to an antidepressant treatment will not be considered to 
have failed that antidepressant treatment. The use of historical data to define nonresponse to 
treatment prior to patient enrollment in a treatment study  is considered practical and valid. The 
MGH -ATRQ is a validated tool to assess treatment response.
In addition, at the start of the screening/prospective observational phase, the subject must be 
taking a different oral antidepressant treatment (on the MGH -ATRQ) for at lea st the previous 
2weeks at or above the minimum therapeutic dose . This antidepressant treatment, as well as any 
other medications being taken for depression at screening (including adjunctive/augmentation 
therapies), will continue from the start of Week 1 through the end of Week 4 of the 
screening/prospective observational phase. Dose adjustment is permitted per clinical judgment, 
but the oral antidepressant treatment is to remain at or above the minimum therapeutic dose (per 
the MGH -ATRQ) through the end of Week 4.
Non-response at the end of the screening/prospective observational phase is defined as ≤25% 
improvement in the MADRS total score from Week 1 to Week 4and a MADRS total score of 
≥24on Week 2 and Week 4.
The subject’s current major depressive episode, depression symptom severity (Week 1 MADRS
total score ≥2 4required ), and antidepressant treatment response in their current depressive
episode (retrospectivel y assessed) must be deemed valid for participation in the clinical study  
based on a Site Independent Qualification Assessment. The Site Independent Qualification 
Assessment is a tool to facilitate subject selection for MDD clinical studies, with a goal to ensure 
enrollment of subjects who have symptoms that reflect the current state of illness and that these 
symptoms can be reliably  measured with appropriate measurement tools, as well as to minimize 
placebo response.
3.2.2. Study Phases
The 4 -week duration of the screening/prospective observational phase will provide adequate time 
to assess subject eligibility  according to the study  entry criteria, while also allowing for a 
prospective confirmation of nonresponse to the current antidepressant treatment(s) that is 
continued for the duration of this phase. The dose of all antidepressant 
medication(s) /treatment(s) should remain unchanged throughout the screening/prospective 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 76observational phase. This method of recruitment allows subjects to enter the study  on a variet y of 
different antidepressant medications that they had been taking, which mimics clinical practice 
and yet allows for prospective demonstration of treatment resistance to the current antidepressant 
treatment. Even though there is no depression rating score available at the start of the 
antidepressant treatment, the subjects at screening will have to meet criteria formoderate to 
severe depression.
After 4 weeks of prospective observation of continuation of the current antidepressant treatment 
and assessment of treatment response, subjects who meet the predefined nonresponse criteria and 
are eligible to enter the double -blind induction phase will discontinue all of the current 
antidepressant treatment s, including adjunctive/augmentation therapies, prior to starting the next 
phase.
Nonresponders who are eligible to enter the double -blind induction phase are permitted to have 
up to 3additional weeks to taper and discontinue their current antidepressant treatment prior to 
entry  into the double -blind induction phase per the local prescribing information or clinical 
judgment (eg, tolerability  concerns). The optiona l taper of up to 3 weeks is expected to provide 
an adequate amount of time for taper and discontinuation. This 3 week period may also be used 
to optimize medical management if needed to facilitate subject participation (eg, treatment of 
blood pressure or diabetes, wean from other medication, etc,). In such cases, if there is no 
planned taper, the oral regimen should be continued in the interim and then discontinued by 
Day 1 of the double -blind induction phase.
As described in Section 1.1.2 , the duration of the 4-week double -blind induction phase was 
selected based upon the onset of effect of typical antidepressant treatments, with a 4week 
duration considered to be sufficientl y long to show the antidepressant effects of the active 
comparator . Preliminary findings from an analysis of antidepressant treatments were presented 
recentl y, as well asa completed analy sis of 24 recent MDD studies that compared study
durations of 4, 6,and 8weeks. Exploratory  analyses were conducted for each of the study 
durations using mixed- effects model for repeated measures (MMRM) , but excluding data bey ond 
the duration of interest. These preliminary  findings suggest that it is plausible to shorten the
study duration down to 4 weeks.48,97Similarly ,it has been demonstrated that improvement of 
25% on the Hamilton Depression 17-item Rating Scale (HDRS) on Day 14 was a significant 
cutoff value to pre dict response after 5 weeks of treatme nt and a lack of improvement (ie , <25%) 
by Day 14 predicted poor response after 5weeks of treatment.63All togethe r, these results 
suggest that a 4-week duration should be adequate to assess antidepressant response.
For subjects entering the follow -up phase, the 2-week duration following the last dose of 
intranasal study  medication will allow sufficient time to assess safet y and tolerability after 
cessation of intranasal study medication , including potential withdrawal symptoms. During this 
follow -up phase, further clinical/standard of care for the treatment of depression will be arranged 
by the study  investigator and/or the subject’s treating phy sician.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 773.2.3. Blinding and Randomization
Blinded intranasal treatment will be used to reduce potential bias during data collection and 
evaluation of clinical endpoints.
An intranasal placebo control will be used in the double -blind induction phase to establish the 
frequency  and magnitude of changes in clinical endpoints that may occur in the absence of 
intranasal active treatment.
Randomization will be used to minimize bias in the assignment of subjects to intranasal 
treatment groups, to increase the likelihood that known and unknown subjec t attributes (eg, 
demographic and baseline characteristics) are evenly  balanced across treatment groups, and to 
enhance the validity  of statistical comparisons across treatment groups. The randomization will 
be stratified b y country  and class of antidepressant (S NRI or S SRI) with an allocation ratio of 1:1 
to intranasal placebo orintranasal esketamine. The stratification is aimed at balancing treatment 
groups across country  and class of antidepressant .
3.2.4. Treatment Groups and Dose Selection
The 2 treatment gr oups in the double -blind induction phase are:
Intranasal esketamine ( 28 mg, 56 mg  or 84 mg) 
Intranasal placebo
Of note, to improve tolerability , subjects who are assigned to esketamine will start with 28 mg of 
intranasal esketamine on Day 1.
In all treatm ent groups, subjects will switch to a new, oral antidepressant, initiated on Day 1 of 
the double -blind induction phase, that will continue for the duration of the phase and longer, if 
applicable.
The treatment groups will allow for an evaluation of the efficacy , safety , and tolerability  of 
flexibly  dosed intranasal esketamine , plus a newly initiated oral antidepressant as compared with
a newl y initiated oral antidepressant treatment plus intranasal placebo as an active comparator in 
elderl y subjects with TR D. 
Intranasal Study Drug
The dose selection (28 mg, 56 mg and 84mg) and administration interval (2 treatment sessions 
per week for 4 weeks) for this study  were based on the sponsor’s previous clinical data; in 
particular the results from Studies ESKETIVT RD2001, KETIVTRD2002, ESKETI NTRD1001, 
ESKETINTRD1003, ESKETINTRD1012 and Panel A of the ESKETINTRD2003 study , 
described above in Section 1.1.2 . 
The data from Study  ESKETINTRD2003 Panel A support the hypotheses that both the 56mg 
and 84 mg doses are effective as a treatment for depression in subjects with TRD, that they have 
a rapid onset of effect, and that 2 treatment sessions per week can sustain the response 
throughout the 4week duration of the double -blind induc tion phase. In addition, the 56mg and 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 7884mg dosages were generally  well tolerated by subjects. PK data from study 
ESKETINTRD1003 (CSR ESKETI NTRD1003 in preparation) which evaluated intranasally 
administered esketamine in elderl y (65 years of age) a nd younger adult subjects (18 to 55 years 
of age, inclusive), indicate dplasma esketamine Cmaxand AUC values are relativel y comparable 
between the elderl y and younger adults.11More recentl y, Study  ESKETINTRD1012 evaluated 
the pharmacokinetics and safet y of a single intranasal 84 mg dose in elderly subjects ≥75 years 
of age. Preliminary  data showed the means of the Cmaxand AUC ∞were approximately  48% and 
31% higher, respectivel y, in the elderly  compared with younger adult subjects. Differences were 
greater based on median Cmaxand AUC ∞values (97% and 63% higher in the elderl y, 
respectivel y).Based on PK data from ESKETI NTRD1012 it is also possible that the 28 mg dose 
in the elderl y may overlap with the 56 mg dose in younger patients, so addition of the 28 mg 
dose in the elderl y ma y provide an ef ficacious dose while improving safet y.
In the current study , subjects who are randomly assigned to esketamine will start with 28mg of 
intranasal esketamine on Day 1. The dose of esketamine may be maintained at 28mg or 
increased to 56 mgon Day 4. On Day 8, 11 or 15the dose may be maintained, increased or 
reduced by 28 mg, with no further increases in dose permitted after Day 15. The dose may be 
decreased by 28 mg on subsequent dosing days. The rationale for this approach is that using the 
lower starting dose (28 mg) initially  and then adjusting the dose in increments of 28 mg based on 
efficacy  and tolerability may allow subjects to adjust to the effects of the lower dose before 
going to higher dose s. For example, internal data from the CADSS suggest a dose response, with 
the greatest effect seen initially  on the 84 mg dose (ESKETINTRD2003). However, on 
subsequent repeated dosing, dissociative symptoms lessen. Starting with the lower dose may 
therefore limit the number of elderl y subjects discontinuing thestudy treatment because of 
intolerability . 
The use of flexible dosing ,rather than using a fixed dose,of intranasal esketamine is considered 
to facilitate improved tolerability  by graduall y increasing to a higher dose and will also inform 
clinical pract ice, as many  clinicians prefer to gradually  increase, and then adjust as clinically 
required, the dose of an antidepressant medication in the elderl y population.
Oral Antidepressant
On Day 1 of the double -blind induction phase , a new, open -label oral antidepressant treatment 
will be initiated in all subjects. Each subject will be assigned to receive 1 of 4 oral antidepressant 
medications from 2 different classes of antidepressant treatments, an SSRI  (escitalopram or 
sertraline) or an SNRI (duloxetine or venlafaxine XR ).
The assignment of the oral antidepressant treatment will bedone by the investigator based on 
review of the MGH -ATRQ and relevant prior antidepressant medication treatment information .
These 2 classes were selected because they are the most commonly  prescribed antidepressant 
classes in this population and are generall y well- tolerated. The oral antidepressant treatment
assigned will be one that the subje ct has not previously  had a nonresponse to in the current 
depressive episode, has not been previously  intolerant to (lifetime), and is available in the 
participating country . Dosing of the oral antidepressant will begin on Day 1.A mandatory 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 79titration schedule is provided (Attachment 3)to ensure that the oral antidepressant is taken at an 
adequa te dosage and duration for efficacy  assessment at the end of the double -blind induction 
phase as well as for potential maintenance of effect (in the subsequent ESKETINTRD3004
study ).Doses are not to exceed the maximum dose defined in the titration schedul e. If higher 
doses are not tolerated, a down -titration is permitted based on clinician’s judgment.
3.2.5. Efficacy  Measures
MADRS
The 10-item clinician -administered MADRS was designed to be used in subjects with MDD to 
measure the overall severity  of depressive s ymptoms .53,54The MADRS scale has been selected
as the primary  efficacy  measure for this study  because it is validated, reliable, and acceptable to 
regulatory  health authorities as a primary  scale to determine efficacy  in major depression.
The primary  efficacy  endpoint is the change in the MADRS total score from baseline 
(Day 1prior to randomization) to the end of the 4 -week double -blind induction phase.
In this stud y, subjects in either of the 2treatment groups who respond to the study  medication 
(ie,responders) are defined as subjects who meet the criterion for response defined as 50% 
reduction in the MADRS total score from baseline (Day  1 pre-randomization) to the end of the 
4-week double -blind induction phase.
MADRS will also be used to evaluate a secondary  objective assessing proportion of subjects 
with response and those in remission (defined as subjects with a MADRS total score 12)at the 
end of the 4-week double -blind induction phase.50
Clinical Global Impression –Severity (CGI -S)
The CGI-S is included to rate the severity  of the subject’s illness at the time of assessment, 
relative to the clinician’s past experi ence with subjects who have the same diagnosis and 
improvement with treatment .35Please refer to Section 9.2.1.2.1 for additional information 
regarding CGI-S. 
EuroQo l-5 Dimension -5 Level (EQ -5D- 5L)
The EQ-5D-5L is included as a standardized patient- completed instrument for use as a measure 
of health-related quality of life and health status.27,31Please refer to Section 9.2.1.3.1 for 
additional information regarding EQ -5D- 5L.
3.2.6. Safety  Evaluations
Physical examination, body  weight, vital signs (including blood pressure measurements) , 12-lead 
ECG, pulse oximetry , clinical laboratory  tests, nasal examinations, and evaluation of TEAEs and 
concomitant therapies will be performed throughout the study  to monitor subject safet y. 
TEAEs of special interest will be examined separately grouped in the following categories: drug 
abuse, dependence and withdrawal (standardized Medical Dictionary  for Regulatory  Activities 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 80[MedDRA] queries [SMQ]) , increased blood pressure, increased heart rate, transient 
dizziness/vertigo ,impaired cognition ,anxiety ,and c ystitis.
A subject -completed nasal symptom questionnaire will also be conducted as per the Time and 
Event Schedule to assess for an y treatment -emergent nasal tolerability  symptoms .
The Columbia Suicide Severit y Rating Scale (C-SSRS )69will be performed to assess suicidal 
ideation and behavior, the CADSS will be administered to assess treatment -emergent 
dissociative symptoms, the BPRS+ will be administered to assess treatment-emergent psychotic 
symptoms, the Modif ied Observer’s Assessment of Alertness/Sedation (MOAA/S )will be used 
to measure treatment-emergent sedation, the Clinical Global Assessment of Discharge Readiness 
(CGA DR)will beused to measure the subject’s readiness for discharge based on parameters 
including sedation, blood pressure and adverse events, and the Physician Withdrawal Checklist; 
20-item (PWC -20)will be administered (as applicable) to assess potential withdrawal symptoms 
after cessation of esketamine treatment.
Given the potential for treatment emergent transient elevation in systolic and diastolic blood 
pressure, heart rate and blood pressure will be monitored throughout the study  and at multiple 
time points on dosing days. Specific guidance to be followed on intranasal dosing days is 
provided in Section 6.2.1 .
Even though it is anticipated that the potential risk for treatment -emergent cystitis is very low 
based upon the doses to be used in this study , subjects will be monitored for symptoms of 
cystitis , bladder pain, and i nterstitial cystitis using the subject -completed Bladder Pain/ Interstitial 
Cystitis Symptom Score (BPIC -SS) at specific time points.40A score >18 on the BPIC-SS scale 
is considered as probable cystitis ,and any subjects that meet this cut-off will have a urinal ysis 
and culture conducted at that visit to assess for potential urinary  tract infection .Those without 
evidence of an ongoing urinary  tract infection will be referred to a specialist for diagnostic 
workup. There are no definitive tests for diagnosing ulcerative cystitis. If a subject is determined 
to have a diagnosis of ulcerative cystitis ,the subject must be discontinued from the study  and 
followed up with appropriate medical care. 
The effect of intranasal esketamine on cognition over the 4-week double -blind induction phase 
will be assessed using acomputerized cognitive battery  and Hopkins Verbal Learning 
Test-Revised (HVLT -R). The cognitive battery  will provide assessment of multiple cognitive 
domains, including attention, visual learning and memory , and executive function. The HVLT -R 
is a measure of verbal learning and memory .
The University  of Pennsy lvania Smell Identification Test (UPS IT) will be performed to assess 
any treatment- emergent effects on the sense of smell.
On all intranasal dosing days, subjects must remain at the site until study  procedures have been 
completed and the subject is ready for discharge . Subjects should be accompanied by a 
responsible adult when r eleased from the clinical site. Subjects must not drive a car or work with 
machines for 24 hours after receiving intranasal study  drug.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 81A list of prohibited medications is provided in Attachment 1as general guidance forthe 
investigator ( but is not all- inclusive).
3.2.7. Other A ssessments
Patient Adherence Questionnaire
During the screening/prospective observational phase, the patient -reported Patient Adherence 
Questionnaire (PAQ) will be used to assess how often the subject has taken, and whether he or 
she has made any changes to, his or her antidepressant treatment regimen in the last 2week s. 
This assessment will provide confirmation of medication adherence when evaluating 
antidepressant treatment response. Subjects who repor t missing 4days of antidepressant 
medication during a 2- week recall period will be discontinued because of inadequate adherence .
3.2.8. Pharmacokinetic Assessments
Pharmacokinetic samples will be obtained during the study  for measurement of the plasma 
concentra tions of esketamine, noresketamine, and/or additional metabolites, if warranted.
3.2.9. Biomarker, Pharmacogenomic (DNA ), and Expression (RNA ) 
Evaluations
Assessment of biomarkers (protein and RNA) and their potential relationship to the different 
treatment group s and to maintenance/stabilization of response, nonresponse, and relapse will be 
explored. Blood samples will be collected to measure genetic and epigenetic markers (including 
but not limited to BDNF allelic variants) and protein markers (including but notlimited to 
growth factors, inflammation, endocrine, or metabolic). Samples of deox yribonucleic acid 
(DNA) and biomarkers may be used to help address emerging issues and to enable the 
development of safer, more effective, and ultimately individualized ther apies.
Genetic variation can be an important contributory  factor to inter-individual differences in drug 
distribution and response, and can also serve as a marker for disease susceptibility  and prognosis. 
Pharmacogenomic research may help to explain inter-individual variability in clinical outcomes 
and may help to identify population subgroups that respond differentl y to a drug or subgroups 
that are more susceptible to relapse. In addition, pharmacogenomics research may allow for the 
identification of genet ic factors that influence the PK, PD, efficacy , safet y, or tolerability  of the 
different treatment groups, and for the identification ofgenetic factors associated with TRD or 
MDD. Specifically , genetic and epigenetic changes in genes known to be in pathwa ys relevant to 
depression (eg,hypothalam ic-pituitary -adrenal [HPA] axis, inflammation, growth factors, 
monoamine transporters, ion channels, and circadian rhythm, etc .) will be evaluated.
Protein, metabolite, and ribonucleic acid (RNA) biomarkers may aid in the elucidation of the 
mechanism of action of the different treatment groups or help to explain inter-individual 
variability  in clinical outcomes or may help to identify  population subgroups that respond 
differentl y to a drug or may help to identify  subgroups that are more susceptible to relapse . The 
goal of the biomarker analy ses is to evaluate the PD of the different treatment groups, and aid in 
evaluating the drug- clinical response relationship.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 82On the day of biomarker sample collection, it is recomme nded that subjects adhere to a low fat 
diet (as an alternative to fasting) to reduce the level of postprandial lipemia in blood samples 
because moderately  or grossly  lipemic specimens may  interfere with assay  results.
4. STUDY POPULA TION
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the 
following 2 subsections. If there is a question about the inclusion or exclusion criteria below, the 
investigator must consult with the appropriate sponsor representative and resolve any issues 
before enrolling a subject in the study . Waivers are not allowed.
4.1. Inclusion Criteria
1.Each potential subject must satisfy all of the following criteria to be enrolled in the study . 
At the time of signing the informed consent form (ICF), subject must be a man or 
woman 65 years of age or older .
2. At the start of the screening /prospective observational p hase, subject must meet the DSM -5
diagnostic criteria for single -episode MDD (if single episode MDD , the duration of episode 
must be 2 years) or recurrent MDD, without psychotic features, based upon clinical 
assessment and confirmed by  the Mini International Neurops ychiatric Interview (MINI).
3.Criteri onmodified per A mendment 1
3.1 Criterion modified per Amendment 2
3.2 Criterion modified per Amendment 3
3.3 At the start of the screening /prospective observational p hase, subject must have had 
nonresponse (≤25% improvement) to 1but 8 (if current episode is >2 years, upper limit 
applicable to only the last 2 years) oral antidepressant treatment sin the current episode of 
depression, assessed using the MGH -ATRQ and confirmed by documented records (eg, 
medical/pharmacy /prescription records ,or aletter from the treating physician, etc,). In 
addition, subject is taking a different oral antidepressant treatment (on the MGH -ATRQ) for 
at least the previous 2 weeks at or above the minimum therapeutic dose .
For specific tricyclic antidepressants which are ongoing and being taken at a dose 
below the MGH -ATRQ minimum therapeutic dose, a blood level that is within the
therapeutic (antidepressant) range, is acceptable to establish the adequacy  of the 
antidepressant tre atment.
Subjects must be adherent to the continued oral antidepressant medication(s) (without 
adjustment in dosage) through the screening/prospective observational phase, as 
documented on the PAQ. Missing 4days of antidepressant medication in the prior 
2-week period will be considered as inadequate adherence.
Subjects who are nonresponders to the antidepressant medication (s)from the 
screening/prospective observational phase (as assessed by  independent, remote rater s) 
may be eligible for randomization if all other entry  criteria are met.Non-response at 
the end of the screening/prospective observational phase is defined as ≤25% 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 83improvement in the MADRS total score from Week 1 to Week 4 and a MADRS total 
score of ≥24on Week 2 and Week 4.
4. Criterion modified per Amendment 3
4.1. At the start of the screening /prospective observational phase, subject must have an 
IDS-C30 total score of  31.
5. Criterion modified per Amendment 2
5.1. Criterion modified per Amendment 3
5.2 The subject’s current major depressive episode , depression symptom severit y 
(Week 1 MADRS total score ≥24 required ),and antidepressant treatment response in the
current depressive episode, must be confirmed using the Site Independent Qualification 
Assessment .
6. Subject must be medically  stable on the basis of physical examination, medical histo ry, vital 
signs (including blood pressure) ,pulse oximetry ,and 12-lead ECG performed in the
screening /prospective observational phase . If there are any abnormalities that are not 
specified in the inclusion and exclusion criteria, the determination of their clinical 
significance must be determined by the investigator and recorded in the subject's source 
documents and initialed by  the investigator.
7.Criteri onmodified per A mendment 1
7.1 Criterion modified per Amendment 2
7.2 Criterion modified per Amendment 3
7.3 Subject must be medically  stable on the basis of clinical laboratory tests 
performed in the screening/prospective observational phase. If the results of the serum 
chemistry  panel, hematology , or urinal ysis are outside the normal reference ranges, t he 
subject may be included only if the investigator judges the abnormalities or deviations from 
normal to be not clinically  significant or to be appropriate and reasonable for the population 
under study . This determination must be recorded in the subject's source documents and 
initialed by  the investigator.
Subjects with a pre-existing history  of thyroid disease/disorder who are treated with 
thyroid hormones must be on a stable dosage for 3 months prior to the start of the 
screening/prospective observatio nal phase .
For any subject (regardless of thyroid history ), if the thyroid stimulating hormone 
(TSH )value is out of range, a free thy roxin e (fT4) will be conducted. If the f T4 value 
is abnormal and considered to be clinicall y significant (after discussion with the 
medical monitor) , the subject is not eligible .
8. Subject must be comfortable with self-administration of intranasal medication and be able to 
follow the intranasal administration instructions provided.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 849. Criterion modified per Amendment 2
9.1. Criterio n modified per Amendment 3
9.2 During the study  (ie, from Day 1  o f the double-blind induction phase, prior to 
randomization) and for a minimum of 1 spermatogenesis cycle (defined as approximately  
90days) after receiving the last dose of intranasal study  medication, a man who is sexually  
active with a woman of childbearing potential
must be practicing a highly  effective method of contraception with his female partner 
from those listed above (see examples of highly  effective methods of contraception 
provided for female subjects). 
must use a condom if his partner is pregnant .
must agree not to donate sperm.
Note: If the female partner ’s childbearing potential changes after start of the study , the female 
partner of a male study subject must begin a highl y effective method of birth control, as
described above.
10. Subject must be willing and able to adhere to the prohibitions and restrictions specified in 
this protocol.
11.Each subject must sign an ICF indicating that he or she understands the purpose of and 
procedure s required for the study  and is willing to participate in the stud y.
4.2. Exclusion Criteria
1.Criteri onmodified per A mendment 1
1.1.Criterion modified per Amendment 2
1.2. Any potential subject who meets any of the following criteria will be excluded from 
participating in the stud y.
The subject’s depressive symptoms have previously  demonstrated nonresponse to:
Esketamine or ketamine in the current major depressive episode per clinical judgment, 
or
All of the oral antidepressant treatment options available in the respective country  for 
the double -blind induction phase (ie, duloxetine, escitalopram, sertraline, and 
venlafaxine XR) in the current major depressive episode (based on MGH -ATRQ), or
An adequate course of treatment with electroconvulsive therap y (ECT) inthe current 
major depressive episode, defined as at least 7 treatments with unilateral /bilateral ECT. 
2. Criterion modified per Amendment 2
2.1. Subject who has received vagal nerve stimulation (VNS) or who has received deep brain 
stimulation (DBS) in the c urrent episode of depression will be excluded.
3. Criterion modified per A mendment 1
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 853.1.Criterion modified per Amendment 2
3.2. Subject has a current or prior DSM -5 diagnosis of a psychotic disorder or MDD with
psychotic features , bipolar or related disorde rs (confirmed by the MINI), obsessive 
compulsive disorder (current episode only), intellectual disability  (DSM -5 diagnostic codes 
317, 318.0, 318.1, 318.2, 315.8, and 319), autism spectrum disorder, borderline personality 
disorder, antisocial personality  disorder, histrionic personality  disorder, or narcissistic 
personality  disorder.
4.Subject has homicidal ideation/intent, per the investigator’s clinical judgment, or has suicidal 
ideation with some intent to act within 6 months prior to the start of the 
screening/prospective observational phase, per the investigator’s clinical judgment or based 
on the Columbia Suicide Severity  Rating Scale (C-SSRS), corresponding to a response of 
“Yes” on Item 4 (active suicidal ideation with some intent to act, without speci fic plan) or 
5(active suicidal ideation with specific plan and intent) for suicidal ideation on the C-SSRS, 
or a history  of suicidal behavior within the past year prior to start of the 
screening/prospective observational phase. Subjects reporting suicidal ideation with intent to 
act or suicidal behavior prior to the start of the double -blind induction phase should be 
excluded.
5. Subject has a history  of moderate or severe substance or alcohol use disorder according to 
DSM -5 criteria, except nicotine or caffe ine, within 6 months before the start of the 
screening/prospective observational phase. 
A history  (lifetime) of ketamine, phency clidine (PCP), lysergic acid diethy lamide 
(LSD), or 3, 4-methy lenedioxy -methamphetamine (MDMA) hallucinogen -related use 
disorder
6.Subjects with a current or past history  of seizures (uncomplicated childhood febrile seizures 
with no sequelae are not exclusionary )
7. Criterion deleted per Amendment 3
8. Criterion modified per Amendment 2
8.1. Subject has one of the following cardiovascular- related conditions:
Cerebrovascular disease with a history  of stroke or transient ischemic attack.
Aneury smal vascular disease (including intracranial, thoracic, or abdominal aorta, or 
peripheral arterial vessels) .
Coronary  artery  disease with myocardial infarction, unstable angina, or
revascularization procedure (eg, coronary  angioplasty  or bypass graft surgery ) within 
12months before the start of the screening/prospective observational phase. Subjects 
who have had a revascularization performed >12 mont hs prior to screening and are 
clinically  stable and symptom -free, per investigator’s clinical judgment, can be 
included.
Hemody namicall y significant valvular heart disease such as mitral regurgitation, aortic 
stenosis, or aortic regurgitation. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 86New York Heart Association (NYHA) Class III-IV heart failure of any etiology  (refer 
to Attachment 2).
9. Criterion modified per Amendment 2
9.1. Subject has a history  of uncontrolled hypertension despite diet, exercise, or 
antihy perte nsive therapy at the start of the screening/prospective observational phase or any 
past history  of hypertensive crisis or ongoing evidence of uncontrolled hypertension defined 
as a supine systolic blood pressure (SBP) >150 mm Hg or diastolic blood pressure (DBP) 
>90 mm Hg during screening/prospective observational phase which continues to be above 
this range with repeated testing during this phase. Note: On Day 1 of the double -blind 
induction phase prior to randomization a supine SBP >150 mm Hg or DBP >90 mm Hg is 
exclusionary .
A potential subject may have his/her current antihy pertensive medication (s)adjusted 
during the screening/prospective observational phase and be re-evaluated to assess their 
blood pressure control. The subject must be on a stable regimen for at least 2weeks 
before Day 1 of the double -blind induction phase.
10. Subject has a current or past history  of significant pulmonary  insufficiency /condition or with 
an arterial blood oxygen saturation of <93% at the start of the screening/prospective 
observational phase or Day 1 prior to randomization will be excluded. 
11. Criterion modified per Amendment 3.
11.1. Subject has a Mini Mental State Examination (MMSE) <25 or <22 for those 
subjects with less than an equivalent of high school educa tion.
12.Criteri on modified per Amendment 3. 
12.1. Subject has neurodege nerative disorder (eg, Alzheimer’s Disease, Vascular 
dementia, Parkinson’s disease with clinical evidence of cognitive impair ment ) or evidence of
mild cognitive impairment (MCI ).
13. Criterion modified per Amendment 2
13.1. Criterion modified per Amendment 3
13.2. Subject has clinically significant ECG abnormalities at the start of the 
screening/prospective observational phase or on Day 1 of the double -blind induction phase
prior to randomization, define d as:
During screening a QT interval corrected according to Fridericia's formula (QTcF ): 
450 msec; if the QTcFis prolonged on the initial ECG, the average QTcF of 
three ECGs, recorded at least 4 minutes apart must not be  450 ms ec.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 87On Day 1 (predose), a QT interval corrected according to Fridericia's formula (QTcF): 
450 msecbased on the site-evaluated ECG ; if the QTcF is prolonged on the initial 
ECG, the average QTcF of three ECGs, recorded at least 4 minutes apart, must not be 
450msec.
Evidence of 2nd and 3rd degree AV block, or, complete left bundle branch block 
(LBBB), or complete right bundle branch block (RBBB) .
Features of new ischemia .
Arrh ythmia (except premature atrial contractions [PACs] and premature ventricular 
contractions [PVCs]).
14.Criteri on modified per Amendment 2
14.1 Subject has a history  of additional risk factors for Torsades des Pointes (eg, heart 
failure, h ypokalemia, family  history  of Long QT Sy ndrome) .
15. Criterion modified per Amendment 2
15.1 Subject has history  of, or symptoms and signs suggestive of, liver cirrhosis (eg, 
esophageal varices, ascites, and increased prothrombin time) OR alanine aminotransferase 
(ALT) or aspartate aminotransferase (AST) values 2 times the upper limit of normal or total 
bilirubin >1.5 times the ULN in the screening/prospective observational phase.
Repeat of thescreening test for abnormal ALT and AST is permitted once during the 
screening period, per investigator discretion, provided there is an explanation for a 
transient out of range value.
For eleva tions in bilirubin if, in the opinion of the investigator and agreed upon by the 
sponsor’s medical officer, the elevation in bilirubin is consistent with Gilbert’s disease, 
the subject may  participate in the study .
16. Criterion modified per Amendment 2
16.1. Criterion modified per Amendment 3
16.2 Subject has positive test result(s) for drugs of abuse (including barbiturates, 
methadone, opiates, cocaine, phency clidine, and amphetamine/methamphetamine) at the 
start of the screening/prospective observational pha se or Day  1 of the double -blind induction 
phase prior to randomization.
Subjects who have a positive test result at screening due to prescribed psychostimulants 
(eg, amphetamine, methy lphenidate, etc,) taken for an indication other than MDD are 
permitted to continue to take this medication during the study  in accordance with 
Attachment 1.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 88Otherwise, subjects who have a positive test result at screening due to prescribed/o ver-
the-counter opiates, or barbiturates may be permitted to continue in the 
screening/ prospective observational phase if the medication is discontinued at least 
1week or 5half-lives, whichever is longer, before Day 1 of the double -blind induction 
phase (prior to randomization) (for barbiturates or amphetamines/methamphetamine ) or
used in accordance with Attachment 1restrictions (for opiates). The result of the Day 1 
(prior to randomization) test for drugs of abuse must be negative for the subject to be 
randomized.
oRetesting is not permitted for positive test result(s), except for reasons stated above.
Prior intermittent use of cannabinoids prior to the start of the screening/prospective 
observational phase is not exclusionary  as long as the subject does not meet the criteria 
for substance use disorder. Although tested at screening, a positive test for cannabinoids 
at the start of the screening/prospective phase is not exclusionary ; however, a positive 
test result for cannabinoids predose on Day 1  of the double -blind induction phase is 
exclusionary .
17.Subjec ts who are taking a total daily  dose of benzodiazepines greater than the equivalent of 
6mg/day  of lorazepam at the start of the screening/prospective observational phase.
18. Criterion modified per Amendment 2
18.1. Subject has uncontrolled diabetes mellitus, as evidenced by HbA1c >9% in the 
screening/prospective observational phase or history  in the prior 3 months prior to the start of 
the screening/prospective observational phase of diabetic ketoacidosis, hypergly cemic coma, 
or severe h ypogl ycemia with loss of consciousness.
19. Subject has untreated glaucoma, current penetrating or perforating eye injury , brain injury , 
hypertensive encephalopathy , intrathecal therapy  with ventricular shunts, or any other 
condition associated with increased intracranial pressure or increased intraocular pressure or 
planned ey e surgery .
20. Criterion modified per Amendment 2
20.1. Subject has any anatomical or medical condition that, per the investigator’s clinical 
judgment based on assessment, may impede delivery  or absorption of theintranasal study 
drug.
21. Criterion deleted per Amendment 2 
22. Subject has a history  of malignancy  within 5 years before the start of the 
screening/prospective observational phase (exceptions are squamous and basal cell 
carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that, in the opinion 
of the investigator, with concurrence with the sponsor's medical monitor, is considered cured 
with minimal risk of recurrence).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 8923. Subject has known allergies, hypersensitivity , intolerance, or contraindi cations to 
esketamine/ketamine and/or its excipients or all of the available oral antidepressant treatment 
options for the double-blind induction phase.
24.Subject has taken an y prohibited therapies that would not permit dosing on Day  1, as noted in 
Section 8(Prestudy  and Concomitant Therapy ) and Attachment 1.
25. Criterion modified per Amendment 2
25.1 Subject has a score of 5 on the STOP -Bang questionnaire, in which case obstructi ve 
sleep apnea must be ruled out (eg, apnea -hypopnea index [AHI ] <30). A subject with 
obstructive sleep apnea can be included if he or she is using a positive airway  pressure device 
or other treatment/therapy that is effectivel y treating (ie, AHI <30) his or her sleep apnea.
26. Criterion modified per Amendment 2
26.1 Subject has received an investigational drug (including investigational vaccines) or used 
an invasive investigational medical device within 60 days before the start of the 
screening/prospective observational phase, or has participated in 2 or more MDD or other 
psychiatric condition clinical interventional studies (with different investigational drugs 
including investigational vaccines or investigational medical devices for each study )in the 
previous 1 year before the start of the screening/prospective observational phase, or is 
currentl y enrolled in an investigational interventional study .
27. Subject has a diagnosis of acquired immunodeficiency  syndrome (AIDS). Human 
immunodeficiency  virus (HIV) testi ng is not required for this stud y.
28. Subject has any condition or situation/circumstance for which, in the opinion of the 
investigator, participation would not be in the best interest of the subject (eg, compromise the 
well-being) or that could prevent, limi t, or confound the protocol -specified assessments.
29. Subject has had major surgery , (eg, requiring general anesthesia) within 12 weeks before the 
start of the screening/prospective observational phase, or will not have fully  recovered from 
surgery , or has surgery  planned during the time the subject is expected to participate in the 
study . 
Note: subjects with planned surgical procedures to be conducted under local anesthesia 
may participate.
30. Subject is an employ ee of the investigator or study  site, with direc t involvement in the 
proposed study  or other studies under the direction of that investigator or study  site, as well 
as family  members of the employ ees or the investigator.
31.Subject has severe renal impairment (creatinine clearance <30 ml/min).
NOTE: Investigators should ensure that all study  enrollment criteria have been met. If a 
subject’s status changes (including laboratory  results or receipt of additional medical records) 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 90before the first dose of study  drug is given such that he or she no longer meets all eligibility 
criteria, then the subject should be excluded from participation in the study . Section 17.4, Source 
Documentation, describes the required documentation to support meeting the enrollment criteria.
The sponsor will evaluate and approve/reject requests to rescreen an individual subject on a case -
by-case basis.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the c ourse of the study  to be eligible for participation:
Refer to Section 4.1, I nclusion Criteria for information regarding contraception requirements
for males who are sexually  active with a woman of childbearing p otential .
Refer to Section 8(Prestudy  and Concomitant Therap y) and Attachment 1(Prohibited 
Concomitant Medications for Intranasal Study  Medication [Esketamine or Placebo]) for 
further information on prohibited therapies.
Subjects taking benzodiazepines (at dosages equal to or less than the equivalent of 6 mg/day 
of lorazepam) and/or permitted non-benzodiazepine sleep medications (eg, zolpidem, 
zaleplon) during the screening/prospective observational phase can continue these 
medications during the induction phase. No dose increases beyond the equivalent of 6 
mg/day  of lorazepam or new benzodiazepine medications are permitted during the induction 
phase, with the exception of theuse of permitted benzodiazepine rescue medication. 
Benzodiazepines and non-benzodiazepine sleeping medication (eg, zolpidem, zaleplon, 
eszopiclone, and ramelteon) are prohibited within 12 hours prior to the start of each 
intranasal treatment session or co gnition testing.
A positive urine drug screen after Day 1  for use of PCP or cocaine from Day 1  ofthe 
induction phase through the final visit in the double -blind induction phase will lead to 
discontinuation .
Subjects must abstain from using alcohol within 24 hours before and after each intranasal 
treatment session. If a subject appears intoxicated, dosing should not occur (delay ed per the 
permitted visit window; see the Time and Events Schedule).
On all intranasal study  drug dosing days, all subjects must remain at the clinical study  site 
until study  procedures have been completed and the subject is ready for discharge . Subjects 
should be accompanied by a responsible adult when released from the clinical study  site. 
Subjects must not drive a car or work with machines for 24 hours after study  drug dosing.
ECT, DBS , transcranial magnetic stimulation (TMS), and VNS are prohibited from study  
entry  through the end of the double -blind induction phase.
Subjects receiving psychotherap y (including cognitive behavioral therapy ; CBT) can 
continue receiving ps ychotherap y; however, CBT must have been ongoing for the last 
3months prior to the screening/prospective observational phase. With the exception of new 
CBT, which is prohibited, new psychotherapy  is allowed during this study . Any change in 
existing therap y or new therap y must be documented on the concomitant therapies form.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 915. TREA TMENT ALLOCA TION AND BLINDING
Treatment Allocation and Randomization
Central randomization will be implemented in this study . Subjects will be randomly  assigned to 
1 of 2 treatment groups in a 1:1ratio based on a computer -generated randomization schedule 
prepared before the study  by or under the supervision of the sponsor. The randomization will be 
balanced by using randomly  permuted blocks and will be stratified by country  and class of oral 
antidepressant (SNRI  or SSRI ) to be initiated in the double -blind induction phase The interactive 
web response system (IWRS) will assign a unique treatment code, which will dictate the 
treatment assignment and matching study  drug kitsfor the subject. After the investigator selects 
the oral antidepressant treatment for the double -blind induction phase, the site will enter this 
information into IWRS.The requestor must use his or her own user identification and personal 
identification number when contacting the IWRS, and will then give the relevant subject details 
to uniquely  identify  the subject.
Blinding
The investigator will not be provided with randomization codes. The codes will be maintained 
within theIWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subject.
Data that may potentially  unblind the treatment assignment (eg, intranasal study  drug plasma 
concentrations , treatment allocation) will be handled with special care to ensure that the integrity  
of the blind is maintained and the potential for bias is minimized. This can include making 
special provisions, such as segregating the data in question from view by the investigators, 
clinical team, or others as appropriate until the time of database lock and unblinding.
Under normal circumstances, the blind should not be broken until all subjects have completed 
the study  and the database is finalized. Otherwise, the blind should be broken only if specific 
emerg ency  treatment/course of action would be dictated by knowing the treatment status of the 
subject. In such cases, the investigator may in an emergency  determine the identity  of the 
treatment by  contacting the I WRS. It is recommended that the investigator co ntact the sponsor or 
its designee ,if possible ,to discuss the particular situation, before breaking the blind. Telephone 
contact with the sponsor or its designee will be available 24hours per day, 7days per week. In 
the event the blind is broken, the sponsor must be informed as soon as possible. The date and
time of the unblinding will be documented by the IWRS, and reason for the unblinding must be 
documented inthe electronic CRF ( eCRF )and in the source document. The documentation 
received from the IWRS indicating the code break must be retained with the subject’ s source 
documents in a secure manner .
Subjects who have had their treatment assignment unblinded should continue to return for 
scheduled earl y withdrawal and follow -upvisits .
In general, randomization codes will be disclosed fully  only if the study is completed and the 
clinical database is closed. Forinterim analy sis, the randomization codes and, if required, the 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 92translation of randomization codes into treatment and control groups will be disclosed to those 
authorized and only  for those subjects included in the interim anal ysis.
To maintain the blinding of intranasal study  medication , the esketamine and placebo intranasal 
devices will be indistinguishable. Please refer to Section 14(Study  Drug Information) for 
information on the physical characteristics of the study  drugs and devices .In order to manage 
clinical supplies, the clinical supplies group will be informed of the decision made at interim 
analysis so that onl y the required amount of stud y medication will be packaged.
6. DOSA GE A ND A DMINISTR ATION
6.1. Screening/Prospective Observational Phase
As described in Section 9.1.2 , at the start of screening/prospec tive observational phase, the 
subject must have had documented nonresponse to at least one antidepressant treatment (based 
on MGH -ATRQ criteria) in the current episode of depression, and the subject is taking a 
different oral antidepressant treatment (on t he MGH -ATRQ) for at least the previous 2weeks at 
or above the minimum therapeutic dose. This antidepr essant treatment, as well as any other 
ongoing medications being taken for depression at screening (including adjunctive/augmentation 
therapies), will continue from the start of Week 1 through the end of Week 4 of the 
screening /prospective observational phase .Dose adjustment is permitted per clinical judgment, 
but the oral antidepressant treatment is to remain at or above the minimum therapeutic dose (per 
the MGH -ATRQ) through the end of Week 4. 
Non-response at the end of the screening/prospective observational phase is defined as ≤25% 
improvement in the MADRS total score from Week1 to Week 4 and a MADRS total score of 
≥24on Week 2and Week 4.
The spons or will not supply these antidepressant medication(s).
During this phase, antidepressant treatment adherence will be assessed using the PAQ.
After the completion of 4weeks of prospective antidepressant treatment and assessment of the 
antidepressant treatm ent response, eligible subjects will have all antidepressant medication(s), 
including adjunctive/augmentation therapies discontinued. Of note, subjects taking 
benzodiazepines (at dosages equal to or less than the equivalent of 6 mg/day  of lorazepam) 
and/or permitted non-benzodiazepine sleep medications (eg, zolpidem, zaleplon) during the 
screening/prospective observational phase can continue these medications. No dose increases 
beyond the equivalent of 6 mg/day  of lorazepam or new benzodiazepine medications are 
permitted during the screening/prospective observational phase . If clinically  indicated, the 
antidepressant treatment(s) may be tapered and discontinued over a period of up to 3week sper 
the local prescribing information or clinical judgment (eg, antidepressants with short half-lives, 
such as venlafaxine XR).Eligible subjects who do not require a tapered discontinuation of their 
antidepressant treatment (s) can immediatel y proceed into the double -blind induction phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 936.2. Double -Blind Induction Phase
During this phase subjects will self-administer double -blind intranasal treatment with flexibly  
dosed intranasal esketamine ( 28 mg, 56 mg or 84 mg) or placebo twice per week for 4 weeks as a 
flexible dose regimen at the study  site.In addition, subjects will simultaneously  initiate a new, 
open -label oral antidepressant ( ie, duloxetine, escitalopram, sertraline, or venlafaxine XR) on 
Day 1 that will be continued for the duration of this phase.
Intranasal Study Drug
On all intranasal treatment session days, a site staff member with training in cardiopulmonary 
resuscitation (eg, Basic Life Support course or equivalent courses) that is up to date per local 
regulations must be present with the subject during the intranasal treatment sessions and the 
postdose observa tion period . In addition, equipment for supportive ventilation and resuscitation 
needs to be present.
Table 3describes how each intranasal treatment session will be administered in the double -blind 
induction phase . Please refer to Section 6.2.1 for guidance on blood pressure monitoring on 
intranasal dosing day s.
Table 3: Intranasal Treatment Sessions Adm inistration During the Double -blind Inductio n Phase
Time of Intranasal Device Administration
Intranasal Treatment 0a5 minutes 10 minutes
Intranasal Deviceb1st2nd 3rd
Placebo for 28 mg 1 spray of placebo to each 
nostrilNot applicable Not applicable
Esketamine 28 mg 1 spray of esketamine to 
each nostrilNot applicable Not applicable
Placebo for 56 mg 1 spray of placebo to each 
nostril1 spray of placebo to each 
nostrilNot applicable
Esketamine 56 mg 1 spray of esketamine to 
each nostril1 spray of esketamine to 
each nostrilNot applicable
Placebo for 84 mg 1 spray of placebo to each 
nostril1 spray of placebo to each 
nostril1 spray of placebo to each 
nostril
Esketamine 84 mg 1 spray of esketamine to 
each nostril1 spray of esketamine to 
each nostril1 spray of esketamine to 
each nostril
aTime 0 is defined as the time of administration of the first intranasal spray to one nostril from the first intranasal 
device. 
bOne device will be used at each time point. Each individual intranasal device contains 2 sprays. The intranasal 
devices con taining esketamine deliver 14 mg per spray, for a total of 28 mg per individual device (i e, 2 sprays).
Instructions for use documents (subject and healthcare provider versions) for intranasal study 
drug administration will be provided as separate document s. Details regarding study  drug 
administration will be recorded in the source documents and the eCRF.
All subjects will self-administer the intranasal study  drug (esketamine or placebo) at treatment 
sessions twice a week for 4 weeks at the study  site. The first treatment session will be on Day 1. 
Intranasal treatment sessions should not take place on consecutive day s.
Prior to the first intranasal dose on Day 1, subjects will practice spray ing (into the air, not 
intranasall y) a demonstration intranasal devi ce that is filled with a placebo solution .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 94Instructions for intranasal dosing:
After Day  1 (28 mg), all dosing decisions are to be determined by  the investigator based 
on efficacy  and tolerability .
Prior to intranasal dosing, subjects must not have a blood pressure >150 mmHg systolic 
and/or >90 mm Hg diastolic .
Prior to any dose escalation, subjects must have had a postdose blood pressure, on the 
prior intranasal dosing day, of <180 mm Hg for systolic and <100 mm Hg for diastolic 
blood pressure .
Dose titra tion of intranasal esketamine will be performed as outlined in Table 4:
Table 4 Dose Titration of Intranasal Esketamine*
Day Dose Dose Titration Guidance
Day 1 28 mg
Day 4 28 or 56 mg The dose may remain at 28mg  or be increased to 56mg , as 
determined by the investigator based on efficacy and tolerability
Days 8, 11, 15 28, 56 or 84 mg The dose may be maintained, or increased or reduced by 28mg 
from the previous dosing session, as determined by the 
investigator based on efficacy and tolerability. No dose increase 
is permitted beyond Day 15.
Days 18, 22 and 25 28, 56 or 84 mg No dose increase is permitted beyond Day 15. If needed for 
tolerability, dose reduction by 28mg from the p revious dose is 
permitted on Days 18, 22 and 25.
* Dose changes are determined by the investigator based on efficacy and tolerability and in accordance w ith blood 
pressure guidelines.
From Day 8 to Day 15, inclusive, for those who have had a prior down titration from a higher 
dose, a dose increase b y 28mg is allowed based on clinical judgment. 
Food will be restricted for at least 2 hours before each administration of study  drug. Drinking of 
any fluids will be restricted for at least 30 minutes before the first nasal spray .
If the subject has nasal congestion on the dosing day an intranasal decongestant may be used to 
reduce congestion. Subjects should wait for at least 1 hour after using an intranasal decongestant 
before administering intranasal study  drug.
For all intranasal treatment sessions, subjects must remain at the clinical site until study 
procedures have been completed and the subject is ready for discharge, and should be 
accompanied by a responsible adult when released from the clinical study site. Subjects must not 
drive a car or work with machines for 24 hours after intranasal treatment sessions.
Oral Antidepressant Medication
Starting on Day 1, a new , open -label oral antidepressant treatment will be initiated in all subjects , 
and continued for the duration of this phase. The oral antidepressant will be 1 of 4 oral 
antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR). The 
antidepressant medication will be assigned by the investigator based on review of the 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 95MGH -ATRQ and relevant information regarding prior antidepressant treatments, and will be one
that the subject has not previously  had a nonresponse to in the current depressive episode, has 
not been previousl y intolerant to (lifetime), and is available in the p articipating country . 
Dosing of the oral antidepressant will begin on Day 1. A mandatory titration schedule is 
provided in Attachment 3. Doses are not to exceed the maximum dose defined in the titration 
schedule .As patients may not be able to tolerate the higher doses of the oral antidepressant 
during the induction phase, a down titration of the dose is permitted based on clinician’s 
judgment.
All subjects entering the follow -up phase will be provided with an additional 2-week supply  of 
the oral antidepressant medication following the double -blind induction phase, to ensure there is 
no interruption of antidepressant therapy  during the transition to further clinical/standard of care 
in the follow -upphase .
Study -site personnel will instruct subjects on how to take/use and store the oral antidepressants 
supplied during this study for at-home use as indicated in this protocol. A subject diary  to 
capture oral antidepressant study  medication use will be provided.
On intranasal dosing days, it is recommended that the oral antidepressant medication not be 
taken until at least 3 hours after an intranasal treatment session. 
6.2.1. Guidance for Blood Pressure Monitoring on Intranasal Treatment 
Session Days
Given the potential for treatment emergent transient elevation in systolic and diastolic blood 
pressure, the following guidance should be followed on intranasal dosing day s:
If subsequent to fulfilling the inclusion and exclusion criteria on Day  1(ie, applicable for all 
other intranasal treatment session day s after Day 1), a subject ’s predose SBP is >150 mmHg 
and/or DBP is >90mmHg, it is recommended that the blood pressure measurement is 
repeated after the subject rests in sitting or recumbent position. If after rest and repeated 
measur ements, the predose SBP is >150 mmHg and/or the DBP is >90mmHg, then dosing 
should be postponed and the subject scheduled to return on the following day or within the 
given visit window. If the blood pressure elevation still persists on the next visit, the subject 
will be scheduled for a consultation by cardiologist, other specialist ,or a primary  care 
physician prior to further dosing.
If at any postdose time point on the dosing day the SBP is 180 mm Hg but <190 mm Hg 
and/or the DBP is 100 mm Hg but <110 mm Hg, further intranasal dosing should be 
interrupted and the subject should be referred to a cardiologist , other specialist, or primary 
care ph ysician for a follow -up assessment.
After the assessment by a  cardiologist, other specialist, or primary  carephysician, if 
recommended by the referring doctor and considered appropriate according to the 
clinical judgment of the investigator for the subject to continue in the study, the subject 
may continue with intranasal dosing if the pre -dose blood pressure at the next scheduled 
visit is within the acceptable range (see bullet above).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 96If at any postdose time point on a dosing day the SBP is 190 mm Hg and/or the DBP is 
110mm Hg, the subject must discontinue from further dosing and be referred to a 
cardiologis t, other specialist, or primary  care phy sician for a follow -up assessment .
During the double -blind induction phase, at 1.5 hours postdose, if the SBP is 160 mm Hg 
and/or the DBP 100 mm Hg, assessments should continue every  30 minutes until :
the blood pressure is <160 mm Hg SBP and <100 mm Hg DBP, or 
in the investigator’s clinical judgment, the subject is clinically  stable and can be 
discharged from the study site, or 
the subject is referred for appropriate medical care if clinically  indicated .
If the blood pressure remains ≥ 180 SBP and/or  ≥110 mmHg DBP  2 hours after dosing, the 
subject should be referred for immediate medical treatment.
6.3. Follow -up Phase
Subjects who receive at least 1 dose of intranasal study  medication in the double -blind induction 
phase, but do not enter the subsequent ESKETINTRD3004 safet y study, will proceed into the 
2-week follow -up phase .A 2-week suppl y of oral antidepressant will be provided for subjects 
entering the follow -up phase.
No intranasal stud y medication will be administered during this phase.
At the start of the follow -up phase, further clinical/standard of care for the treatment of 
depression will be arranged by the study  investigator and/or the subject’s treating physician. All 
subjects will be provided with an addit ional 2-week supply  of the oral antidepressant medication 
to ensure there is no interruption of antidepressant therapy  during the transition to further 
clinical/standard of care . 
The decision to continue the oral antidepressant medication in this phase wi ll be at the discretion 
of the investigator ;however, in order to better assess potential withdrawal symptoms from the 
intranasal study  medication and facilitate maintenance of clinical benefit following the 4-week 
double blind treatment phase, the oral antidepressant medication should be continued for the 
2weeks of the follow -up phase unless determined as not clinically  appropriate.
7. TREA TMENT COMPLIA NCE
The investigator or designated study -site personnel will maintain a log of all intranasal study 
drug and oral antidepressant medication dispensed and returned. Drug supplies for each subject 
will be inventoried and acco unted for throughout the study .
Subjects will receive instructions on compliance with the oral antidepressant treatment . During 
the course o f the study , the investigator or designated study -site personnel will be responsible for 
providing additional instruction to re-educate any subject to ensure compliance with taking the 
oral antidepressant .A subject diary  will be provided to capture oral antidepressant study 
medication use.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 97Antidepressant treatment adherence during the screening/prospective observational phase will be 
assessed using the PAQ. Missing 4days of antidepressant medication in the prior 2-week 
period will be considered inadequat e compliance .
Antidepressant treatment adherence during the double -blind induction and follow -up phase swill 
be assessed b y performing pill counts (ie, compliance check) and drug accountability .
All doses ofintranasal study  drug will be self-administered by the subjects at the investigative 
site under the direct supervision of the investigator or designee , and will be recorded .
8. PRESTUDY AND CONCOMI TANTTHERAPY
Prestudy  non-antidepressant therapies administered up to 30 days before the start of the 
screenin g/prospective observational phase must be recor ded at the start of this phase.
All antidepressant treatment(s), including adjunctive treatment for MDD, taken during the 
current depressive episode (ie,including those taken more than 30 days prior to the start of the 
screening/prospective observational phase) will be recorded at the start of the 
screening/prospective observational phase. In addition, information will also be obtained 
regarding any history of intolerance to any of the 4 antidepressant choices (ie,duloxetine, 
escitalopram, sertraline , and venlafaxine XR).Antidepressant treatments which are not listed on 
the MGH -ATRQ but were used or are currentl y being used as antidepressant treatment in the 
current depressi ve episode must be recorded on the ‘Concomitant Therap y’ eCRF .
Any medication that is listed on the MGH -ATRQ and is being taken at the start of the 
screening/prospective observational phase foran indication other than depression (eg, insom nia) 
should be continued during the screening/pro spective observa tional phase but must be 
discontinued before the start of the double- blind phase.
Concomitant therapies must be recorded throughout the study , beginning with signing of the 
informed consent and continuing up to the last visit. Information on concomitant therapies 
should also be obtained beyond this time only in conjunction with new or worsening adverse 
events until resolution of the event.
Subjects should continue to take their permi tted concomitant medications (eg, antihy pertensive 
medication s) at their regular schedule, taking into account any restrictions as outlined in 
Section 4.3 and Attachment 1.Of note, if a subject has routinely  taken his/her oral 
antihy pertensive medications in the morning, the morning dose should be taken prior to 
intranasal dosing.
Subjects receiving psychotherap y (including cognitive behavioral therapy ; CBT) can continue 
receiving psychotherap y; however, CBT must have been ongoing for the last 3 months prior to 
the start of the screening/prospective observational phase . With the exception of new CBT, 
which is prohibited, new psychotherap y is allowed during the study . Any change in existing 
therap y or new therap y must be documented on the concomitant therapies form.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 98All therapies (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; nonpharmacologic therapies such as psychotherapy , electrical stimulatio n [eg, VNS 
or DBS ], acupuncture, special diets, and exercise regimens, cognitive behavioral therapy ) 
different from the study  drug must be recorded in the eCRF. Modification of an effective 
preexisting therap y should not be made for the explicit purpose of entering a subject into the 
study , unless pe rmitted by  protocol (eg , adjustment of blood pressure medications).
Rescue Medications
Rescue medications will not be supplied by the sponsor . In case of treatment-emergent adverse 
events that cannot be resolved by stopping further administration of intranasal 
esketamine/placebo, the following rescue medications may  be considered:
For agitation or anxiety : As required, midazolam (maximum dose 2.5 mg orally  or IM) or 
short acting benzodiazepine
For nausea: As required, ondansetron 8 mg sublinguall y, metoclop ramide (10 mg orally or 
IV or IM) or dimenh ydrinate (25 to 50 mg, IV or IM)
Unless clinicall y indicated, itis recommended that transient increases in blood pressure not 
be treated, as the blood pressure typically  returns to predose values in 2 hours. The effect of 
any treatment may result in hy potension. 
Prohibited Medications
A list of prohibited medications is provided in Attachment 1as general guidance for the 
investigator (but is not all inclusive).
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule summarizes the frequency  and timing of efficacy , PK, biom arker, 
pharmacogenomic, health economic, and safet y measurements applicable to this study .
With the exception of postdose assessments, visit-specific patient -reported outcomes (PRO )
assessments should be conducted or completed before any tests, procedures, or other 
consultations for that visit to prevent influencing subject perceptions. A recommended order of 
study  procedures will be provided to the sites as a separate document.
Actual dates and times of assessments will be recorded in the source documenta tion and eCRF.
The approximate total blood volume to be collected from each subject will be approximately
112.0 mL(Table 5). Repeat or unscheduled samples may be taken for safet y reasons or for 
technical issues with the samples. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 99Table 5: Volume of Blood to Be Collected From Each Subject
Type of Sam pleVolume per 
Sample (mL)No. of Samples 
per SubjectTotal Volum e of 
Blood (mL)a
Screening/Prospective Observational Phase
Serum chemistryb5 1 5
TSH 3.5 1 3.5
Hem atologyc2 1 2
Biomarker: protein 10 1 10
Biomarker: DNA
      Biomarker: RNA
      Tricyclic Antidepressant Blood leveld6
2.5
61
1
16
2.5
6
fT4e3.5 1 3.5
Double -blind Induction Phase
Serum chemistry 2.5 2 5
Hematology 2 2 4
Pharm acokinetic 2 2 4
Biomarker: protein (at Visits 2.1 , 2.3,and 2.8) 10 3 30
Biomarker: DNA 6 1 6
Biomarker: RNA 2.5 3 7.5
Follow -up Phase
Serum chemistry 2.5 1 2.5
Hem atology 2 1 2
Biomarker: protein 10 1 10
Biomarker : RNA 2.5 1 2.5
Approxim ate volume of blood collected during the study 112.0mL
Abbreviations: DNA, deoxyribonucleic acid; fT4, free thyroxine; RNA, ribonucleic acid; TSH, thyroid-stimulating hormone.
aCalculated as number of samples multiplied by amoun t of blood per sample.
bSerum chemistry includes lipid panel.
cAs needed, HbA1c will be measured from the sample collected for hematology.
dFor specific tricyclic antidepressants which are being taken at a dose below the MGH -ATRQ minimum therapeutic dos e, a   
blood level that is within the therapeutic (antidepressant) range, is acceptable to establish the adequacy of the antidepress ant  
treatment.
eFor any subject (regardless of thyroid history), if the TSH value is out of range, a free thyroxine (FT4) will be conducted.
Note: An indwelling IV cannula may be used for blood sample collection.
Note: Repeat or unscheduled samples may be taken for safety reasons or technical issues with the samples.
9.1.2. Screening /Prospective Observational Phase
Prior to conduc ting any study  procedure, the investigator (or designated study  personnel) will 
review and explain the written ICF to each subject. After signing the ICF, subjects who are 
65years of age and older , will be screened to determine eligibility  for study  participation (please 
refer to the study  entry  criteria listed in Section 4).
Subjects must meet DSM -5 diagnostic criteria for single episode MDD (if single episode MDD , 
duration of episode must be 2 years) or recur rent MDD, without psy chotic features, based upon 
clinical assessment and confirmed by the MINI. Subjects must also have a mini mental state 
exam ination (MMSE) total score of <25. In addition, at the start of the screening/prospective 
observational phase, t he subject must have an IDS-C 30total score  31.
At the start of this phase, subjects must have had non response (≤25% improvement) to 1but 8
(if current episode is >2 years, upper limit applicable to only the last 2 years) different oral 
antidepressant treatment staken at adequate dosage and for adequate duration , as assessed using
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 100the MGH -ATRQ and document ed by records (eg, medical /pharmacy /prescription records ora 
letter from treating ph ysician , etc,) for the current episode of depression . 
At the start of the screening/prospective observational phase, the subject must have had 
documented nonresponse to at least one antidepressant treatment (based on the MGH -ATRQ
criteria) in the current episode of depression, and the subject is taking a different oral 
antidepressant treatment (on the MGH -ATRQ) for at least the previous 2weeks at or above the 
minimum therapeuti c dose. This antidepressant treatment, as well as any other ongoing 
medications being taken for depression at screening (including adjunctive/augmentation 
therapies), will continue from the start of Week 1 through the end of Week 4 of the 
screening/prospec tive observational phase . Dose adjustment is permitted per clinical judgment, 
but the oral antidepressant treatment is to remain at or above the minimum therapeutic dose (per 
the MGH -ATRQ) through the end of Week 4.
Antidepressant treatment adherence will be assessed using the PAQ. Missing 4days of 
antidepressant medication in the prior 2-week period will be considered as inadequate adherence.
The subject’s current major depressive episode , depression symptom severity  (Week 1 MADRS 
total score ≥24require d)and antidepressant treatment response to antidepressant therapies used 
during the current depressive episode will be confirmed using the Site Independent Qualification 
Assessment .
An independent, blinded rater will perform remote MADRS assessments to assess depressive 
symptoms during this phase. 
After 4 weeks, subjects who are nonresponders to the current oral antidepressant treatment may 
be eligible to proceed to the double -blind induction phase. Non -response at the end of the 
screening/prospective observational phase is defined as ≤25% improvement in the MADRS total 
score from Week 1 to Week 4and a MADRS total score of ≥24on Week 2 and Week 4. Eligible 
subjects who are entering the double -blind induction phase will discontinue all of their current 
medication(s) being used for depression treatment, including adjunctive/augmentation therapies 
and any other prohibited psychotropic medications, including adjunctive atypical antipsy chotics. 
Subjects who are taking b enzodiazepines (at dosages equal to or less than the equivalent of 
6mg/day  of lorazepam) and/or permitted nonbenzodiazepine sleep medications (eg, zolpidem, 
zaleplon) during the screening/prospective observational phase can continue these medications 
during the induction phase. No dose increases beyond the equivalent of 6mg/day  of lorazepam 
or new benzodiazepine medications are permitted during the induction phase, with the exception 
of the use of permitted benzodiazepine rescue medication. Benzodiazepines and non-
benzodiazepine sleeping medicat ions (eg, zolpidem, zaleplon, eszopiclone, and ramelteon) are 
prohibited within 12hours prior to the start of each intranasal treatment session or cognition 
testing.
All other subjects who do not proceed to the double -blind induction phase will end study 
participation at this time .Nofurther stud y visits or follow -up isrequired.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 101Optional Antidepressant Taper Period
Since all nonresponder subjects will be starting a new oral antidepressant during the double -blind 
induction phase, no washout or drug-free period is required after discontinuing the current 
antidepressant treatment. However, an additional, optional period of up to 3 weeks is permitted 
to taper and discontinue the current oral antidepressant medication per the local prescribing 
information or c linical judgment.
If clinicall y indicated, a subject’s current antidepressant treatment(s) may be tapered and 
discontinued over an additional optional period of up to 3 weeks, per the local prescribing
information or per clinical judgment. This 3 week period may also be used to optimize medical 
management if needed to facilitate subject participation (eg, treatment of blood pressure or 
diabetes, wean from other medications, etc,). In such cases, if there is no planned taper, the oral 
regimen should be conti nued in the interim and then discontinued by Day1 of the double -blind 
induction phase.   
The taper period should notbegin until after the completion of 4 weeks of prospective 
antidepressant treatment and assessment of the antidepressant treatment respons e.
9.1.3. Double -Blind Induction Phase
During this phase, subjects will self-administer double -blind intranasal treatment with 
flexibly -dosed intranasal esketamine (28 mg, 56 mg or 84 mg) or placebo twice per week for 
4weeks as aflexible dose regimen. In addition, subjects will simultaneously  initiate a new, 
open -label oral antidepressant (please refer to Section 6, Dosage and Administration).
On Day 1, approximately 148eligible subjects with TRD will be random ly assignedto 1 of the 
following 2 double -blind treatment groups , in a 1:1 ratio ( approximately  74subjects per group):
Intranasal placebo
Intranasal esketamine
On the same day (ie, Day 1), subjects will be switched to a new, open -label oral antidepressant 
treatment. The oral antidepressant will be 1 of 4 oral antidepressant medications (duloxetine, 
escitalopram, sertraline, or venlafaxine XR). The selection of the antidepressant medication 
assigned by the investigator (based on review of the MGH -ATRQ and releva nt prior 
antidepressant treatment information )and will be one that the subject has not previously  had a 
nonresponse to in the current depressive episode, has not been previously  intolerant to (lifetime), 
and is available in the participating country . Dosing of the oral antidepressant will begin on 
Day 1.A mandatory  titration schedule is provided in Attachment 3. Doses are not to exceed the 
maximum dose defined in the titration schedule. A dose reduction for tolerability is permitted.
For information obtained via telephone contact, written documentation of the communication 
must be available for review in the source documents. During telephone contact visits with the 
subject b y site personnel, adverse event and concomitan t therap y information will be obtained . In 
addition, specified clinician -administered assessments (eg, PWC -20) will be performed by 
appropriately qualified staff.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 102At the end of the double -blind induction phase, subjects may be eligible to enter the subsequent 
long term safety study  (Study  ESKETINTRD3004 ).Subjects who do not complete the induction 
phase of this study  will not be eligible to participate in the ESKETINTRD3004 study .To 
maintain study  blinding, the blind will not be broken for subjects enterin g
Study ESKETINTRD300 4.Participation in ESKETINTRD3004 will begin immediately  after the 
completion of the double -blind induction phase .These subjects will be instructed to continue 
taking their oral antidepressant medication through their next study visit (ie, first study visit 
Study  ESKETINTRD3004).
Those subjects who do not enter Study  ESKETINTRD3004 will proceed into a 2-week 
follow -up phase. 
Early Withdrawal
If a subject withdraws before the end of the double -blind induction phase for reasons other than 
withdrawal of consent, the Earl y Withdrawal visit should be conducted within 1 week of the date 
of discontinuation, followed by the follow -upphase .If the Early Withdrawal visit occurs on the 
same day as a scheduled visit, the early withdrawal visit can be performed on the same day and 
duplicate assessments are not required.
Further clinical/standard of care for the treatment of depression will be arranged by the study 
investigator and/or the subject’s treating physician. The study  investigator and/or treating 
physician will determine whether or not the current oral antidepressant medication will continue.
Subjects who withdraw early will receive additional oral antidepressant medication, if 
applicable, and they should continue taking the oral antidepre ssant medication for the2weeks of 
the follow- up phase, unless determined as not clinically  appropriate.
9.1.4. Follow -up Phase
All subjects who receive at least 1 dose of intranasal study  medication in the double -blind 
induction phase and are not participating in the subsequent ESKETINTRD300 4study  will 
proceed into the 2-week follow -up phase. Clinic visits and remote assessment visits will be 
performed as specified in the Time and Events Schedule . During this phase , safet y and 
tolerability , including potential withdrawal symptoms, following discontinuation of intranasal 
esketamine will be assessed . In order to better assess potential withdrawal symptoms from the 
intranasal medication it is recommended that the oral antidepressant medication be continued in 
the follow -upphase unless determined as not clinically  appropriate.
Further clinical/standard of care for the treatment of depression will be arranged by the study 
investigator and/or the subject’s treating physician. No intranasal study  medication will be
administered during this phase. All subjects will be provided with an additional 2-week suppl y of 
their oral antidepressant medication ,to ensure there is no interruption of antidepressant therapy  
during the transition to further clinical/standard of care. Inorder to better assess potential 
withdrawal symptoms from the intranasal medication and facilitate maintenance of clinical 
benefit following the 4-week double blind treatment phase, the oral antidepressant medication 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 103should be continued for the 2 weeks ofthe follow -upphase unless determined as not clinically 
appropriate. The decision to continue the antidepressant will be at the discretion of the 
investigator.
If information is obtained via telephone contact, written documentation of the communication 
must be available for review in the source documents. 
Any clinicall y significant abnormalities persisting at the end of the study  will be followed by  the 
investigator until resolution or until a clinicall y stable endpoint is reached. All adverse events 
and special reporting situations, whether serious or non -serious, will be reported until completion 
of the subject's last study -related procedure.
9.2. Efficacy
9.2.1. Evaluations
It is recommended that the patient -reported outcome assessments be completed prior to other 
procedures. 
9.2.1.1. Primary  Efficacy  Evaluation
The primary  efficacy  evaluation will be the change from baseline in the MADRS total score 
from Day 1  p re-randomization to the end of the 4-week double -blind induction phase. The 
structured interview guide for the MADRS (SIGMA) will be used for each administration. The 
MADRS will be performed by independent remote raters during the study .
The MADRS is a clinician -rated scale designed to measure depression severit y and detects 
changes due to antidepressant treatment .49Thescale consists of 10 items, each of which is scored 
from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a 
total possible score of 60. Higher scores represent a more severe condition. The MADRS 
evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, 
lassitude, inability  to feel (interest level ), pessimistic thoughts, and suicidal thoughts. The test 
exhibits high inter -rater reliabi lity. 
The typical recall period for the MADRS is 7 days and will be used for the primary  efficacy 
evaluation.
9.2.1.2. Secondary  Efficacy Evaluations (Clinician -completed)
9.2.1.2.1. CGI-S
The CGI-S provides an overall clinician -determined summary  measure of the severit y of the 
subject’s illness that takes into account all available information, including knowledge of the 
subject’s history , psychosocial circumstances, symptoms, behavior, and the impact of the 
symptoms on the subject’s abilit y to function .35The CGI-S evaluates the severit y of 
psychopathology  on a scale of 0 to 7. Considering total clinical experience, a subject is assessed 
on severity  of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at 
all ill); 2=borderline mentally  ill; 3=mildly  ill; 4=moderatel y ill; 5=markedly  ill; 6=severel y ill; 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 1047=among the most extremely  ill patients. The CGI-S permits a global evaluation of the subject’s 
condition at a given time.
9.2.1.3. Other Secondary  Efficacy  Evaluations (Patient -reported Outcomes)
9.2.1.3.1. EQ-5D-5L
The EQ-5D- 5L is a standardized instrument for use as a measure of health outcome, primarily 
designed for self -completion by  respondents. It consists of the EQ -5D- 5Ldescriptive sy stem and 
the EQ visual analogue scale (EQ- VAS). The EQ-5D- 5L descriptive system comprises the 
following 5 dimensions: mobility , self-care, usual activities, pain/discomfort and 
anxiety /depression. Each of the 5 dimensions is divided into 5 levels of perceived problems 
(Level 1 indicati ng no problem, Level 2 indicating slight problems, Level 3 indicating moderate 
problems, Level 4 indicating severe problems, and L evel 5 indicating extreme problems).27,31
The subject selects an answer for each of the 5 dimensions considering the response that best 
matches his or her health “today .” The descriptive system can be represented as a health state. 
The EQ-VAS self-rating records the respondent’s own assessm ent of his or heroverall health 
status at the time of completion, on a scale of 0 to 100 . 
The time taken to complete the questionnaire varies with age, health status, and setting but is 
likely  to be around 1 minute. 
9.2.2. Endpoints
9.2.2.1. Primary  Endpoint
The primar y efficacy  endpoint is the change in the MADRS total score as measur ed by the 
change from baseline (Day  1  prior to randomization) to the end of the 4-week double -blind 
induction phase.
9.2.2.2. Secondary  Endpoints
Proportion of responders ( 50% reduction from basel ine in MADRS total score) at the end of 
the 4- week double -blind induction phase
Proportion of subjects in remission (MADRS 12) at the end of the 4-week double -blind 
induction phase
Change from baseline (Day  1 prior to randomization) to the end of the 4 week double -blind 
induction phase in: 
oSeverity  ofdepressive illness, using the CGI -S
oHealth-related qualit y of life and health status, as assessed b y the EQ -5D- 5L
9.3. Pharmacokinetics
Whole blood samples will be used to evaluate the PK of esketamine. Plasma collected forPK 
may additionally  be used to evaluate safet y or efficacy  aspects that address concerns arising 
during or after the study  period. Genetic analyses will not be performed on these serum samples. 
Subject confidentiality will be maintained.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 1059.3.1. Evalua tions
Venous blood samples of approximately 2mL will be collected for measurement of plasma 
concentrations ofesketamine, noresketamine, and other metabolites (if warranted) at the time 
points specified in the Time and Events Schedule. The exact dates and times of PK blood 
sampling must be recorded.
9.3.2. Analytical Procedures
Plasma samples will be analyzed to determine concentrations of esketamine (and noresketamine, 
if warranted) using a validated, specific, achiral, and sensitive liquid chromatograph y-tandem
mass spectrometry  (LC-MS/MS) method by or under the supervision of the sponsor. If required, 
some plasma samples may be analy zed to document the presence of other analytes (eg, 
circulating metabolites or denatonium) using a qualified research method. In addition, plasma PK 
samples may  be stored for future anal ysis of the metabolite profile.
The bioanaly tical report, including a description of the assay  and a summary  of the assay  
performance data, will be included in the final clinical study  report as an ad dendum .
9.3.3. Pharmacokinetic Parameters
The plasma concentration -time data of esketamine (and noresketamine , if warranted) will be 
analyzed using population PKmodeling. Typical population values of basic PKparameters (eg,
esketamine clearance distribution volume) will be estimated together with the inter-individual 
variability . Effects of subject demographics, laboratory  parameter values, and other covariates on 
the PKof esketamine will be explored. The results of the population PKanalyses may be 
reported se paratel y.
9.4. Pharmacokinetic/Pharmacody namic Evaluations
The relationship between MADRS total score (and possibly  selected AEs as additional 
PDparameters) and PKmetrics of esketamine may be evaluated. If there is any visual trend in 
graphical analysis, suit able models will be applied to describe the exposure -effect relationships. 
The results of the exposure -response evaluations will be presented in a separate report.
9.5. Biomarker, Pharmacogenomic (DNA ), and Expression (RNA ) Evaluations
During the study , blood will be collected for the assessment of biomarkers at the time points 
indicated in the Time and Events schedule. The biomarker blood samples should be collected 
prior to dosing . It is preferred that subjects adhere to a low fat diet on the day of sample 
collection .
In blood, biomarkers (protein, metabolite, and ribonucleic acid [RNA]) related to (but not limited 
to) the immune system activity , HPA axis activation, neurotrophic factors, and metabolic factors 
will be investigated .Biomarkers may be added or deleted based on scientific information or 
technical innovations under the condition that the total volume of blood collected will not be 
increased.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 106The biomarker data obtained from this study  may also be included in an ongoing cross- study 
analysis to invest igate the relationship between depression severity and phenot ypes and 
biomarkers.
Blood samples for DNA analyses will be collected at the time points indicated in the Time and 
Events Schedule for the assessment of genetic and epigenetic variation in genes in pathway s 
relevant to depression (eg, HPA axis, inflammation, growth factors, monoamine transporters, ion 
channels, and circadian rhy thm).
Genoty ping will be conducted onl y on the screening sample; pharmacogenomic and epigenetic 
evaluations may  be perfor med on an y/all collected samples.
DNA samples will be used for research related to esketamine, oral antidepressants, TRD, or 
MDD. They  may  also be used to develop tests/assay s related to esketamine, oral antidepressants, 
TRD, or MDD. Pharmacogenomic resear ch may consist of the analy sis of 1 or more candidate 
genes or of the analysis of genetic markers throughout the genome (as appropriate) in relation to 
esketamine, oral antidepressants, TRD, or MDD clinical endpoints.
Further information regarding handling , shipment, and labeling of biological samples will be 
provided in a separate laboratory  manual.
9.6. Safety  Evaluations
Details regarding the Independent Data Monitoring Committee are provided in Section 11.9.
Any clinically  relevant changes occurring during the study  must be recorded on the Adverse 
Event section of the eCRF.
Any clinically  significant abnormalities persisting at the end of the study/earl y withdrawal will 
be followed b y the investigator until resolut ion or until a clinically  stable endpoint is reached.
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the Time and Events Schedule.
There may be instances when a subject has started a scheduled clinic visit which includes a 
planned intranasal treatment session, but due to predo se vital sign measurements (eg, blood 
pressure value), a decision is made to postpone/delay  the intranasal treatment session within the 
visit window permitted per protocol. In such cases, all time points (including predose , if 
applicable ) of the following assessments must be repeated on the actual intranasal treatment 
session day: vital signs (ie, blood pressure, pulse, respiratory  rate, and temperature), 12-lead 
ECG, C- SSRS (since last visit), MOAA/S, pulse oximetry , BPRS+, and CADSS.
Adverse Events
Adverse events will be reported by the subject (or, when appropriate, by a caregiver, surrogate, 
or the subject's legall yacceptable representative) for the duration of the study . Adverse events 
will be followed by  the investigator as specified in Section 12, Adverse Event Reporting.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 107TEAEs of special interest will be examined separately  (please refer to Sections 3.2.6 and 11.8).
Clinical Laboratory Tests
Blood samples for serum chemistry  and hematology  and a urine sample for urinal ysis will be 
collected. The investigator must review the labor atory  report, document this review, and record 
any clinically  relevant changes occurring during the study  in the adverse event section of the 
eCRF. The laboratory  reports must be filed with the source documents.
The use of local laboratories is allowed in cases where initiation of treatment or safety  follow -up 
is time-critical and the central laboratory  results are not expected to be available before the need 
to begin dosing or if actions need to be taken for safet y reasons.
The following tests will be perf ormed by  the central laboratory , unless noted otherwise:
Hematology  Panel
-hemoglobin -platelet count
-hematocrit
-red blood cell (RBC) count
-white blood cell (WBC) count with differential
Serum Chemistry  Panel
-sodium -alkaline phosphatase
-potassium -creatine phosphokinase (CPK)
-chloride -calcium
-bicarbonate -phosphate
-blood urea nitrogen (BUN) -albumin
-creatinine -total protein
-glucose -total bilirubin
-aspartate aminotransferase (AST)
-alanine aminotransferase (ALT)
-gamma -gluta myltransferase (GGT)
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 108Urinaly sis
DipstickSediment (if dipstick result is
abnormal)
-specific gravit y -red blood cells
-pH -white blood cells
-glucose -epithelial cells
-protein -crystals
-blood -casts
-ketones -bacteria
-bilirubin
-urobilino gen
-nitrite
-leukocy te esterase
If dipstick result is abnormal, flow cytometry  or microscop y will be used to measure 
sediment. In case of discordance between the dipstick results and the flow cytometric 
results, the sediment will be examined micr oscopically .
The following tests will be done at time points specified in the Time and Events Schedule or as 
required based on subject status (noted below) :
Lipid panel: total cholesterol, low density  lipoprotein (LDL)-cholesterol, high density  
lipoprotei n (HDL) -cholesterol, and trigl ycerides
Urine Drug Screen : barbiturates, methadone, opiates, cocaine, cannabinoids (cannabinoids 
are only exclusionary  at Day  1 predose), PCP, and amphetamine/methamphetamine
Alcohol breath test 
Thyroid- stimulating hormone ( TSH) 
Free thy roxine , only  if required for abnormal TSH (see inclusion criterion 7.2 in Section 4.1)
Calculation of creatinine clearance
Glycated hemoglobin (HbA1c) test (Screening only )
Single, 12-Lead ECG
During the collection of ECGs, subjects should be in a quiet setting without distractions (eg, 
television, cell phones). Subjects should rest in a supine position for at least 5minutes before 
ECG collection and should refrain from talking or moving arms or le gs.
All ECG tracings will be sent to a central ECG laboratory . The ECGs will be read at the 
scheduled time points and summarized by  a central ECG laboratory . The central ECG laboratory 
will send the sponsor an electronic copy of the data for inclusion in the clinical database. In 
addition, the investigator or sub-investigator is required to review all ECGs at the study  visit to 
assess for any potential safet y concerns or evidence of exclusionary  conditions.
The subject must be discontinued at an y time point after baseline (Day  1, predose) if:
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 109QTcF change from baseline is ≥60 msec AND QTcF >480 ms ec, or
QTcF >500 ms ec.
Vital Signs (temperature, pulse/heart rate, respiratory  rate, blood pressure)
Blood pressure and pulse/ heart rate measurements will be assesse d in a supine position with a 
completely  automated device or using m anual techniques.
Blood pressure and pulse/heart rate measurements should be preceded by at least 5 minutes of 
rest in a quiet setting without distractions (eg, television, cell phones).
For further details regarding blood pressure, please see Guidance for Blood Pressure Monitoring 
on Intranasal Dosing Day s (Section 6.2.1 ).
Tympanic temperature is recommended.
An automated device will be used for measurement of respiratory  rate.
Pulse Oximetry
Pulse oximetry  will be used to measure arterial oxygen saturation. 
On each dosing day, the device will be attached to the finger, toe, or ear before the first nasal 
spray  and then, after the first spray  it will be monitored and documented. Any arterial oxygen 
saturation <93% should be confirmed b y an additional measurement on another part of the body.
On intranasal treatment session days, pulse oximetry  will be performed every 15 minutes from 
predose to t=1.5 hours postdose. If oxygen saturation levels are <93% at any time during the 1.5 
hour postdose interval, pulse oximetry  will be performed every  5 m inutes until the level returns 
to 93% or until the subject is referred for appropriate medical care ,if clinically  indicated.
Physical Examination, Height, Body Weight and Neck Circumference
Physical examinations, body  weight, and height will be performed or measured per the Time and 
Events Schedule.
In addition ,body  mass index (BMI) will be calculated and neck circumference measured as part 
of the information required for the STOP -Bang questionnaire.
Nasal Examinations 
Nasal examinations (including the upper respiratory  tract/throat) will be conducted by  a qualified 
healthcare practitioner. The objective of the examination at screening isto rule out any subjects 
with anatomical or medical conditions that may  impede drug delivery  or absorption. 
Subsequent examinations will consist of a visual inspection of the nostrils, nasal mucosa, and 
throat for nasal erythema, rhinorrhea, rhinitis, capillary /blood vessel disruption ,and epistaxis ,
and will be graded as follows: absent , mild, moderate, or severe.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 110Nasal Symptom Questionnaire
Subjects will complete a nasal symptom questionnaire. The nasal symptom questionnair e was 
developed by the sponsor to assess nasal symptom sfollowing intranasal administration of study 
drug. The questionnaire asks about nasal s ymptoms, which are rated by  the subject as none, mild, 
moderate, or severe, based on how he or she feels at the t ime of the assessment.
C-SSRS
The C -SSRS will be performed to assess potential suicidal ideation and behavior. 
The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was 
developed in the National Institute of Mental Heal th Treatment of Adolescent Suicide 
Attempters Study  to assess severit y and track suicidal events through any treatment.69It is a 
clinical interview providing a summary  of both suicidal ideation and behavior that can be 
administered during any  evaluation or risk assessment to identify  the level and ty pe of suicidality  
present. The C -SSRS can also be used during treatment to monitor for clinical worsening.
Two versions of the C-SSRS will be used in this study , theBaseline/Screening version, and the 
Since Last Visit version. The Baseline/Screening version of the C-SSRS will be used in the 
screening/prospective observational phase. In this version, suicidal ideation will be assessed at 
2time points (“lifetime” and “in the past 6 months”) and suicidal behavior will be assessed at 
2time points (“lifetime” and “in the past year”). All subsequent C-SSRS assessments in this 
study  will use the Since Last Visit version, which will assess suicidal ideation and behavior sin ce 
the subject’s last visit.
CADSS
The CADSS is an instrument for the measurement of present- state dissociative symptoms ,5and 
will be administered to assess treatment -emergent dissociative sy mptoms.
The CADSS consists of 23 subjective items, divided into 3 components: Depersonalization 
(Items 3 to 7, 20, and 23), derealization (Items 1, 2, 8 to 13, 16 to 19, and 21) and amnesia 
(Items 14, 15, and 22). Participant’s responses are coded on a 5-point scale (0=not at all to 
4=extremely ). CADSS has excellent inter -rater reliability  and internal consistency . 
BPRS+
Four items of the BPRS will be administered to assess potential treatment -emergent psychotic 
symptoms. 
The BPRS is an 18-item rating scale that is used to assess a range of psychotic and affective 
symptoms ,rated from both observation of the subject and the subject's own report.61It reportedl y 
provides a rapid and efficient evaluation of treatment response in clinic drug studies and in 
clinical settings.75
Only  the 4-item positive symptom subscale BPRS+ ( ie,suspiciousness, hallucinations, unusual 
thought content, and conceptual disorganization) will be used in this study. It is highl y sensitive 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 111to change, and excellent inter-rater reliability  can be achieved with training and a standard 
interview procedure. 
MOAA/S
The MOAA/S will be used to measure treatment -emergent sedation ,with correlation to levels of 
sedation def ined b y the American Societ y of Anesthesiologists (ASA) continuum.64
The MOAA/S scores range from 0=no response to painful stimulus (corresponds to ASA 
continuum for general anesthesia )to 5=readil y responds to name spoken in normal tone (awake; 
corresponds to ASA continuum for minimal sedation).
On each intranasal treatment session day, the MOAA/S will be performed every  15 minutes from 
predose to t=+1.5 hours postdose. 
If the score is 3 at any time during the1.5 hour postdose interval, the MOAA/S will be 
performed every  5 minutes until a score of 4 is reached (at which point a frequency  of every 
15 minutes can be resumed until t=+1.5 hours post dose). 
If a subject does not have a score of at least 5 at t=+1.5 hours postdose, they  should continue 
to be monitored. For subjects with a score of 4, the assessment should be repeated every  15 
minutes. And for subjects with a score of 3, the assessment should be repeated every  5 
minutes until the score returns to 5 or the subject is referred for appropriate medical care, if 
clinically  indicated .
CGADR
The CGADR will be used to measure the subject’s current clinical status and is the clinician’s 
assessment of the readiness to be discharged from the study site. 
The clinician will answer “Yes” or “No” to the question “Is the subject considered ready to be 
discharged based on their overall clinical status ( eg, sedation, blood pressure, and other adverse 
events )?”
On intranasal treatment session days, the CGADR will be performed at 1 hour, and 1.5 hours 
postdose; if the response is not “Yes” at 1.5 hours postdose, the assessment will be repeated 
every  15 minutes until a “Yes” response is achieved or until the subject is referred for 
appropriate medical care if clinically  indicated. A subject should not be discharged prior to 
the 1.5 hour time point.
On all intranasal treatment session days, subjects must remain at the clinical site until study 
procedures have been completed and the subject is read y for discharge.
PWC -20
ThePWC -20 will be administered to assess potential withdrawal symptoms following cessation 
of intranasal esketamine treatment. An assessment will be performed for all subjects on Day 25 
to establish a baseline prior to discontinuation of intranasal esketamin e treatment (if applicable) . 
In order to better assess potential withdrawal symptoms from the intranasal medication it is 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 112recommended that the oral antidepressant medication be continued for the 2 weeks of the follow -
upphase unless determined as not clini cally appropriate.
The PWC -20 is a 20-item simple and accurate method to assess potential development of 
discontinuation symptoms after stopping of study drug. The PWC -20 is a reliable and sensitive 
instrument for the assessment of discontinuation symptoms .72Discontinuation symptoms occur 
early and disappear rather swiftl y, depending upon speed of taper, daily medication dose, and 
drug elimination half- life. 
BPIC- SS
The BPIC-SS is a patient -reported outcome measure that was developed to identify  an 
appropriate bladder pain syndrome/interstitial cystitis population for clinical studies evaluating
new treatments for bladder pain s yndrome .40
The BPIC-SS will be used to monitor subjects for potential symptoms of cystitis, bladder pain, 
and interstitial cy stitis. 
The BPIC-SS includes 8 questions with a recall period of the past 7 days, and addresses key 
symptoms identified by subjects with BPS including symptom concepts ofpain and/or pressure
of the bladder, and urinary  frequency . Subjects respond to items using a 5-point scale (0=never , 
1=rarely, 2=sometimes, 3=most of the time, 4=alway sfor frequency -based questions ,and 0=not 
at all , 1=a little, 2=somewhat, 3=moderately, and 4=a great deal for items related to bother 
associated with symptoms ). Question 8 records the worst bladder pain in the last 7 days using a 
0-10 numerical rating scale. A total score is calculated by adding up the numbers beside the 
response options c hosen by  the subject . The range of scores for the scale is 0 to 38.
A total score of 19 or more has demonstrated good sensitivity /specificity  and is considered a 
relevant cut -off to distinguish those with significant bladder s ymptoms and/or cy titis.40
If any items are missing, a total score cannot be calculated.
In the current study , if a subject has a score >18 on the BPIC-SS scale and there is no evidence 
of urinary  tract infection based on urinal ysis and microscop y, he or she will be referred to a 
specialist for further evaluation. If a subject is determined to have a diagnosis of ulcerative 
cystitis, the subject must be discontinued from the study  and followed up with appropriate 
medical care. As such, in addition to urinaly sis, a urine culture should also be obtain if BPIC-SS 
score is >18 on applicable study  day.
Cognition Testing: Computerized Cognitive Battery and HVLT -R
The computerized cognitive battery  provides assessment of multiple cognitive domains,
including attention, visual learning and memory , and executive function. The tests use culture -
neutral stimuli, enabling use in multilingual/multicultural settings. The computerized battery  
includes:
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 113Simple and choice reaction time tests; scored for speed ofrespon se (mean of the 
log10-transformed reaction times for correct responses)
Visual episodic memory ; visual recall test scored using arcsine transformation of the 
proportion of correct responses
Working memory  (n-back); scored for speed of correct respo nse (mean of the 
log10-transformed reaction times for correct responses)
Executive function; maze/sequencing test ,scored for total number of errors
All measures have been validated against traditional neuropsy chological tests and are sensitive to 
the effects of various drugs on cognitive performance ,including alcohol and benzodiazepines.
Completing the cognitive battery requires approximately  25 minutes.
The HVLT -R, a measure of verbal learning and memory , is a 12-item word list recall test.
Administrati on includes 3 learning trials, a delay ed recall (20-minute) trial, and a 24-word 
recognition list (including 12 target and 12foil words ).4The test administrator reads instructions 
and word lists aloud, and records word srecalled /recognized by the subject.S cores include 
learning, delay ed recall , and recognition. The HVLT -R is a well-validated and wide ly used 
measure of verbal episodic memory .49
The tests will be administered in the following order: HVLT -R, computerized cognitive test 
battery , and HVLT -R D elayed.
All subjects will complete a practice session for the computerized cognitive battery  during the 
screening/prospective observational phase. There is no practice session for the HVLT- R.
UPSIT
To assess any potential treatme nt-emergent effects on the sense of smell, olfactory  function will 
be qualitatively  and quantitatively  assessed using a validated standardized olfactory  testprior to
and at specified time point s during the study . 
The UPSI Tassesses a subject ’s ability  to identify odors. This standardized test, the most widel y 
used olfactory  test in the world, is derived from basic psy chological test measurement theory  and 
focuses on the comparative ability  of subjects to identi fy odorants at the suprathreshold level. 
The UPSI T consists of 3envelope -sized booklets, each containing 10“scratch and sniff” 
odorants embedded in 10-to 50-µm polymer microcapsules positioned on brown strips at the 
bottom of the pages of the booklets. The internal consistency  and test-retest reliability  
coefficients of this instrument are >0.90.22,21Numerous studies have shown this and related tests 
to be sensitive to subtle changes in smell function associated with multiple etiologies, including 
those due to viruses, head trauma, and a number of neurodegenerative diseases.
TheUPSI Ttest will be administered bilaterally  (ie, both nostrils at the same time). Testing will 
occur during the screening /prospective observational phase to establish a subject’s baseline 
sensitivit y. The degree of change from this baseline will be determined subsequently  over time. 
The percent change from baseline will serve as the dependent measure for each subject for each 
test. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 1149.7. Other Evaluations
MINI
Subjects will undergo MIN I (a brief, structured diagnostic interview) to confirm the diagnosis of 
MDD and to determine if there are other psychiatric conditions present. It has an administration 
time of approximately  15 minutes .
MGH -ATRQ
The MGH -ATRQ is used to determine treatment resistance in MDD .18
The MGH -ATRQ evaluates the adequacy  of duration and dosage of all antidepressant 
medications used for the current major depressive episode . In addition, the MGH -ATRQ assesses 
the degree of improvement on a scale from 0% (not improved at all) to 100% (completely 
improved). The MGH -ATRQ will be completed by the clinician ,in collaboration with the 
subject.
MMSE
The MMSE is a validated, brief examination that rates subjects on orientation (total score, 10), 
registration (total score, 3), attention andcalculation (total score, 5), recall (total score, 3), and 
language (total score, 9).32The MMSE is effective as a screening tool for cognitive impairment 
with older communit y dwelling, hospitalized and institutionalized adults. The maximum score is 
30. The MMSE will be completed at screening only. A total score <25 or <22for those subjects 
with less than an equivalent of a high school education, will be used in the current study  in order 
to exclude subjects with potential neurodegenerat ive disorder.
STOP -Bang Questionnaire 
Snoring, Tiredness, Observ ed Apnea, High Blood Pressure, Body Mass Index, Age, Neck 
Size, G ender (STOP -Bang) Questionnaire 
The STOP -Bang questionnaire is a concise, easy-to-use, validated, and sensitive screening tool 
for obstructive sleep apnea (OSA) . This questionnaire has 8 ite ms which address key risk factors 
for obstructive sleep apnea: snoring, tiredness, observed breathing interruption during sleep, high 
blood pressure, body  mass index, age, neck size, and gender. The STOP -Bang questions do not 
specify  a  recall period. Subje cts will answer yes or no to questions about snoring, tiredness, 
observed breathing interruption, and high blood pressure (these are the STOP items in the 
STOP -Bang acron ym); this takes approximately  1 minute.6
Study  site staff will answer yes or no to questions about body  mass index (more than 35 kg/m²?), 
age (older than 50 years?), neck circumference (larger than 17 inches [43 cm] in men, or larger 
than 16 inches [41 cm] in women?), and gender (male?).
The total STOP -Bang score is calculated by  summing the number of positive responses, yielding 
a score range of 0 to 8. A score of 5 on the STOP -Bang indicates a moderate to severe risk for 
OSA (A HIof >30) .6
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 115Site Ind ependent Qualification Assessment
Independent psychiatrists/psy chologists will perform the Site Independent Qualification 
Assessment in the screening/prospective observational phase for all subjects to confirm diagnosis 
of depression and eligibility  for t he stud y.86
Further information regarding this assessment will be provided to sites in a separate document.
IDS-C30
The 30-item IDS-C30is designed to assess the severit y of depressive symptoms.76The IDS 
assesses all the criterion symptom domains designated by the DSM -5to diagnose a major 
depressive episode. These assessments can be used to screen for depression, although they have 
been used predominantly as measure s of sy mptom severit y. The 7- day period prior to assessment 
is the usual time frame for assessing symptom severit y. The psychometric properties of the 
IDS-C30have been established in various study  samples.86
PAQ
Subjects ’ adherence to their oral antidepressant treatment regimen during the 
screening/prospective observational phase will be assessed using the PAQ. It is a brief, 2-item 
self-report scale, developed at the University  of Texas Southwestern Medical Center to assess 
how often the subject has taken, and whether heor she has made any changes to, his/her 
antidepressant treatment regimen in the last 2 weeks . The total score is based on the response 
selected to Question 1 , and is interpreted as 0-1=adherent and 2 or more=nonadherent.58
9.8. Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the eCRF or laboratory 
requisition form. If blood samples are collected via an indwelling cannula, an appropriate 
amount (1 mL) of serosanguineous fluid slightly  greater than the dead space volume of the lock 
will be removed from the cannula and discarded before each blood sample is taken. After blood 
sample collection, the cannula will be flushed with 0.9% sodium chloride, United States 
Pharmacopeia (USP) (or equivalent) and charged with a volume equal to the dead space volume 
of the lock.
Refer to the T ime and Events Schedule for the timing and frequency  of all sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory  manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperatu re conditions as indicated 
in the laboratory  manual.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 11610. SUBJECT COMPLETION/W ITHDRA WAL
10.1. Completion
A subject will be considered to have completed the double -blind induction phase of the study  if 
he or she has completed the MADRS assessments at the end of the 4-week double -blind 
induction phase (ie, Day  28 MADRS) .
Subjects who prematurely discontinue study  treatment for any reason before completion of the 
double -blind induction phase will not be considered to have completed the double -blind 
induction phase of the study .
10.2. Withdrawal F rom the Study
A subject will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up
Withdrawal of consent (Note: See “Withdrawal of Consent” section below; this should only 
be selected as a reason for withdrawal if the subject does not agree to any further study 
assessments or procedures. If the subject is agreeable to participating in the Earl y Withdrawal 
visit and the follow -up phase, another reason for withdrawal should be selected.)
Violation of protocol proc edures (determined on a case- by-case basis)
Blind is broken (double -blind induction phase)
Lack of efficacy
The investigator or sponsor believes (eg, that for safet y or tolerability  reasons such as an 
adverse event) it is in the best interest of the subjec t to discontinue the study .See also 
guidance on blood pressure monitoring on intranasal dosing day s (Section 6.2.1).
At any  time point after baseline (Day  1, predose), the subject has a:
QTcF change from baseline ≥60 msec AND QTcF >480 ms ec, or
QTcF >500 ms ec
Death
Study  is terminated by  Sponsor for futility
If the subject withdraws from the study  before the end of the double -blind induction phase, an 
Early Withdrawal visit is to be performed.
If a subject is lost to follow -up, every reasonable effort must be made by  the study  site personnel 
to contact the subject and determine the reason for discontinuation/withdrawal. This should 
include at least 3 telephone calls, certified letters, email requests, etc. To ens ure access to follow -
up subjects, the study  sites should attempt to obtain both primary  and secondary  telephone 
contact numbers (eg, home, work, and mobile phone numbers including phone numbers of 
relatives ), as well as other contact information (eg, e-mail addresses) from subjects before 
randomization. In addition, the study  site should emphasize the importance of follow -up 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 117information to the subject before randomization. The measures taken to follow up must be 
documented.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in the eCRF and in the source document. Subjects who withdraw will not be 
replaced. 
Withdrawal of Consent
Every  effort will be made in the study  to ensure withdrawal of consent is not sele cted as a reason 
for discontinuation when in fact the subject withdrew for an identifiable reason (eg, due to an 
adverse event or lack of efficacy ). 
Subjects who wish to withdraw from the study  should be asked if they are agreeable to continue 
to an earlywithdrawal visit (if withdrawing from the double -blind induction phase) and the 
follow -up phase, or to be contacted to collect follow -up information. Subjects who are not 
agreeable to follow -up contact will be withdrawn from the study  as “withdrawal of consent.”
Subjects who no longer wish to take study  drug but agree to provide follow -up information will 
be withdrawn from the double -blind induction phase with the reason noted as “Other” and will 
specify  the reason wh y.
For a subject who withdraws consent, it is recommended that the subject withdraw consent in 
writing; if the subject refuses or is physicall y unavailable, the study  site should document and 
sign the reason for the subject’s failure to withdraw consent in writing and maintain it with the 
subje ct’s source records.
The investigator will be responsible for making all required notifications to the Institutional 
Review Board (I RB) or Independent Ethics Committee (IEC).
10.3. Withdrawal From the Use of Sample s in Future Research
The subject may  withdraw co nsent for use of sample sfor research ( refer to Section 16.2.5 , Long-
Term Retention of Samples for Additional Future Research). In such a case, samples will be 
destroy ed after they are no longer needed for the clinical study . Details of the sample retention
for research are presented in the main I CF.
11. STATISTICA L METHODS
Statistical analy sis will be done by the sponsor or under the authority  of the sponsor. A general 
description of the statistical methods to be us ed to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Statistical Analy sis Plan.
11.1. Subject Information
The primary  efficacy  and safet y analysis sets are defined below.
Full Analysis Set: All randomized subjec ts who receive at least 1 dose of intranasal study  
medication and 1 dose of oral antidepressant medication in the double -blind induction phase. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 118Safety Analysis Set: All randomized subjects who receive at least 1 dose of intranasal study 
medication or 1 do se of oral antidepressant medication in the double -blind induction phase.
11.2. Sample Size Determination
The maximum sample size planned for this study  was calculated assuming a treatment difference 
after 4 weeks of treatment in the double -blind induction phase of 6.5 points in MADRS total 
score between esketamine and the active comparator, a standard deviation of 12, a 1-sided 
significance level of 0.025, and a drop-out rate of 25%. A maximum of about 74 subjects will 
need to be randomized to each treatment group to achieve 80% power using a fixed design with 
no interim analy sis. The treatment difference and standard deviation used in this calculation were 
based on results of Panel A of the ESKETINTRD2003 study  and clinical judgment.
As detailed below, an interim analysis is planned to re-estimate sample size or to stop the study  
due to futility .
11.3. Interim A nalysis for Sample Size Re -estimation or Stopping for Futility
One unblinded interim analy sis will be performed 4 weeks after randomizing 50 subjects in the 
study (approximately  25 per treatment group). It is projected that at that time approximately  
36subjects in the full analy sis set would have completed the double -blind induction phase of the 
study  (approximately  18 subjects per treatment group). The dropout rate will be monitored to 
ensure that a sufficient number of subjects areincluded in the interim analy sis. As the 
assumptions of the expected treatment difference and variability  may or may not be upheld, the 
purpose of the interim analy sis is to either re-estimate sample size or to stop the study  due to 
futility . The sample size may be adjusted to achieve the desired power while maintaining control 
of the overall Type I error. The maximum sample size planned for this study  is 74per treatment 
group.
A rigorous interim statistical analy sis plan (SAP) and charter will be developed detailing the 
algorithm for a sample size re-estimation based on the interim data and how the analy sis will be 
executed. An IDMC will perform the interim analy sis and will make recommendations for any 
sample size adjustment based on the rules defined in the interim SAP. Any changes to sample 
size will be communicated by the IDMC (or the statistician from the Statistical Support Group) 
to the IWRS vendor to ensure that the appropria te number of subjects is enrolled in the study . 
None of the esketamine team members or staff members at the investigational sites conducting 
the clinical study will be informed of the results of the interim analy sis or of anyspecific sample 
size adjustmen t resulting from this interim analy sis.However, the Clinical Supplies group will 
be informed of the decision made at the interim analysis so that only the required amount of 
study  medication will be packaged.
Procedures will be in place to ensure that theresults of the interim analy sis do not influence the 
conduct of the stud y, investigators, or subjects.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 11911.4. Efficacy  Analyses
Efficacy  analy ses will be performed on the FAS, which will include all randomized subjects who 
receive at least 1 dose of intranasal study medication and 1 dose of oral antidepressant 
medication during the double -blind induction phase .
With the exception of the European Union ( EU)dossier, the primary  efficacy  variable, change 
from baseline in MADRS total score at Week 4 in the double -blind induction phase, will be 
analyzed using MMRM. The model will include baseline MADRS total score as a covariate, and 
treatment, country , class of antidepressant (SNRIor SSRI), day, and day-by-treatment 
interaction as fixed effects, and a random subject effect. Comparison of the intranasal esketamine 
plus oral antidepressant arm versus oral antidepressant plus intranasal placebo will be performed 
using the appropriate contrast.
For the EU dossier, the primary  efficacy  analysis will be based on an analysis of covariance 
(ANCOVA) model using last observation carried forward (LOCF) data. The model will include 
factors for treatment, country , and class of oral antidepressant (SNRIorSSRI) and baseline 
MADRS total score as a covariate. Comparison of the intranasal esketamine plus oral 
antidepressant arm versus intranasal placebo plus oral antidepressant will be performed using the 
appropriate contrast .
Response and remission rates wil l be summarized at each visit.
The ranks of change from baseline in CGI-S scores at the end of the double -blind induction 
phase will be analyzed based on LOCF data using an ANCOVA model, with country  and class 
of antidepressant (SNRI or SSRI) as factors, and the baseline score (unranked score) as the 
covariate. 
Dimension scores of EQ-5D- 5L, health status index, and the overall health status score will be 
summarized over time.
Additionally , scores of all efficacy  endpoints will be summarized for all visits in the double -
blind induction phase . Summaries will be provided to show consistency  of effect among relevant 
subgroups (eg, antidepressant class SN RI and S SRI).
11.5. Pharmacokinetic A nalyses
Plasma esketamine (and noresketamine, if warranted) concentrations will be listed for all 
subjects. The plasma concentration -time data of esketami ne (and noresketamine, if warranted) 
will be analyzed using population PKmodeling. Data may be combined with those of other 
selected studies to support a relevant structural model. Typical population values of basic PK
parameters will be estimated togethe r with the inter-individual variability . Effects of subject 
demographics, laboratory parameter values, and other covariates on the PKof esketamine will be 
explored. The results of the population PKanalyses may  be reported separately .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 12011.6. Pharmacokinetic/Phar macody namic A nalyses
The relationship between MADRS total score (and possibly  selected adverse events as additional 
PDparameters) ,and PKmetrics of esketamine may be evaluated. If there is any visual trend in 
graphical analysis, suitable models will be applied to describe the exposure -effect relationships. 
The results of the PK/PD analysesmay be reported separately .
11.7. Biomarker and Pharmacogenomic Analyses
Baseline biomarker values and changes from baseline biomarker values to the time points 
specified in the Time and Even ts Schedule will be summarized. Exploratory  analyses may 
include comparison of biomarker measures between the treatment groups and correlation with 
baseline and change from baseline biomarker values in the efficacy and other measures. 
Addi tional exploratory  analyses may also include relationship of baseline and change from 
baseline in biomarker measures to clinical response, maintenance/stabilization of response, 
relapse, and nonresponse .
Pharmacogenomic analyses may include candidate gene analy ses or genome -wide association 
analyses in relation to treatment response, maintenance/stabilization of response, relapse, and 
nonresponse , and MDD/TRD. Expression analy ses may include testing of known messenger 
RNA/microRNA (mRNA/miRNA) transcripts or transcriptome -wide analy sis in relationship to 
antidepressant treatment response and MDD/TRD.
Details of the analy sis plan and summary  of result sfrom both biomarker and pharmacogenomics 
analyses will be reported separately .
11.8. Safety  Analyses
Safety  data will be analy zed forthedouble -blind induction phase using the safety  analysis set.
The safet y data from the follow -up phase will be summarized separatel y.
Adverse Events
The verbatim terms used in the eCRF by investigators to identify  adverse events will be coded 
using the MedDRA . All reported adverse events with onset during the double -blind induction 
phase (ie, TEAEs, and adverse events that have worsened since baseline) will be included in the 
analysis. For each adverse event, the percentage of subjects who experience at least 1 occurrence 
of the given event will be summarized by treatment group. Adverse events occurring during the 
follow -up phase will be summarized separatel y.
TEAEs of special interest will be examined separatel y(please refer to Sectio n 3.2.6 ). Adverse 
events of special interest will be further listed in the SAP.
Subjects who die, who discontinue treatment due to an adverse event, or who experience a severe 
or a serious adverse event will be summarized separatel y.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 121Clinical Laboratory Tests
Laboratory  data will be summarized by type of laboratory  test. Reference ranges and markedl y 
abnormal results (specified in the Statistical Analy sis Plan) will be used in the summary  of 
laboratory  data.Desc riptive statistics will be calculated for each laboratory  analyte at baseline 
and at each scheduled time point in each phase of the study .Changes from baseline results will 
be presented. Frequency tabulations of the abnormalities will be provided . Listing sof subjects 
with laboratory  results outside the reference ranges andmarkedl y abnormal results will also be 
provided.
ECG
The effects on cardiovascular variables will be evaluated by means of descriptive statistics and 
frequency  tabulations. These tables will include observed values and change from baseline 
values.
Electrocardiogram data will be summarized by ECG parameter . Descriptive statistics will be 
calculated at baseline ,and for observed values and changes from baseline at each scheduled time 
point . Frequency  tabulations of the abnormalities will be made.
The ECG variables that will be analy zed are heart rate, PR interval, QRS interval, QT interval, 
and corrected QT (QTc) interval using the following correction methods QT corrected accordin g 
to Fridericia's formula (QTcF), which will be the primary  correction factor , and QT corrected 
according to Bazett's formula (QT cB).39,76
Descriptive statistics of QTc intervals and changes from double -blind baseline will be 
summarized at each scheduled time point. The percentage of subjects with QTc interval 
>450 msec , >480 msec , or >500 msec will be summarized, as will the percentage of subjects 
with QT c interval increases f rom baseline <30 msec, 30 -60 msec, or >60 msec .
All important abnormalities in ECG waveform that are changes from the baseline readings will 
be reported (eg, changes in T-wave morphology  or the occurrence of U -waves).
Vital Signs
Descriptive statistics of temperature, pulse/heart rate, respiratory  rate, pulse oximetry , and blood 
pressure (s ystolic and diastolic) (supine) values and changes from baseline will be summarized at 
each scheduled time point. The percentage of subjects with values beyond clinically important 
limits will be summarized.
Nasal Exam ination
Changes in findings from the baseline nasal examination (including the upper respiratory  
tract/throat) will be listed by treatment group. Examinations will provide ratings (absent , mild, 
moderate, orsevere) that are based on a visual inspection of the nostrils, nasal mucosa, and 
throat for nasal erythema, rhinorrhea, rhinitis, capillary /blood vessel disruption and epistaxis. A 
shift table for changes from double -blind baseline in rating sfor each examination will be 
presented b y treatment group.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 122Nasal Symptom Questionnaire
Scoring from the nasal symptom questionnaire will be summarized descriptivel y for each 
scheduled time point by treatment group.
C-SSRS 
Suicide -related thoughts and behaviors based on the C-SSRS will be summarized by treatment 
group in incidence and shift tables. Separate endpoints for suicidal ideation and suicidal behavior 
will be defined and summarized descriptively  by treatment group. Missing scores will not be 
imputed.
CADSS, BP RS+, and MOAA/S
Descriptive statistics of each of the scores and changes from predose will be summarized at each 
scheduled time point.
CGADR , PWC -20, UPSIT, BPIC- SS
Descriptive statistics of each of the scores and changes and/or percent changes from baseli ne will 
be summarized at each scheduled time point.
Cognition Testing
Descriptive statistics of each of the cognitive domain scores and changes from baseline will be 
summarized at each scheduled time point.
11.9. Independent Data Monitoring Committee
An IDMC wil l be established to monitor data on an ongoing basis to ensure the continuing safet y 
of the subjects enrolled in this study . In addition, the committee will review 1interim analy sis 
for a sample size re-estimation. The committee will meet every  6months to review safety  data 
and will meet once to review efficacy  data after the interim analysis has been completed. After 
the reviews, the IDMC will make recommendations regarding the continuation of the study  or,in 
the case of the interim analy sis for efficac y,to either stop the study  due to futility  or to adjust the 
sample size to achieve the desired power while maintaining control of the overall Type I error. 
The details will be provided in a separate IDMC charter.
The IDMC will consist of at least onemedi cal expert in the relevant therapeutic area and at least 
one statistician. The IDMC responsibilities, authorities, and procedures will be documented in its 
charter.
12. ADVERSE EVENT REPORT ING
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
regulatory  agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requiremen ts worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 12312.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Eve nt
An adverse event is any untoward medical occurrence in a clinical study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational or non-investigational) product, whether or not 
related to that medicinal (inve stigational or non-investigational) product. (Definition per 
International Conference on Harmonisation [I CH])
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.1 , All Adverse Events, for time of last adverse ev ent recording).
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death
Is life -threatening (for example, the subject was at risk of death at the time of the event. “L ife 
threatening” does not refer to an event that hypothetically  might have caused death if it were 
more severe).
Requires inpatient hospitalization or prolongation of existing hospitalization
Resu lts in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is medicall y important *
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above. 
These should usually  be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  drug and the event (eg, death from anaph ylaxis), the event must 
be reported as a serious and unexpected suspected adverse reaction even if it is a component of 
the study  endpoint (eg, all -cause mortalit y).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 124Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable product reference safet y information. Foresketamine, the expectedness of an adverse 
event will be determined by whether or not it is listed in the Reference Safet y Information 
Section of the Investigator's Brochure. 
For duloxetine, escitalopram, sertraline, and venlafaxine XR, the expectedness of an adverse 
event will be determined by whether or not it is listed in the SmPC or US prescribing 
information.24,23,28,29,81,82,87,88
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
proba ble, or very  likel y by the definitions listed in Section 12.1.2 .
12.1.2. Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, eg,
concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg, confirmed by dechallenge). An alternative explanation is less likely , eg,concomitant 
drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by an alternat ive explanation, eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
12.1.3. Severity Criteria
An assessment of severity  grade will be made using the following general categorical 
descriptors:
Mild : Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 125Moderate : Sufficient discomfort is present to cause interference with normal activity .
Severe : Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnorma lities).
12.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drugthat may require expedited reporting and/or 
safet y evaluation include, but are not limited to:
Overdose of a sponsor study  drug
Suspected abuse/misuse of a sponsor study drug
Inadvertent or accidental exposure to a sponsor study  drug
Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  drug , eg, name confusion)
Special reporting situations should be recorded in the eCRF . Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the eCRF .
12.3. Procedures
12.3.1. All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICFis obtained until completion of the subject's last 
study -related procedure (which may include contact for follow -up of safety ), with the exception 
of pregnancy  which will be reported up to 6weeks after the last dose of study  medication 
(females) or 90 days after the last dose of study  medication (partners of male participants) .
Serious adverse events, including those spontaneously  reported to the investigator , must be 
reported using the Serious Adverse Event Form. The sponsor will evaluate any safet y 
information that is spontaneously reported by an investigator beyond the time frame specified in 
the protocol.
All events that meet the definition of a serious adverse event will be reported as serious adverse 
events, regardless of whether they are protocol -specific assessments. Anticipated events will be 
recorded and reported as described in Attachment 4.
All adverse events, regardless of seriousness, severi ty, or presumed relationship to study  drug, 
must be recorded using medical terminology  in the source document and the eCRF . Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg,cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respiratory  infection"). Investigators must record in the eCRF their opinion concerning the 
relationship of the adverse event to study  therapy . All measures required for adverse event 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 126management must be recorded in the source document and reported according to sponsor 
instructions.
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and thehead of the investigational 
institute where required) all suspected unexpected serious adverse reactions (SUSARs). The 
investigator (or sponsor where required) must report SUSARs to the appropriate Independent 
Ethics Committee/Institutional Review Board (IEC/I RB) that approved the protocol unless 
otherwise required and documented by the IEC/IRB. A SUSAR will be reported to regulatory 
authorities unblinded. Participating investigators and IEC/I RB will receive a blinded SUSAR 
summary , unless otherwise specif ied.
For all studies with an outpatient phase, including open -label studies, the subject must be 
provided with a "wallet (study )card" and instructed to carry  this card with them for the duration 
of the study  indicating the following:
Study number
Stateme nt, in the local language(s), that the subject is participating in a clinical study
Investigator's name and 24-hour contact telephone number
Local sponsor's name and 24 -hour contact telephone number (for medical staff only )
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
12.3.2. Serious A dverse Events
All serious adverse events occurring during thestudymust be reported to the appropriate sponsor 
contact person b ystudy -site personnel within 24 hours of their knowledge of the event.
Information regarding serious adverse events will be transmitted to the sponsor using the Serious 
Adverse Event Form, which must be completed and signed by a physician from the study  site, 
and transmitted to the sponsor within 24 hours. The initial and follow -up reports of a serious 
adverse event should be made b y facsimile (fax) .
All serious adverse events that have not resolved by the end of the study , or that have not 
resolved upon discontinuation of the subject's participatio n in the study , must be followed until 
any of the following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to study 
conduct
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 127It becomes unlikel y that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration of 
due diligence with follow -up efforts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospitalization (or prolongation of 
hospitalization) that occurs during the course of a subject's participation in a study  must be 
reported as a serious adverse event, except hospitalizations for the following:
Hospitalizations not intended to treat an acute illness or adverse event (eg, social reasons 
such as pending placement in long -term care facility ).
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF ). Note: Hospitalizations that were planned before the signing of the ICF, and where 
the underl ying condition for which the hospitalization was planned has not worsened ,will 
not be consid ered serious adverse events. Any  adverse event that results in a prolongation of 
the originall y planned hospitalization is to be reported as a new serious adverse event.
For convenience the investigator may choose to hospitalize the subject during a treatm ent 
period.
The cause of death of a subject in a study , whether or not the event is expected or associated with 
the study  drug , is considered a serious adverse event.
12.3.3. Pregnancy
All initial reports of pregnancy  must be reported to the sponsor by the study -site personnel 
within 24 hours of their knowledge of the event using the appropriate pregnancy  notification 
form. Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy ) are considered serious adverse events and must be reported using 
the Serious Adverse Event Form. 
Because the effect of the study  drug on sperm is unknown, pregnancies in partners of male subjects 
included in the study  will be reported by the study -site personnel within 24 hour s of their 
knowledge of the event using the appropriate pregnancy  notification form.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required .
12.4. Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safet y issues or questions regarding the study  are listed on the Contact Information 
page(s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliabilit y of a product, including its labe ling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 128and the sponsor ,and are mandated by regulatory  agencies worldwide. The sponsor has 
established procedures in conformity  with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures.
13.1. Procedures
All initial PQCs must be reported to the sponsor by the study -site personnel within 1 business 
dayafter being made aware of the event .
If the defect is combined with a serious adverse event, thestudy -site personnel must report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if requested by the sponsor .
13.2. Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality  issues are listed on the Contact Information page(s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug(s)
Intranasal Study Drug
Esketamine will be supplied as a clear, colorless intranasal solution of esketamine HCl
(16.14% weig ht/volume [w/v]; equivalent to 14% w/v of esketamine base) in a nasal spray 
pump . The solution will consist of 161.4 mg/mL  esketamine HCl (equivalent to 140mg of 
esketamine base) formulated in 0.12 mg/mL ethylenediaminetetraacetic acid (EDTA) and 
1.5mg/m L citric acid at a pH of 4.5 in water for injection. It is provided in a nasal spray  pump, 
which delivers 16.14 mg esketamine HCl (14 mg esketamine base) per 100-Lspray . Each 
individual nasal spray  pump (device) contains a total of 28 mg (ie, 2 spray s). 
The placebo solution will besupplied as a clear, colorless intranasal solution of water for 
injection ,with a bittering agent (denatonium benzoate [Bitrex®] at a final concentration of 
0.001mg/mL) added to simulate the taste of the intranasal solution with active drug. The placebo 
solution will be provided in matching nasal spray  pump devices. Benzalkonium chloride is added 
as a preservative at a concentration of 0.3 mg/mL. Each individual nasal spray  pump (device) 
contains 2 sprays.
Esketamine and placeb o will be manufactured and provided under the responsibility  of the 
sponsor. Please refer to the Investigator’s Brochure for a list of excipients.42
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 129Oral Antidepressant Medications
Duloxetine
Duloxetine 30 mg will be obtained from commercial stock and provided under the responsibility 
of the sponsor. Refer to the SmPC/USPI  for the phy sical description and a list of excipients.24,23
Escitalopram
Escitalopram 10mg will be obtained from commercial stock and provided under the 
responsibility  of the sponsor. Refer to the SmPC/USPI for thephysical description and a list of 
excipients.28,29
Sertraline
Sertraline 25 mg and 50 mg (as applicable) will be obtained from commercial stock and provided 
under the responsibility  of the sponsor. Refer to the SmPC/USPI for the physical description and 
a list of excipients.81,82
Venlafaxine XR
Venlafaxine 37.5mg and 75 mg (as applicable) will be obtained from commercial stock and 
provided under the responsibility  of the sponsor. Refer to the SmPC/USPI for the physical 
description and a list of excipients.87,88
14.2. Packaging
Intranasal Study Drug
Study drug (ie, intranasal esketamine andplacebo solution) will be supplied by the sponsor in a 
bi-dose nasal spray  device. The devices will contain 230 µL(of which ~30µL is the residual 
volume) . Each device delivers 16.14 mg esketamine HCl (14mg esketamine base) or 0.1µg of 
denatonium benzoa te per 100 µLspray . 
Each nasal spray  device will be individuall y packaged in a blister tray and subsequentl y put into a 
carton box. Each carton box constitutes anon-child -resistant subjec t kit, labeled with a unique 
medication kit number.
Device for Pr acticing Intranasal Study Drug Administration
The demonstration intranasal device will also be supplied by the sponsor and will contain placebo 
solution. Subjects will practice spray ing (into the air, not intranasall y).
Oral Antidepressant Medication
Oral antidepressant tablets or capsules will remain in their commercial packaging. 
If blisters are supplied; each blister will be packaged into a child -resistant dose pack to constitute a 
subject kit. All kits will be labeled with a unique medication kit numbe r, and labeled according to 
applicable regulatory  requirements.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 13014.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory requirements.
14.4. Preparation, Handling, and Storage
Study  drug will be stored at the study  site in a secure area with restricted access until dispensed to 
the subjects. 
All study  drug must be stored at controlled temperatures as indicated on the product -specific 
labeling.
Refer to the pharmacy  manual/ study  site investigational product manual for additional guida nce on 
study  drug preparation ,handling , and storage .
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study .
The dispensing of study drug to the subje ct, and the return of study  drug from the subject (if 
applicable), must be documented on the drug accountability  form. Subjects must be instructed to 
return all original containers, whether empt y or containing study drug.
The study  drug administered to the subject must be documented on the drug accountability  form. 
All study  drug will be stored and disposed of according to the sponsor's instructions. Study-site 
personnel must not combine contents of the study  drug containers.
Study  drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug,and study  drug returned by the subject, must be 
available for verification by the sponsor's study  site monitor during on -site monitoring visits. The 
return to the sponsor of unused study  drug, or used returned study  drug for destruction, will be 
documented on the investigational product destruction form . When the study site is an authorized 
destruction unit and study  drug supplies are destroy ed on-site, this must also be documented on 
the investigational product destruction form .
Potentially  hazardous materials such as used ampules, needles, syringes andvials containing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accountability  purposes. 
Study  drug should be dispensed under the supervision of the investigator or a qualified member 
of the study -site personnel , or by a hospital/clinic pharmacist. Study  drug will be supplied only 
to subjects participating in the study . Returned study  drug must not be dispensed again, even to 
the same subject.
Whenever a subject brings his or her study  drug to the study  site for pill count (ie, compliance 
check), this is not seen as a return of supplies.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 131Study  drug may not be relabeled or reassigned for use by other subjects. The investigator agrees 
neither to dispense the study  drug from, nor store it at, any site other than the study  sites agreed 
upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following supplies:
Practice intranasal devices
Investigator’s Brochure for esketamine
Local prescribing information for o ral antidepressant options in double -blind induction phase
Investigational Product (IP) Binder, including the IP Procedures Manual
Laboratory  manual and materials
Clinician -administered and patient-reported outcome assessments
oPaper versions, as applicable
oElectronic devices and associated materials
IWRS Manual
ECG equipment and associated materials (e g, manual )
Instructions for Use documents (subject and healthcare provider versions) for intranasal 
study  medication
Rater qualifications/requirements for select clinician -administered assessments
Computerized cognitive battery  and HVLT -R, and all associated equipment and materials
Device to measure respiratory  rate
Procedural documents for SiteIndependent Qualification Assessment
Procedural documents for independent, remote rater interviews
Guidance on recommended order of study  procedures
MGH -ATRQ guidance document
SmPCs of the active comparators: Duloxetine, escitalopram, sertraline, and venlafaxine XR
Subject diary
16. ETHICA L ASPECTS
16.1. Study -specific Design Con siderations
Clinical Study in Treatment-resistant Major Depression
Major depressive disorder is a common, severe, chronic ,and often life-threatening illness. It is 
now the leading cause of disability  worldwide. There is a clear need to develop novel and 
improved therapeutics for treatment -resistant depression in the elderly population.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 132Studies with esketamine have shown robust antidepressant effects in several clinical studies and 
it has been well tolerated in these clinical studies.
Selection of Subjects
The primary  aim of the study  is to evaluate the efficacy  of intranasal esketamine plus an oral 
antidepressant for the treatment of TRD in the elderl y population . Thus, the study  cannot be 
completed in health y subjects. 
Potential subjects will be fully informed of the risks and requirements of the study  and, during the 
study , subjects will be given any new information that may affect their decision to continue 
participation.
For eligibility , subjects must have had nonresponse to at least one prior antidepre ssant treatment 
and be currentl y taking an antidepressant treatment at the start of the screening/prospective 
observation al phase that will be continued as prospective treatment in the 
screening/prospective/observational phase. Only subjects with nonresponse to their current 
antidepressant treatment after 4 weeks of prospectively  observed treatment (for a total duration 
of antidepressant treatment of at least 6weeks by the end of the screening/prospective 
observational phase), will be eligible to proceed to the double -blind induction phase, when all 
subject swill receive a new oral antidepressant in addition tointranasal esketamine or placebo. 
Subjects will receive 4 weeks of treatment in the double -blind induction phase and at the end of 
this phase, may participate in the open -label safety study  (ESKETINTRD3004). Subjects who do 
not complete the double -blind induction phase of this study  will not be eligible to participate in the 
ESKETINTRD3004 study . Subjects who choose not to enter the ESKETINTRD3 004 study will 
proceed to the 2-week follow -up phase, during which all subjects will be provided with an 
additional 2-week suppl y of oral antidepressant and appropriate follow -upcare will be arranged.
They  will be told that their consent to participate in the st udy is voluntary  and may  be withdrawn at 
any time with no reason given and without penalt y or loss of benefits to which they would 
otherwise be entitled. Only  subjects who are fully able to understand the risks, benefits, and 
potential adverse events of th e study , and provide their consent voluntaril y will be enrolled.
Justification for Using Placebo
Intranasal placebo is being used as a double -blind for intranasal esketamine to maintain study  
blinding . All subjects will also receive anewly initiated oral antidepressant during the induction 
phase. Subjects will not be on placebo alone. Assessment of the potential efficacy  of a new 
compound for the treatment of treatment -resistant major depression requires adequate and 
well-controlled clinical studies. This superiority  study will compare intranasal esketamine plus a 
newly -initiated oral antidepressant to switching to an oral antidepressant as an active comparator. 
Recent analyses have shown response to placebo varies considerabl y,from 10% to 55%. 
Therefore, there is a concern that randomized, controlled studies that rely on comparison with 
standard antidepressant treatment s alone will generate unreliable results with limited assay  
sensitivity . However, some have considered it unethical to do placebo -controll ed studies in major 
depression due to the potential risk of irreversible harm.74In a  m eta-analy sis of drug studies 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 133conducted in MDD , it was reported that adult subjects did not have higher rates of suicide 
beha viors or attempts in the placebo group compared with those receiving an active 
antidepressant.47These studies show edannual suicide rates of 0.8% on the investigational drug, 
0.7% on the active comparator, and 0.4% on placebo. Thus, t he risk of irreversible harm was not 
higher in the placebo arm compared with the active control arms.
Some subjects may  decide not to participate in a placebo -controlled study  due to the potential for 
increased distress and d ysfunct ion from prolonged depression. 
Therefore, the use of anactive -controlled study  allows for assessment of efficacy  of a new 
compound to allow for scientifically  meaningful results. 
Moreover, the duration of the double -blind induction phase is relativel y short (4-week duration). 
Subjects will visit the study  site at least twice a week during the double -blind induction phase,
and their symptoms will be carefully  monitored during each study  visit. Safety  evaluations will 
include evaluation of suicidal ideatio n/behavior at each clinic visit. At any  point in the study ,the 
subject may withdraw consent or be removed from the study  by the investigator if there are any 
clinical concerns.
Intranasal esketamine may not be available for subjects after the study . Howev er, following 
completion of the double -blind induction phase, those subjects not continuing into the 
ESKETINTRD3004 study  can be treated according to standard of care. 
Precautions to Ensure Subject Safety in the Study 
Subjects may participate in the study only if they have adequate capacity  to give consent and 
after fully  understanding the potential risks and giving an informed consent. Determination of 
capacity  will be made by the study  investigator. Subjects may discontinue the study  at any time. 
The probability  of receiving placebo and the concept of random assignment will be explained to 
the subject. The duration of the study  is short, minimizing the time on intranasal placebo (which 
is being administered with a newly -initiated oral antidepressant) . Potential disadvantages and 
adverse events of participating in the study  and alternative treatment options will be discussed. 
For subjects who do not meet predefined response criteria during the study , clinical care will be 
arranged between the study  investi gator and their phy sician.
Compensation for any procedure will be fair per local standards and approved by the 
participating sites IRB in order to not offer an y undue incentive to participate in the study .
Subjects will be carefully monitored during the study and subjects who are unable to tolerate 
study  drug during the double -blind induction phase will be discontinued from the study . If the 
investigator judges it to be necessary  to immediately  stop study  drug, he or she has the option to 
do so.Specific guidance is provided regarding blood pressure monitoring on intranasal dosing 
days(Section 6.2.1) .In addition to a 12 lead ECG performed at Screening and pre -dose and post -
dose on Day 1 (baseline), on subsequent dosing days all subjects will have an ECG at1 hour 
post-dose.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 134Only  subjects who had nonresponse to their current oral antidepressant treatment, where a 
clinician would consider changing it in the future due to lack of response ,will be enrolled.
Only  qualified and trained investigators will participate in the study .
The total blood volume to be collected is considered to be within the normal range allowed for this 
subject population over this time frame. The approximate total blood volume to be collected is 
approximatel y 117mL,which will be less than a Red Cross blood donation.
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compl iance with this standard provides public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki ,and that the study  data are credible.
16.2.2. Independent Eth ics Committee or Institutional Review  Board
(IEC/IRB)
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copies of the following documents (as required by local 
regulations) :
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Sponsor -approved training and informational materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as doc umented 
by the IEC/IRB)
Information regarding funding, name of the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purel y administrative, with no 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 135consequences for subjects, data or study  conduct ), the ICF, applicable recruiting material s, and 
subject compensation programs, and the sponsor has received a copy of this approval. This 
approval letter must be dated and must clearly  identify  the IEC/I RB and the documents being 
approved.
During the study  the investigator (or sponsor where requi red) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s ) to ICFand any  other written materials to be provided to subjects
If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the stud y, if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of adverse events that are serious, unlisted/unexpec ted, and associated with the study  
drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct) , the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where 
required . The reapproval should be documented in writing (excluding the ones that are purel y 
administrative, with no consequences for subjects, data, or stud y conduct) .
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion.
16.2.3. Informed Consent
Each subjec tmust give written consent according to local requirements after the nature of the 
study  has been fully  explained . The ICF(s) must be signed before performance of any study -
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 136related activity . The ICF(s) that is/areused must be approved by both the sponsor and by the 
reviewing IEC/I RB and be in a language that the subject can read and understand. The informed 
consent should be in accordance with principles that originated in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicable regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Subjects will be informed that their participation is voluntary  and that they may withdraw 
consent to participate at any time. They  will be informed that choosing not to participate will not 
affect the care the subject will receive for the treatment of his or her disease. Subjects will be told 
that alternative treatments are available if they refuse to take part and that such refusal will not 
prejudice future treatment. Finally , they will be told that the investigator will maintain a subject 
identification register for the purposes of long-term follow -upif needed and that their records 
may be accessed by health authorities and authorized sponsor personnel without violating the 
confidentiality  of the subject, to the extent permitted by the applicable law(s) or regulations. By 
signing the ICFthe subject is authorizing such access , and agrees to allow his or her study  
physician to re-contact the subject for the purpose of obtaining consent for additional safet y 
evaluations, if needed .
The subject will be given sufficient time to read the ICF and the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel y recorded 
by means of the subject's personall y dated signature. After having obtained the consent, a copy  of 
the ICFmust be given to the subject.
Where local regulations require, a separate ICF may be used for the required DNA  component of 
the study .
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessar y to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identit y of subjects confidential.
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator /institution to allow direct access to his or her original 
medical records (sourc e data/documents) for study -related monitoring, audit, IEC/IRB review, 
and regulatory  inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 137The subject has the right to request through the investigator a ccess to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the s tudy, and the applicable laws and regulations.
Exploratory  PK, PD, biomarker, DNA, and RNA research is not conducted under standards 
appropriate for the return of data to subjects. In addition, the sponsor cannot make decisions as to 
the significance of any findings resulting from exploratory  research. Therefore, exploratory  
research data will not be returned to subjects or investigators, unless required by lawor local 
regulations . Privacy  and confidentiality  of data generated in the future on stored sampl es will be 
protected b y the same standards applicable to all other clinical data.
16.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additio nal research. Samples will only be used to understand esketamine, oral 
antidepressants, to understand depression, to understand differential drug responders, and to 
develop tests/assay s related to esketamine , oral antidepressants, and depression. The resea rch 
may begin at any  time during the study  orthe post -study  storage period.
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research (refer to Section 10.3, Withdrawal From the Use of Samples in Future 
Research]) .
16.2.6. Country Selection
This study  will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access to the developed product, unless explicitly  addressed as a specific ethical 
consideration in Section 16.1, Study -specific Design Considerations.
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by the sponsor. All protocol amendments must be issued by  the sponsor, and signed and dated by 
the investigator. Protocol amendments must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  the investigator and IEC/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study , the 
IRB (and IEC where requ ired) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representative (see Contact Informatio n page(s) provided separatel y). Except in emergency 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 138situations, this contact should be made before implementing any departure from the protocol. In 
all cases, contact with the sponsor must be made as soon as possible to discuss the situation and 
agree on an appropriate course of action. The data recorded in the eCRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approv al/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2. Required Prestudy  Document ation
The following documents must be provided to the sponsor before shipment of study  drug to the 
study site:
Protocol and amendment(s), if an y, signed and dated by the principal investigator
A copy  of the dated and signed (or sealed, where appropr iate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by title and number and must be signed (or sealed, where appropriate per local 
regulations) by the chairman or authorized designee.
Name and address of the IEC/IRB, including a current list of the IEC/IRB members and their 
function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list.If an investigator or a 
member of the study -site personnel is a member of the IEC/I RB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the vote/opinion 
of the study .
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
Documentation of investigator qualifications (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, which includes th e financial agreement
Any other documentation required by  local regulations
The following documents must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all sub- investigators
Documen tation of sub -investigator qualifications (eg, curriculum vitae)
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 139Name and address of any local laboratory  conducting tests for the study , and a dated copy of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability  (eg,
accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by the 
sponsor study -site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study  file.To ensure subject confidentiality , no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by subject identification
and date of birth. In cases where the subject is not randomized into the study , the date seen and 
date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
17.4. Source Documentation
At a minimum, source documents consistent in the type and level of detail with that commonl y 
recorded at the study  site as a basis for standard medical care must be available for the following: 
subject identification, eligibility , and study  identification; study  discussion and date of signed 
informed consent; dates of visits; results of safety and efficacy  parameters as required by the 
protocol; record of all adverse events and follow -up of adverse events; concomitant medication; 
drug receipt/dispensing/return records; study  drugadministration informat ion; and date of study 
completion and reason for early discontinuation of study  drug or withdrawal from the study , if 
applicable. 
The author of an entry  in the source documents should be identifiable.
Specific details required as source data for the study and source data collection methods will be 
reviewed with the investigator before the study  and will be described in the monitoring 
guidelines (or other equivalent document).
Some subject -and clinician -completed scales and assessments designated by the sponsor will be 
recorded directly  into an electronic device and will be considered source data.
The minimum source documentation requirements for Section 4.1,Inclusion Criteria, and 
Section 4.2(Exclusion Criteria) that specify  a need for documented medical history  are as 
follows:
Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summaries
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 140Antidepressant treatment in the current episode of depression
Inclusion and exclusion criteria not requiring documented medical history  must be verified at a 
minimum by  subject interview or other protocol required assessment (eg, phy sical examination, 
laboratory  assessment) and documente d in the source documents.
17.5. Case Report Form Completion
Case report forms are provided for each subject in electronic format. All CRF entries, corrections, 
and alterations must be made by the investigator or authorized study -site personnel. The 
investigato r must verify  that all data entries in the CRF are accurate and correct.
Electronic Data Capture (eDC) will be used for this study . The study  data will be transcribed by 
study -sitepersonnel from the source documents onto aneCRF, and transmitted in a secure 
manner to the sponsor within the timeframe agreed upon between the sponsor and the study  site. 
The electronic file will be considered to be the eCRF .
Worksheets may be used for the capture of some data to facilitate completion of the eCRF . Any 
such work sheets will become part of the subject’ s source documents. Data must be entered into 
eCRF s in English. Study  site personnel must complete the eCRF as soon as possible after a 
subject visit, and the forms should be available for review at the next scheduled monitoring visit.
The investigator must verify that all data entries in the eCRF s are accurate and correct. All eCRF
entries, corrections, and alterations must be made by the investigator or other authorized study -
site personnel. If necessary , queries will be generated in the eDC tool. The investigator or study -
site personnel must adjust the eCRF (if applicable) and complete the query .
If corrections to aneCRF are needed after the initial entry  into the eCRF , this can be done in 
either of the following ways:
Investigator and study  site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  the eDC tool) .
Sponsor or sponsor delegate can generate a query  for resolution by the investigator and 
study-site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator an d 
study -sitepersonnel before the study , periodic monitoring visits by the sponsor, and uploading 
data transfers from external service providers into the sponsor's data base. Written instructions 
will be provided for collection, handling, storage, and shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the stud y.
The sponsor will review eCRF s for accuracy  and completeness during on-site monitoring visits 
and after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 141designee, as appropriate. After upload of the data into the study database they  will be verified for 
accuracy  and consistency with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF s 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by the applicable regulatory  requirement(s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained u ntil at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by the applicable regulatory  requirements or by an 
agreement with the sponsor. It is the responsibility  of the sponsor to inform the 
investiga tor/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keeping the study  records, custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name and address of the 
new custodian. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the sp onsor .
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
17.8. Monitoring
The sponsor will perform on-site monitori ng visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare the data entered into the eCRF with source documents (eg, 
hospital/clinic/phy sician’s office medical records) ; a sample will be reviewed . The nature and 
location of all source documents will be identified to ensure that all sources of original data 
required to complete the eCRF are known to the sponsor and study -site personnel and are 
accessible for verification by the sponsor study -site contact. If electronic records are maintained 
at the study site, the method of verification must be discussed with the study -site personnel . 
Direct access to source documents (medical records) must be allowed for the purpose of 
verify ing that the recorded data are consistent with the original source data. Findings from this 
review will be discussed with the study -site personnel . The sponsor expects that, during 
monitoring visits, the relevant study -site personnel will be available, the source documents will 
be accessible, and a suitable environment will be provided for review of study -related 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 142document s. The monitor will meet with the investigator on a regular basis during the study to 
provide feedback on the study conduct.
In addition to on-site monitoring visits, the monitor may contact the site by telephone for an 
update on study  progress. It is expe cted that study -site personnel will be available to provide an 
update on the progress of the study  at the site .
17.9. Study Completion/Termination
17.9.1. Study Completion
The study  is considered completed with the last study  assessment for the last subject 
participatin g in the study . The final data from the study site will be sent to the sponsor (or 
designee) after completion of the final subject assessment at that study  site, in the time frame 
specified in the Clinical Trial Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of astudy site by the sponsor or investigator may include but are 
not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/IRB or 
local health authorities, the sponsor's procedures, or GCP guide lines
Inadequate recruitment of subjects by  the investigator
Discontinuation of further study  drug development
Study  is terminated by  the sponsor due to futility .
17.10. On-site A udits
Representatives of the sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspe ction and comparison with the eCRF s. Subject 
privacy  must, however, be respected. The investigator and study -site personnel are responsible 
for being present and available for consultation during routinely  scheduled study -site audit visits 
conducted b y the sponsor or its designees. 
Similar auditing procedures may also be conducted by agents of any regulatory  body, either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 143regulatory  submission. The investigat or should immediately  notify  the sponsor if he or shehas
been contacted b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding esketamine or the sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by the sponsor to the investigator and not 
previously  published, and any data, including pharmacogeno mic or exploratory  biomarker
research data, generated as a result of this study , areconsidered confidential and remain the sole 
propert y of the sponsor. The investigator agrees to maintain this information in confidence and 
use this information only to accomplish this study, and will not use it for other purposes without 
the sponsor's prior written consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of esketamine, and thus may  be disclosed 
as required to other clinical investigators or regulatory  agencies. To permit the information 
derived from the clinical studies to be used, the investigator is obligated to provide the sponsor 
with all data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by the sponsor and 
will contain eCRF data from all study  sites that participated in the study and will represent 
uploaded data transferred from external service provid ers into the sponsor's database . Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator . Results of pharmacogenomic or 
exploratory  biomarker a nalyses performed after the Clinical Study  Report has been issued will 
be reported in a separate report and will not require a revision of the Clinical Study  Report. 
Study  subject identifiers will not be used in publication o f results. Any work created in 
connection with performance of the study  and contained in the data that can benefit from 
copy right protection (except any publication by the investigator as provided for below) shall be 
the propert y of the sponsor as author and owner of cop yright in such w ork.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The inves tigator has the right to publish 
study  site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study ,a copy of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in 
writing, the investigator will withhold such publication for up to an additional 60days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. For multicenter study  designs and sub-study  approaches, secondary  results 
generall y should not be published before the primary  endpoints of a study  have been published. 
Similarly , investigators will recog nize the integrity  of a multicenter study by not submitting for 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 144publication data derived from the individual study  site until the combined results from the 
completed study have been submitted for publication, within 12months of the availability  of the 
final data (tables, listings, graphs), or the sponsor confirms there will be no multicenter study 
publication. Authorship of publications resulting from this study  will be based on the guidelines 
on authorship, such as those described in the Uniform Requireme nts for Manuscripts Submitted 
to Biomedical Journals, which state that the named authors must have made a significant 
contribution to the design of the study  or analy sis and interpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as 
required b y law.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 145REFERENCES
1. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated -dose intravenous ketamine for 
treatment -resistant depression. Biol Psychiatry. 2010;67(2):139 -45.
2. Azar AR, Chopra MP, Cho LY, Coakley E, Rudolph JL. Remission in major depression: results from a 
geriatric primary care population. Int J Geriatr Psychiatry 2011;26:48 -55.
3. Bazett HC. An analysis of the time -relationship of electrocardiograms. Heart. 1920;7:353 -80.
4. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test -Revised: normative data 
and ana lysis of inter -form and test -retest reliability. Clin. Neuropsychologist. 1998;12:43 -55.
5. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM. Measurement of 
dissociative states with the Clinician -Administered Dissociative State s Scale (CADSS). J Trauma Stress. 
1998;11(1):125 -36.
6. Chang T, Savory A, Albin M, Goulet R, Glasko AJ. Metabolic disposition of tritium -labelled ketamine 
(Ketalar®, CI-581) in normal human subjects. Clin Res. 1970;18:597.
7. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep 
apnea. Anesthesiology. 2008;108:812 -21.
8. Clinical Study Protocol ESKETINTRD1012. An Open -Label, Single -Dose Study to Assess the 
Pharm acokinetics, Safety, and Tolerability of Intranasall y Administered Esketamine in Elderly ( 75 Years of 
Age) and Healthy Younger Adult Subjects (18 to 55 Years of Age, Inclusive). Document No. 
EDMS -ERI-92316094 (03 December 2014).
9. Clinical Study Report ESKETINTRD1001. An open -label phase 1 study to evaluate the pharmacokinetics of 
intranasal esketamine administered w ith and without a nasal guide on the intranasal device. Document No. 
EDMS -ERI-73676925 (21 August 2014).
10. Clinical Study Report ESKETINTRD1002. An open -label, single -dose study to assess the pharma cokinetics, 
safety, and tolerability of intranasally administered esketamine in healthy Japanese and Caucasian subjects. 
Document No. EDMS -ERI-74234860 (21 August 2014).
11. Clinical Study Report ESKETINTRD1003. An open -label, single -dose study to assess the p harmacokinetics, 
safety, and tolerability of intranasally administered esketamine in healthy elderly and adult subjects. Document 
No. EDMS -ERI-81854053 (30 December 2014).
12. Clinical Study Report ESKETIVTRD2001. A double -blind, double -randomization, placebo -controlled study of 
the efficacy of intravenous esketamine in adult subjects w ith treatment -resistant depression. Document No. 
EDMS -ERI-63623355 (01 May 2014).
13. Clinical Study Report KETIVTRD2002. A double -blind, randomized, placebo -controlled, parallel gro up, dose 
frequency study of ketamine in subjects with treatment -resistant depression. Document No. EDMS ERI -63976766: 
(5 September 2014).
14. Critchlow DG. A case of ketamine dependence with discontinuation symptoms. Addiction. 
2006;101(8):1212 -3.
15. Curran HV, Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on 
the night of drug use and 3 days later. Addiction. 2000;95(4):575 -90.
16. Cusin C, Hilton GQ, Nierenberg AA, Fava M. Long -term maintenance with intramuscular ketami ne for 
treatment -resistant bipolar II depression. Am J Psychiatry. 2012 Aug;169(8):868 -9.
17. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm R es. 
1993;10(7):1093 -1095.
18. Desseilles M, Witte J, Chang TE, Iovieno N, Dording CM, Ashih H, Nyer M, Freeman MP, Fava M, 
Mischoulon D. Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant 
treatment response questionnaire. J Clin Psychiatry. 2011;72(8):1152 -4.
19. DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment -
resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 14620. Dmitrienko A, Tamhane AC, Wiens BL. General multistage gatekeeping procedures. Biom J. 2008 
Oct;50(5):667 -77.
21. Doty RL, Bromley SM, Stern MB. Olfactory testing as an aid in the diagnosis of Parkinson's disease: 
development of optimal discrimination criteria. Neurodegeneration 1995;4:93 -7.
22. Doty RL. Intranasal trigeminal detection of chemical vapors by humans. P hysiol Behav 1975;14:855 -859.
23. Duloxetine (Cymbalta®): Summary of Product Characteristics. Eli Lilly Nederland, Houten, The Netherlands; 
August 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_ -
_Product_Information/human/000572/WC500036781.pd f (accessed 6 March 2015).
24. Duloxetine (Cymbalta®): US Prescribing Information. Lilly USA, LLC, Indianapolis, Indiana, USA; December 
2014. http://pi.lilly.com/us/cymbalta -pi.pdf (accessed 9 February 2015).
25. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 
2012;338(6103):68 -72.
26. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM. Norketamine, the main metabolite of ketamine, is a non 
competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharm acol. 1997;333:99 -104.
27. Endou M, Hattori Y, Nakaya H, Gotoh Y, Kanno M. Electrophysiologic mechanisms responsible for inotropic 
responses to ketamine in guinea pig and rat myocardium. Anesthesiology. 1992;76:409 -18.
28. Escitalopram (Cipralex®): US Prescri bing Information. Lundbeck Canada Inc., Quebec, Canada; 12 November 
2014. http://www.lundbeck.com/upload/ca/en/files/pdf/product_pi/Cipralex_November_2013/Cipralex.pdf 
(accessed 9 February 2015).
29. Escitalopram: Summary of Product Characteristics. Actavis Gr oup PTC ehf., Iceland; July 2014. 
http://www.medicines.org.uk/emc/medicine/28956 (accessed 6 March 2015).
30. EuroQol Group. About EQ -5D. http://www.euroqol.org/about -eq-5d.html (accessed 27 February 2016).
31. EuroQol Group. EQ -5D-5L User Guide: basic information on how to use the EQ -5D-5L instrument. Version 
2.0; October 2013. 
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ- 5D-
5L_v2.0_October_2013.pdf (accessed 27 Feb 2016).
32. Fava M. Diagnosis and definition of treatment -resistant depression. Biol Psychiatry. 2003 Apr 
15;53(8):649 -59. 
33. Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and 
meta -analysis. Psychopharmacology (Berl). 2014;231(18):3663 -76.
34. Geisslinger G, Hering W, Thomann P, Knoll R, Kamp H -D, Brune K. Pharmacokinetics and 
pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J 
Anaesth. 1993;70:666 -71.
35. Guy W. ECDEU Assessment Manual for Psychopharmacology. Roc kville, MD: U.S. Department of Health, 
Education, and Welfare; 1976.
36. Haas DA, Harper DG. Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. 
Anesth Prog. 1992;39(3):61 -8.
37. Hagelberg NM, Peltoniemi MA, Saari TI, et al. Clarit hromycin, a potent inhibitor of CYP3A, greatly increases 
exposure to oral S -ketamine. Eur J Pain. 2010;14:625 -9.
38. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N -demethylation of 
ketamine in human liver microsomes. Drug Metab Dispos. 2002;30:853 -8.
39. Hodges M, Salerno D, Erlien D. Bazett’s QT correction review ed: evidence that a linear QT correction for 
heart rate is better. J Am Coll Cardiol. 1983;1:694.
40. Humphrey L, Arbuckle R, Moldw in R, et al. The Bladder Pain/Interstitial Cyst itis Symptom Score: 
development, validation, and identification of a cut score. Eur Urology. 2012;61:271 -9.
41. Hurt PH, Ritchie EC. A case of ketamine dependence. Am J Psychiatry. 1994;151(5):779.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 14742. Investigator’s Brochure, JNJ -54135419 -AAC (esketamine hydrochl oride), Document ID: 
EDMS -ERI-49489196 .
43. Jansen KL. Ketamine -can chronic use impair memory? IntJ Addict. 1990; 25:133 -9.
44. Ketalar 10 mg/mL solution for injection/infusion: Summary of Product Characteristics; Aug 2014. Pfizer 
Healthcare Ireland, Dublin, Ireland. 
http://www.medicines.ie/medicine/5913/SPC/Ketalar+10mg+ml+Injection+Infusion/ (accessed 25 Feb 2015).
45. Ketamine HCl Injection: US Prescribing Information; March 2012. JHP Pharmaceuticals, LLC. Rochester, 
Minnesota, USA. http://www.drugs.com/pro/ketalar. html (accessed 25 February 2015).
46. Ketanest -S®[Summary of Product Characteristics]. Ankeveen, The Netherlands: Eurocept BV; 2011.
47. Khan A, Warner HA, Brown WA, Symptom reduction and suicide risk in patients treated with placebo in 
antidepressant clinical tr ials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 
2000 Apr;57(4):311 -7.
48. Khin, NA. Update on FDA Exploratory Analyses of Aggregated Efficacy Data from Depression Trials. Slide 
presentation at NCDEU; May 28 -31, 2013; Hollyw ood, Florida.
49. Lezak, MD, How ieson, DB, Bigler, ED, Tranel, D. (2012). Neuropsychological Assessment 5th edition. New 
York, Oxford University Press.
50. Manthorpe J, Iliffe S. Suicide in later life: public health and practitioner perspectives. Int J Geriatr Ps ychiatry 
2010;25:1230 -8.
51. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta -analysis of 
randomized, double- blind, placebo -controlled trials of ketamine in the rapid treatment of major depressive 
episodes. Psychol Med. 2 015 Mar;45(4):693 -704.
52. Monteggia LM, Zarate C Jr. Antidepressant actions of ketamine: from molecular mechanisms to clinical 
practice. Curr Opin Neurobiol. 2015 Feb;30C:139 -43.
53. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to chan ge. Br J Psychiatry. 
1979;134:382 -9.
54. Montgomery SA. Clinically relevant effect sizes in depression. Eur Neuropsychopharmacology. 1994;(4)283 -4.
55. Moore NN, Bostw ick JM. Ketamine dependence in anesthesia providers. Psychosomatics. 1999;40:356 -359.
56. Morgan CJ, Curran HV; Independent Scientific Committee on Drugs. Ketamine use: a review . Addiction. 
2012;107(1):27 -38.
57. Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self -administration upon 
neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010; 
105(1):121 -33.
58. Morris DW, Toups M, Trivedi MH. Measurement -based care in the treatment of clinical depression. Focus 
2012;X(4):428 -33
59. Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K -hole: 
Phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95(3):219 –29.
60. Murrough JW. Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther. 2012 
Feb;91(2):303 -9.
61. Narendran R, Frankle WG, Keefe R, et al. Altered prefrontal dopaminergic function in chronic recreational 
ketamine users. Am J Psychiatry. 2005 Dec;162(12):2352 -9.
62. Opler LA, Opler MG, Arnsten AF. Ameliorating treatment -refractory depression with intranasal ketamine: 
potential NMDA receptor actions in the pain circuitry representing menta l anguish. CNS Spectr. 
2015 Jan26:1-11.
63. Ostad Haji E, Tadic A, Wagner S, Dragivevic A, et al. Early improvement and serum concentrations of 
citalopram to predict antidepressant drug response of patients with major depression. Pharmacopsychiatry. 
2013 Nov;46(7):261 -6.
64. Overall JE; Gorham D R. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799 -812.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 14865. Pal HR, Berry N, Kumar R, Ray R. Ketamine dependence. Anaesth Intensive Care. 2002;30:382 -4.
66. Persson J. W herefore ketamine? Curr Opin Anaesthesiol. 2010;23(4):455 -60.
67. Pharm acokinetic Report KET -PK-007. A randomized, open -label, single center, single -dose, cross -over study 
to determine the absolute bioavailability and the nasopharyngeal absorption of PMI -150 ( intranasal ketamine) 
in healthy adult volunteers. Javelin Pharmaceuticals, Inc. Document No. EDMS -ERI-44757121 (31 Oct 2008).
68. Portmann S, Kwan HY, Theurillat R, Schmitz A, Mevissen M, Thormann W. Enantioselective capillary 
electrophoresis for identificatio n and characterization of human cytochrome P450 enzymes which metabolize 
ketamine and norketamine in vitro. J Chromatogr A. 2010;1217:7942 -8.
69. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide 
Assessment (C -CAS A): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of 
antidepressants. Am J Psychiatry. 2007;164:1035 -43.
70. Protocol ESKETINTRD2003. A double -blind, doubly -randomized, placebo -controlled study of intranasal 
esketamine in an a daptive treatment protocol to assess safety and efficacy in treatment -resistant depression 
(SYNAPSE). Document ID No. EDMS -ERI-71950055 (28 Apr 2014).
71. Reich DL, Silvay G. Ketamine: An update on the first twenty -five years of clinical experience. Can J Anae sth. 
1989;36:186 -197.
72. Rickels K, Garcia -Espana F, Mandos L, Case GW. Physician Withdrawal Checklist (PWC -20). J Clin 
Psychopharmacol. 2008;28(4):447 –451.
73. Rodda J, Walker Z, Carter J. Depression in older adults. BMJ 2011;343:d5219.
74. Rothman KJ, Michels KB. T he continuing unethical use of placebo controls. N Engl J Med. 1994;331(6):394 -8.
75. Rugani F, Bacciardi S, Rovai L, et al. Symptomatological Features of patients with and without ecstasy use 
during their first psychotic episode. Int. J. Environ. Res. Public Health. 2012;9(7):2283 -92.
76. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology 
(IDS): Psychometric properties. Psychol Med. 1996;26(3):477 -486.
77. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer -term outcom es in depressed outpatients 
requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905 -17.
78. Safety Report (Interim) ESKETINTRD2003. A double -blind, doubly -randomized, placebo -controlled study of 
intranasal esketam ine in an adaptive treatment protocol to assess safety and efficacy in treatment -resistant 
depression (SYNAPSE). Document ID No. EDMS -ERI-97270375 (6 Feb 2015 in preparation ).
79. Sagie A, Larson MG, Goldberg RJ, Bengston JR, Levy D. An improved method for adju sting the QT interval 
for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70:797 -801.
80. Saveanu R, Etkin A, Duchemin AM, et al. The International Study to Predict Optimized Treatment in 
Depression (iSPOT -D): Outcomes from the acute phase of antid epressant treatment. J Psychiatr Res. 
2015;61:1 -12.
81. Sertraline (Zoloft®): US Prescribing Information. Pfizer, Inc., New  York, New York, USA; August 2014. 
http://labeling.pfizer.com/ShowLabeling.aspx?id=517 (accessed 27 Feb 2015).
82. Sertraline: Summary of Pro duct Characteristics. Sandoz Limited, Surrey, United Kingdom; September 2012. 
http://www.medicines.org.uk/emc/medicine/28749/SPC (accessed 6 March 2015).
83. Sheehan DV, Harnett -Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 
1996; 11Suppl 3:89 -95. Review.
84. Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol. 2008;(182):313 -33.
85. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self -report version of PRIME -MD: the PHQ 
primary care study. JAMA. 1999; 282:1737 -44.
86. Trivedi MH, R ush AJ, Ibrahim MH, et al. The Inventory of Depressive Symptomatology, Clinician Rating 
(IDS -C) and Self -Report (IDS -SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating 
(QIDS -C) and Self -Report (QIDS -SR) in public sector patients with mood disorders: a psychometric 
evaluation. Psychol Med. 2004;34(1):73 -82.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 14987. Venlafaxine Extended -release: US Prescribing Information. Pfizer, Inc., New  York, New York, USA; 
August 2014. http://labeling.pfizer.com/ShowLabeling.aspx?id=612 (accessed 9 Feb ruary 2015).
88. Venlafaxine: Summary of Product Characteristics. Actavis Group PTC ehf, Iceland; May 2012. 
http://www.medicines.org.uk/emc/medicine/24329 (accessed 6 March 2015).
89. Vesierra (5 mg/mL solution for injection/infusion): Summary of Product Character istics, June 2014. Pfizer 
Limited, Kent, United Kingdom http://www.drugs.com/uk/vesierra -5-mg-ml-solution -for-injection -leaflet.html 
(accessed 25 February 2015).
90. Vos T, Flaxman AD, Naghavi M, et al. Years lived w ith disability (YLDs) for 1160 sequelae of 2 89 diseases 
and injuries 1990 -2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 
15;380(9859):2163 -96.
91. Walker E, McGee R, Druss B. Mortality in Mental Disorders and Global Disease Burden Implications: A 
System atic Review and Meta -analysis. JAMA Psychiatry. 2015.
92. Whitmyer VG, Dunner DL, Kornstein SG, Meyers AL, Mallinckrodt CH, Wohlreich MM, et al. A comparison 
of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry. 
2007;68:192 1–30.
93. Wieber J, Gugler R, Hengstmann JH, Dengler HJ. Pharmacokinetics of ketamine in man. Anaesthesist. 
1975;24:260 -3.
94. Wiens BL. A fixed sequence Bonferroni procedure for testing multiple endpoints. Pharmaceutical Statistics. 
2003; 2: 211 –215.
95. World Health Organization. Depression (fact sheet). October 2012. 
http://www. who.int/mediacentre/factsheets/fs369/en/ (Accessed on 03 March 2015).
96. Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in N demethylation of ketamine in human 
liver microsomes. Drug Metab Dispos. 2001;29:887 -890.
97. Yang P. Recent Advances in Design and Methodology in Psychiatric Clinical Trials. Slide presentation at Joint 
Statistical Meetings; August 3 -8, 2013; Montréal, QC Canada.
98. Zarate CA Jr, Singh JB, Carlson PJ, et al. A rand omized trial of an N -methyl-D-aspartate antagonist in 
treatment -resistant major depression. Arch Gen Psychiatry. 2006;63(8):856 -64.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 150Attachment 1: Prohibited Concomitant Medications w ith Intranasal Study Medication
(Esketamine or Placebo)
This list of medications is not all-inclusive ; if necessary, please contact the medical monitor for any 
questions regarding a medication(s).
Please refer to the local prescribing information of the subject’s oral antidepressant treatment for 
information regarding prohibited concomitant medications. 
Except where specifically noted, the prohibited medications listed in the following table are prohibited 
from 1 week (or 5 half-lives, whichever is longer) prior to the first dose of intranasal study medication 
until after the last dose of intranasal study medication. Note: If a medication is part of the antidepressant 
treatment regimen being taken at the time of signing the ICF (ie, start of screening/prospective 
observational phase), dose adjustment is permitted per clinical judgment, but the oral antidepressant 
treatment is to remain at or above the minimum therapeutic dose (per the MGH -ATRQ) through the end 
of Week 4. . If the investigator determines it is clinically appropriate, the antidepressant medication may 
be tapered during the optional ,up to 3 -week , taper period.
Note in the following table: N, Prohibited; Y, Perm itted, with restrictions (please refer to the column labeled 
“Comments” for additional guidance)
Drug ClassEpisodic 
Use (as 
need ed)Continuous 
Use CommentsReason for 
Prohibition
ADHD medications (eg, 
atom oxetine, guanfacine)N Y Can be continued but must not be taken 
within 12 hours prior to the intranasal 
treatment session or for 2 hours after the 
intranasal treatment session.Safety
Amantadine N N PD interaction
Anorexiants 
(eg, phentermine, 
phendimetrazine)N N Safety
Anticholinesterase 
inhibitorsN N Subject 
population is 
excluded
Anticonvulsants N N Subjects with seizures are excluded. 
Use as adjunctive treatment for major 
depressive disorder (MDD) is 
prohibited. 
-Note: Anticonvulsants used for 
indications other than seizures may be 
allow ed (eg, valproate for migraine, 
pregabalin)Safety and PD 
interaction
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 151Drug ClassEpisodic 
Use (as 
need ed)Continuous 
Use CommentsReason for 
Prohibition
Antidepressants 
(other than the specific 
antidepressant start ed in 
the induction phase of the 
study)N N-Only 1 of the 4 predefined oral 
antidepressant treatment options are 
permitted
-If a subject is taki ng a monoamine 
oxidase inhibitor (MAOI) during the 
screening/prospective observational 
phase, there must be a min imum 
washout interval of 2 weeks prior to 
the first dose of intranasal study 
medication.
-Even if used for indications other 
than MDD (eg, trazodone or low  dose 
tricyclic antidepressants for sleep), the 
use of any medication listed on the 
ATRQ, isnot permi tted during the 
treatment phase.Safety and PD 
interaction
Antipsychotics N N PD interaction
Benzodiazepines (at 
dosages less than or equal 
to the equivalent of 6 
mg/day of lorazepam) and 
non-benzodiazepine 
sleeping medication 
(including: zolpidem, 
zaleplon, eszopiclone, and 
ramelteon)Y Y Prohibited w ithin 12 hours prior to the 
start of each intranasal treatment session 
or cognition testingSafety and PD 
interaction
Benztropine Y N Prohibited if use is continuous and 
prohibited w ithin 12 hours prior to the 
start of cognition testingSafety and PD 
interaction. 
Chloral hydrate, 
melatonin, valerianN N Safety and PD 
interaction
Clonidine N N Safety and PD 
interaction
Corticosteriods ( system ic) Y N Inhaled, intranasal, topical, and 
ophthalmic steroi ds are not prohibited.
Intermittent IM/IV corticosteroids are 
permitted (chronic use prohibited)PD interaction
Cough/cold 
preparations/nasal 
solutions containing 
vasoconstrictors, 
decongestantsY Y Intranasally -administered decongestants 
(vasoconstrictor s) should not be used 
from 1 hour prior to each intranasal 
study medication administration.
Pseudoephedrine -containing oral
products should not be used within 12 
hours prior to an intranasal treatment 
sessionSafety and PD 
interaction
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 152Drug ClassEpisodic 
Use (as 
need ed)Continuous 
Use CommentsReason for 
Prohibition
CYP3A4 inducers - Potent N N Subjects may not take a known potent 
inducer of hepatic CYP3A activity 
within 2 weeks of the first 
administration of intranasal study 
medication until at least 24 hours after 
the last intranasal dose of study 
medication.
Examples (not all -inclus ive): Efavirenz, 
nevirapine, barbiturates, carbamazepine, 
glucocorticoids, modafinil, 
oxcarbazepine, phenobarbital, 
phenytoin, rifabutin, rifampin, and St. 
John's wortPK
Dextromethorphan N N PD interaction
Diphenhydramine Y N Prohibited w ithin 12 hours prior to the 
start of each intranasal treatment sessionSafety
Ketanserin N N Safety
Lithium N N PD interaction
Mem antine N N PD interaction
Methyldopa N N Safety and PD 
Interaction
Metyrosine N N Safety and PD 
interaction
Non-vitamin K antagon ist 
oral anticoagulation agents 
(eg, dabigatran, 
rivaroxaban, apixaban)N N Safety
Opioids N N PD interaction
Psychostimulants 
(eg, amphetamines, 
methylphenidate 
modafinil, armodafinil)N Y Prescribed psychostimulants taken for 
indications other than MDD can be 
continued but must not be taken within 
12 hours prior to the intranasal 
treatment session or for 2 hours after the 
intranasal treatment session.Cardiovascular 
safety
Reserpine N N PD interaction
Scopolamine N N PD interaction
St. John’s Wo rt N N PD interaction 
and PK
Thyroid hormone 
supplement for treatment 
of thyroid condition only 
(not for depression)N Y Safety
Thyroxine/ 
triiodothyronine (T3), 
thyroid hormone 
prescribed for depressionN N PD interaction
Warfarin N N Primary 
condi tion 
where used is 
excluded
Abbreviations: ADHD, attention deficit hyperactivity disorder; N, Prohibited; PD, pharmacodynamics; PK, 
pharmacokinetics; QTc, QT corrected; Y, Permitted, with restrictions (please refer to the column labeled 
“Comments” for add itional guidance).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 153Attachment 2:New York Heart A ssociation Classification of Cardiac Disease
New York Heart Association Classification of Cardiac Disease
Category Description
Functional Capacity
Class I Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical 
activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.
Class II Patients with cardiac disease resulting in slight limitation of physical activit y. They are comfortable at 
rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable 
at rest. Less than or dinary activity causes fatigue, palpitation, dyspnea, or anginal pain.
Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without 
discomfort. Symptoms of heart failure or the anginal syndrome may be present ev en at rest. If any 
physical activity is undertaken, discomfort is increased.
Objective Assessment
A No objective evidence of cardiovascular disease.
B Objective evidence of minimal cardiovascular disease.
C Objective evidence of moderately severe ca rdiovascular disease.
D Objective evidence of severe cardiovascular disease.
Source: Criteria Committee of the New York Heart Association. Functional capacity and objective assessment. In: 
Dolgin M, ed. Nomenclature and Criteria for Diagnosis of Diseas es of the Heart and Great Vessels, 9th ed. Boston, 
MA: Little, Brow n & Co; 1994, 253 -255.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 154Attachment 3:Oral Antidepressant Titration Schedule for Double -Blind Induction Phase
The titration schedule for the 4 oral antidepre ssants to be used in the current study is provided below . 
Prescribing Inform ation: 
Oral Antidepressant
(Active Com parator)Titration Schedule
Week 1
(Starting Day 1)Week 2
(Starting Day 8)Week 3
(Starting Day 15)Week 4
(Starting Day 22)
Duloxetine 30 mg 60 mg 60 mg 60 mg
Escitalopram 10 mg 10 mg 10 mg 10 mg
Sertraline 25 mg 50 mg 100 mg 150 mg
Venlafaxine XR 37.5 mg 75 mg 150 mg 150 mg
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 155Attachment 4:Anticipated Events
An anticipated event is an adverse event (serious or non -serious) that comm only occurs as a consequence 
of the underlying disease or condition under investigation (disease related) or background regimen. For 
the purposes of this study the following events will be considered anticipated events.24,23,28,29,42,81,82,87,88
For esketamine and major depressive disorder (MDD) (including treatment -resistant depression [TRD]; 
based on DSM -5):
 Suicidal thinking, ideation, and behavior
 Sleep changes, difficulty sleeping, reduced sleep, abnormal sleep, abnormal sleep, tiredness, fatigue, 
and reduced energy
 Difficulty in sexual desire, performance or satisfaction
 Reduced appetite and weight changes (loss or increase)
 Activation or hypomania/ mania
 Excessive happiness
 Irritability, anger, and impulsive behavior
 Agitation, feeling anxious/anxiety, tension, panic attacks, and phobia
For esketamine, regarding events related to concomitant therapy with oral antidepressants (from the 
product’s reference safety information/US prescribing information):
 Duloxetine
 Most commonly observed adverse reactions from pooled studies of all indications (incidence of 
at least 5% and at least twice the incidence in place bo subjects) were nausea, dry mouth, 
somnolence, fatigue, constipation, decreased appetite, and hyperhidrosis (sweating). Duloxetine 
treatment worsens glycemic control in some subjects with diabetes.
 Increased the risk compared to placebo of suicidal think ing and behavior; serotonin syndrome; 
hepatotoxicity; hepatic failure; orthostatic hypotension, syncope; abnormal bleeding; severe 
skin reactions, including erythema multiforme and Stevens -Johnson Syndrome (SJS); activation 
of mania or hypomania; hyponatremia.
 Venlafaxine XR
 According to the US prescribing information, adverse events in short -term studies occurring in 
at least 5% of subjects receiving venlafaxine XR and at a rate twice the incidence in placebo 
subjects: abnormal ejaculation, gastrointestina l complaints (nausea, dry mouth, and anorexia), 
central nervous system complaints (dizziness, somnolence, and abnormal dreams), and 
sweating. Sustained hypertension is noted within Warnings and Precautions section.
 Increased the risk compared to placebo ofsuicidal thinking and behavior, treatment -emergent 
insomnia and nervousness, activation of mania/hypomania, hyponatremia, mydriasis, abnormal 
bleeding, sustained hypertension, and serotonin syndrome.
 Escitalopram
 Most commonly observed adverse reactions ( incidence of approximately 5% or greater and 
approximately twice the incidence in placebo subjects) were insomnia, ejaculation disorder 
(primarily ejaculatory delay), nausea, sweating increased, fatigue, and somnolence.
 Increased the risk compared to place bo of suicidal thinking and behavior, serotonin syndrome, 
activation of mania/hypomania, hyponatremia and abnormal bleeding
 Sertraline
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 156 Most common treatment -emergent AEs associated with sertraline (incidence of at least 5% for 
sertraline or at least twice the incidence in placebo subjects) were ejaculation failure, dry mouth, 
increased sweating, somnolence, tremor, dizziness, fatigue, pain, malaise, abdominal pain, 
anorexia, constipation, diarrhea/loose stools, dyspepsia, nausea, agitation, insomnia, and 
decreased libido, and serotonin syndrome. 
 Increased the risk compared to placebo of suicidal thinking and behavior, activation/mania; 
bleeding events related to SSRI use (have ranged from ecchymosis, hematomas, epistaxis, and 
petechiae to life-threatening hemorrhages), hyponatremia (appears to be the result of the 
syndrome of inappropriate antidiuretic hormone secretion [SIADH]); serotonin syndrome
Reporting of Anticipated Events
These events will be captured on the CRF and in the database, and will be repor ted to the sponsor as 
described in Section 12.3.1 , All Adverse Events. Any event that meets serious adverse event criteria will 
be reported to the sponsor within the appropriate timeline as described in Section 12.3.2, Serious Adverse 
Events. These anticipated events are exempt from expedited reporting as individual single cases to Health 
Authorities. However, if based on an aggregate review, it is determined that an anticipated event is 
possibly related to study drug, the sponsor will report these events in an expedited manner.
Anticipated Event Review Committee (ARC)
An Anticipated Event Review Committee (ARC) will be established to perform reviews of pre-specified 
anticipated events at an aggregate level. The ARC is a safety committee within the sponsor’s organization 
that is independent of the sponsor’s study team. The ARC will meet to aid in the recommendation to the 
sponsor’s study team as to whether there is a reasonable possibility that an anticipated event is related to 
the study drug. 
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan (ASMP).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINTRD3005 Amendment 3
Status: Approved ,Date: 18July 2016 157INVESTIGA TOR AGREEMENT
[STUDY_ID_REMOVED]